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ABSTRACT
Epstein-Barr virus (EBV), a human y-herpesvirus that persistently infects >90% of the adult
population, is causally associated with post-transplant lymphoproliferative disease (PTLD). PTLD
arises in up to 10% of organ transplant recipients and is aggressive, difficult to treat, and fatal in up to
50% of cases despite current treatment. Therefore, novel therapeutic strategies are urgently needed to
combat the disease. One such approach involves the use of ex vivo expanded EBV-specific cytotoxic
T lymphocytes (CTLs). The aim of this study was to establish a pre-clinical SCID mouse model of
PTLD in which to test CTL immunotherapy. SCID mice, which lack functional B and T lymphocytes,
readily accept human xenografts, and the animals are used extensively to model human neoplasia in
vivo.
PTLD biopsies from 5 organ transplant recipients gave rise to PTLD-like tumours in all
(100%) cases. Biopsy and SCID tumour cells from 4 (80%) patients derived from the biopsy
malignant cell. One biopsy (20%) gave rise to a SCID lesion that represented a non-malignant biopsy
'bystander' B cell. Despite the successful xenograft transfer, it was not possible to establish SCID
tumour-derived cell lines in vitro for use in vivo. Therefore, EBV in vitro infected B lymphoblastoid
cell lines (BLCLs) were used to give rise to PTLD-like lesions in SCID mice.
A minimum dose of 2xl06 BLCL cells consistently induced subcutaneous (sc) or
intraperitoneal (ip) human CD45+ve, CD20+ve B immunoblastic tumours in vivo within 5-7 weeks.
Tumours expressed EBV-encoded small RNAs (EBERs), EBV nuclear antigen (EBNA) 2 and latent
membrane protein (LMP) 1 suggestive of unrestricted viral gene expression. A minority of cells
expressed the immediate early virus antigen BZLF1. The lesions mirrored PTLD and were used for
testing CTL immunotherapy.
Intravenous (iv) inoculation of 2 doses of 4xl06-8xl06 autologous CTLs a week apart
significantly delayed sc tumour progression in sc BLCL-injected SCID mice (p=0.01). Similarly, ip
transfer of 1 dose of 50xl06 autologous CTLs, or 3xl06-50xl06 CD8-enriched T cells, into ip BLCL-
inoculated animals significantly delayed tumour development in vivo (p=0.001 for both), and
prevented tumour formation in a significant proportion (40%) of mice inoculated with CD8-enriched
T cells (p=0.001). Immunostaining showed human T cells in the SCID tumours and that the cytotoxic
mechanisms involved perforin and granzyme B cytotoxic molecules. Whilst CD4-enriched T cells
significantly facilitated tumour outgrowth in sc BLCL-injected mice (p=0.04), they did not have any
significant impact on tumour development in ip BLCL-inoculated animals. A combination of
interleukin (IL) 7 and 15 conditioning of CTLs in vitro prior to ip transfer into SCID mice
significantly delayed ip BLCL-derived tumour formation in vivo when compared to CTLs expanded in
vitro using standard methods involving IL2 (p=0.04).
PTLD can be modelled in SCID mice. In the animals, autologous CTLs and CD8-enriched T
cells have a significant capacity to hinder PTLD-like tumour development. However, further studies
are needed in future to delineate the role of (1) cytokine conditioning and (2) CD4-enriched T cells.
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The architecture of the virion determines inclusion in the herpesvirus family,
herpesviridcie (reviewed in Roizman, 1996). A prototype herpesvirus contains a
linear 125-230 kilobasepair (kbp) double-stranded DNA (dsDNA) molecule
encoding 70-100 genes contained in a core enclosed by an icosahedral capsid of 162
capsomeres surrounded by an amorphous tegument and viral glycoprotein (gp) rich
envelope. The whole virion is approximately 100 nm in diameter. Species-specific
herpesviruses have been described for most animals.
The Herpesvirus Study Group devised a formal nomenclature scheme for the
herpesviruses on behalf of the International Committee on Taxonomy of Viruses
(1CTV). The recommendations of the study group were largely based on biological
characteristics of herpesviruses (host range, length of reproductive/lytic cycle,
cytopathology, characteristics of latency/persistence) and were formally reported in
1981 (Roizman et al, 1981). The scheme subdivided the herpesvirus family into 3
subfamilies: alpha (a)-, beta (ft)- and gamma (y)-herpesvirinae. The human
herpesvirus subfamilies contain 2 genera each. Thus, a-herpesvirinae contain the
genera simplexvirus and varicellovirus, (3-herpesvirinae consist of cytomegalovirus
and roseolovirus whilst the y-herpesvirinae contain the lymphocryptovirus and
rhadinovirus genera. Individual viruses are denoted by the taxonomic unit
(family/subfamily) followed by an Arabic number [for example, human herpesvirus
(HHV)-4], However, vernacular and approved names are often still used
interchangeably (for example, HHV-4 and Epstein-Barr virus, EBV).
All herpesviruses encode enzymes necessary for viral DNA replication,
which occurs in the host cell nucleus with assembly of capsids followed by budding
through the nuclear membrane. Lytic cycle involves the release of new progeny virus
which results in host cell death. All known herpesviruses have the ability to persist in
a latent form [latent cycle/latency: reversibly non-productive infection (Sinclair &
Sissons, 1994)] in their hosts which is characterized by a restricted viral gene
expression from covalently closed circular (ccc) viral DNA episomes.
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The a-herpesviruses exhibit a relatively short lytic cycle (18-24 hours)
followed by rapid host cell lysis and spread in vitro (reviewed in Roizman, 1996).
Latency is mainly established in sensory ganglia, and the human members (see Table
1) replicate in epithelium. The p-herpesviruses have long lytic cycles (48-72 hours),
slow in vitro spread and give rise to large infected cells (cytomegalia). Latency is
established in secretory glands, kidneys and lymphoreticular cells (lymphoid cells
and monocytes/macrophages). The human viruses replicate in fibroblasts
(cytomegalovirus, CMV) and T cells (HHV-6,7). The y-herpesviruses are either B or
T lymphotropic and establish latency in the lymphocyte. Replication occurs in
epithelium or fibroblasts as well as the lymphocyte.
To date, eight herpesviruses of a total of over 130 have been isolated from
humans. Their names and some characteristics are summarized in Table 1.
TABLE 1
Human Herpesviruses
Approved Vernacular Subfamily Genus G+C Size
Name1 Name2 (-herpesvirinae) (-virus) Content3 (Kbp)
(Mole %)
HHV-1 HSV-1 a, Simplex 67 152
HHV-2 HSV-2 a. Simplex 69 155
HHV-3 vzv a2 Varicello 46 125
HHV-4 EBV Yi Lymphocrypto 60 172
HHV-5 CMV P, Cytomegalo 57 230
HHV-6 - P2 Roseolo 43 162
HHV-7 - P2 Roseolo 40 145
HHV-8 KSHV Y2 Rhadino 54 141
: H(uman) H(crpes) V(irus); : H(erpes) S(implex) V(irus), V(aricella) Z(oster) V(irus), E(pstein)-
B(arr) V(irus), C(yto)M(egalo)V(irus), K(aposi's) S(arcoma)-associated H(erpes) V(irus);
3: G(uanine) + C(ytosine); Kbp: Kilo (xlO3) base-pair (Adapted from Roizman, 1996)
Following primary infection, the human herpesviruses establish a life-long
latent infection in their hosts. The infection is controlled by the host immune system,
mainly by cellular immunity. Reactivation of virus from latency to lytic infection, as
may occur during inherited, acquired or iatrogenic immunosuppression, results in
clinical disease. Some of the ensuing disorders may prove fatal as is the case with
EBV-associated post-transplant lymphoproliferative disease (PTLD) in
immunosuppressed organ transplant recipients.
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2. Epstein-Barr Virus (EBV)
EBV, a member of the human y-herpesvirus subfamily, was discovered in
African lymphoma cell lines by Epstein, Barr and Achong in 1964 following the
initial description by Burkitt, a British surgeon working in Africa, of an endemic
malignant tumour affecting the jaw of children in Uganda (Burkitt, 1958; Epstein &
Barr, 1964; Epstein et al, 1964). Thus, EBV was the first candidate human tumour
virus. The malignancy affecting African children (Burkitt's lymphoma, BL) is now
known to be of B lymphocyte origin and EBV is thought to be an essential co-factor
in the outgrowth of the endemic form of the tumour. Furthermore, EBV is the
causative agent of infectious mononucleosis (IM), and is aetiologically associated
with a variety of epithelial and lymphoid lesions in the immunocompetent and
immunosuppressed host although its role in some tumours is not yet entirely clear
(Epstein & Crawford, 2005; see Table 2).
TABLE 2
EBV-Associated Malignancies
Condition Initial Description Of EBV Association
By
African (endemic) Burkitt's lymphoma (eBL) Epstein et al, 1964
Sporadic Burkitt's lymphoma (sBL) (subsets) O'Conor et al, 1965
Nasopharyngeal carcinoma (NPC) (subsets) Old et al, 1966
Non-Hodgkin's lymphoma (NHL) in
immunocompromised patients (for example, post-
transplant lymphoproliterative disease, PTLD)
Crawford et at 1980
Hodgkin's lymphoma (HL)
(subsets)
Weiss et al, 1989
T/NK cell lymphoma
(subsets)
Jones et al, 1988
Tumours with suspected EBV-association:
- anaplastic gastric carcinoma
- salivary gland neoplasia
- smooth muscle tumours in immunosuppressed
states
Imaieta/, 1994
Raab-Traub et al, 1991
Lee et al, 1995
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Of lymphoid malignancies, EBV is found in 96% of endemic (African) BL
(eBL; reviewed in Magrath, 1990). In Europe and USA, around 20% of sporadic BL
(sBL) is associated with EBV (reviewed in Sixbey, 2000) as well as approximately
50% of Hodgkin's lymphoma [HL; reviewed in Herbst & Niedobitek (1994) and
Jarrett (2003); Jarrett et al, 2005] and around 90% of non-HL (NHL) arising in organ
transplant recipients (PTLD; reviewed in Macsween & Crawford, 2003).
Additionally, EBV is found in subsets of T/NK cell lymphomas (reviewed in Su,
1996). Furthermore, EBV is detected in almost 100% of undifferentiated (non-
keratinized) and 30-100% of differentiated (keratinized) nasopharyngeal carcinoma
(NPC; reviewed in Raab-Traub, 1992), and up to 10% of gastric carcinomas (GCa;
reviewed in Takada, 2000).
2.1 Biology
EBV is a large enveloped y-herpesvirus which contains a 172 kbp linear
dsDNA genome within an icosahedral capsid. The virus infects B cells in vitro and in
vivo (Pattengale et al, 1973; Klein et al, 1976). In vitro, latent infection involves
expression of latent viral genes without production of virus and is compatible with
host cell growth, whereas expression of the lytic genes in productive/lytic infection
results in host cell death and release of infectious virus (virions).
2.1.1 In Vitro EBV Infection
EBV preferentially infects B lymphocytes in vitro through attachment of the
major viral envelope glycoprotein gp350 to the B cell surface cluster designation
(CD) 21 molecule (the EBV receptor) which is the complement receptor (CR) 2 that
binds the C3d component of complement (Fingeroth et al, 1984). Entry also involves
binding to a cell surface co-receptor, the major histocompatibility complex (MHC)
class 2 molecules, by a second virus envelope glycoprotein, gp42, that complexes
with virus-derived gp25 and gp85 mediating fusion of virus envelope with target cell
membranes (Wang & Hutt-Fletcher, 1998; Speck et al, 2000; Borza & Hutt-Fletcher,
2002). Whilst CD21 is the main receptor for EBV, deletion mutants lacking gp350
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may still infect B cells suggesting alternative means of virus entry (for example,
through cell-to-cell contact) into B (and epithelial) cells (Janz et al, 2000; Shannon-
Lowe et al, 2006). Although EBV has been shown to infect epithelial cells in vitro
and in vivo (Sixbey et al, 1983, 1984; Tugizov et al, 2003; Pegtel et al, 2004),
whether a CD21 homologue is normally present on epithelial cells, and the role of
epithelial cells in EBV infection, is still unclear. Alternative (CD21-independent)
modes of EBV entry into epithelial cells have been proposed since oropharyngeal
epithelium in vivo may be one source of infectious virus in saliva. Thus, in their in
vitro model of human polarized tongue and pharyngeal cells, Tugizov et al (2003)
showed that EBV can enter epithelial cells by (1) direct cell-to-cell contact of apical
cell membranes with EBV-infected lymphocytes; (2) interaction between the (lytic)
virus envelope BMRF2 gp and (31 (or oc5(31) integrins at basolateral membrane sites;
(3) direct virus spread across lateral membranes. In this model, virus egress occurred
from apical and basolateral membranes.
Similar to other herpesviruses, the linear EBV DNA molecule forms a ccc
episome in the nucleus of latently infected cells which is where the virus replicates.
Cellular DNA polymerase amplifies the episome giving rise to multiple identical
copies in the host cell. During latency, the episomes are replicated once every cell
cycle in synchrony with host cell DNA. Equal partitioning to progeny cells maintains
a stable number of identical viral genomes per host cell which gives rise to a virus
clonal population (Kieff & Rickinson, 2007).
In vitro, 1-10% of the infected B cell pool are 'immortalized' by EBV giving
rise to continually proliferating B lymphoblastoid cell lines (BLCL; Pope et al, 1968;
Tosato et al, 1985). In contrast to B cells, EBV infection of epithelial cells in vitro is
difficult and does not result in full latent gene expression or lytic infection.
Therefore, BLCL serve as the main in vitro model of EBV infection, latency and
oncogenesis. Similar to antigen-stimulated B lymphocytes, BLCL express the B cell
activation markers CD23, CD30, CD39 and CD70 as well as the cell adhesion
molecules (CAMs) lymphocyte function-associated antigen (LFA)-l (or CD1 la/18),
LFA-3 (or CD58) and intercellular adhesion molecule (ICAM)-l (or CD54) (Rowe et
al, 1987; Kieff & Rickinson, 2007). In contrast, these markers are virtually absent on
resting B lymphocytes.
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BLCL express all EBV latent proteins which constitute only 10 of a possible
70 viral-encoded proteins (Baer et al, 1984): six EBV nuclear antigens [EBNA-
Leader Protein (LP), 1, 2, 3a, 3b and 3c] that constitute the EBNA complex, three
latent membrane proteins (LMP1, 2a and 2b), and possibly one (or more) proteins of
the BARFO open reading frame from the BamHl A region of the virus genome
(BART transcripts; for an overview of EBV latent transcripts, see Table 3).
Additionally, two small non-polyadenylated (and, thus, non-coding) EBV-encoded
RNAs (EBER1 and 2) are abundantly expressed during latency. Analysis of virus
deletion mutants in the BLCL model has shown that of the latent virus proteins, only
EBNA1, 2, 3a, 3c and LMP1 are essential for in vitro mmortalization whereas
EBNA-3b, LMP2a, 2b and EBERs are not (see Table 3). Whilst EBNA-LP deletion
mutants have a reduced in vitro immortalizing capacity in B cells compared with
wild-type EBV, the role of BART transcripts in immortalization remains unclear (for
a review of latent virus gene expression, see Young & Rickinson, 2004).
Latent viral infection has been defined as latency 1, 2 or 3 based on EBV
promoter usage and latent gene expression. Thus, 'latency 3' (observed in BLCL and
most PTLD) is characterized by transcription of all the EBNAs together with the 3
LMPs. In contrast, 'latency 1' (seen in EBV-associated BL and early passage BL cell
lines) involves the transcription of EBNA1 only. 'Latency T (detected in EBV-
associated HL and NPC) entails EBNA1 expression together with a variable
expression of the LMPs. EBERs and BARTs are expressed in all forms of latency
(Kieff & Rickinson, 2007). However, since viral gene expression found in clinical
samples does not always conform to the above latency types, this text uses an
alternative scheme that refers to persistent infection as either 'unrestricted' or
'restricted'. The former expression pattern refers to a latency 3-type infection whereas
the latter refers to any other more restricted profile.
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Lytic EBV infection involves productive viral DNA replication, expression of
most virus genes, release of infectious virus and host cell death. The majority of
EBV-encoded proteins are expressed during lytic infection although only a small
number of BLCL cells enter lytic cycle at any given time. Since herpesviruses do not
encode an RNA polymerase, EBV utilises host cell RNA polymerase II for
transcription of its viral messenger RNA (mRNA). The immediate early (IE) viral
proteins BRLF1 and BZLF1 initiate lytic cycle which is characterized by the
sequential expression of early antigen (EA) complex, viral capsid antigen (VCA)
complex and membrane antigen (MA) complex proteins. Each complex consists of
several proteins (reviewed in Kieff & Rickinson, 2007). The early (IE and EA) lytic
proteins are operationally differentiated from the late (VCA and MA) lytic antigens
by the persistent expression of the former, but not the latter, in the presence of viral
DNA synthesis inhibitors. During lytic infection, EBV also expresses a human
interleukin (1L) 10 homologue (viral IL10, vILlO). Furthermore, EBNA1, LMP1, 2a,
2b and EBERs continue to be transcribed.
Based on coding sequence differences of EBNA2, 3a, 3b, 3c and EBERs,
EBV is of two types referred to as 'type 1' and 'type 2' (or 'type A' and 'type B').
Both virus types have a worldwide distribution. However, Caucasian and Oriental
populations are predominantly infected with type 1 virus whereas type 2 virus is
frequently found in African populations (Sixbey et al, 1989). In contrast,
immunocompromised hosts may harbour both types simultaneously (Yao et al,
1996a,b).
2.1.2 In Vivo EBV Infection
EBV is a ubiquitous agent as demonstrated by seroepidemiological studies
with >90% of adults worldwide testing positive when analyzed for past infection
(Henle & Henle, 1966). Infectious virus can be found in throat washings (TW) from
healthy virus carriers (and IM patients), and EBV transmission occurs horizontally
via saliva (Hoagland, 1955; Gerber et al, 1972). However, the source of virus in
saliva, whether in oropharyngeal epithelial cells or intraepithelial B cells, remains
uncertain.
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Seroprevalence increases with the age of the population with neonates being
protected by maternal anti-EBV IgG antibodies up to the age of 6 months (Biggar et
al, 1978). Primary infection is usually asymptomatic in children. In developing
societies, primary infection occurs most commonly before 3 years of age (Henle &
Henle, 1969; Lang et al, 1977), whereas primary infection in Western societies
occurs later and may even be delayed until adolescence. Seroepidemiological studies
in the UK have shown 2 peaks of EBV seroconversion, one occurring at the ages of
1-6 years and the other at 14-20 years (UHP-PHLS, 1971; Crawford & Edwards,
1990). Previous studies showed that 28-70% of adults acquiring a primary infection
at 17-25 years of age suffered 1M, an acute self-limiting lymphoproliferative disease
(Niederman et al, 1970; Sawyer et al, 1971). However, in a recent study on 2006
university students in the UK, 510 (25%) students were found to be EBV-
seronegative at the time of enrolment into university (Crawford et al, 2006). A
second blood sample was obtained from 241 (47%) of the seronegative population
after 3 years of studies. Of these, 110 (46%) had experienced EBV seroconversion
during their study time, and 27 (25%) had experienced 1M. Penetrative sexual
intercourse was a risk factor for EBV seroconversion and IM. Furthermore, EBV
type 1 was significantly over-represented in the IM group. Taken together, the results
suggested that IM was caused by exposure during sexual intercourse to a large EBV
type 1 load.
IM has an incubation period of 30-50 days and is characterized by the classic
triad of pharyngitis, generalised lymphadenopathy and fever (Macsween &
Crawford, 2003). Additional signs include splenomegaly and mild hepatomegaly as
well as fatigue (which may be prolonged) and (occasionally) a maculopapular rash.
The disease is manifest by an absolute lymphocytosis consisting of 'atypical'
lymphocytes (Downey & McKinlay, 1923) which are found to be antigen-driven
mono- or oligoclonal CD8+ve T cells when T cell receptor (TCR) V(3 chain usage is
analyzed (Crawford et al, 1981a; Callan et al, 1996). These cells express the
CD45RO memory marker together with low expression of bcl-2 that correlates with
their apoptosis in vitro (Akbar et al, 1993). Evidence suggests that efficient
resolution of IM symptoms is associated with a broad cytotoxic T lymphocyte (CTL)
response to a wide range of EBV-derived target latent and lytic epitopes (Bharadwaj
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et al, 2001). Whilst EBV DNA viral load (VL; as measured by polymerase chain
reaction, PCR) in peripheral blood decreases rapidly during convalescence, salivary
VL remains high (6 months post-diagnosis), and IM patients remain highly infectious
during this time (Balfour et al, 2005; Fafi-Kremer et al, 2005).
Following primary infection, EBV persists in vivo in a latent form at a fairly
constant level in approximately 1-10 per 106 circulating B cells (Tosato & Blaese,
1985; Miyashita et al, 1995; Babcock et al, 1998). Around 90% of seropositive virus
carriers (cumulative results when assayed on several occasions) give rise to BLCLs
in vitro when (1) their peripheral blood leukocytes (PBLs) are cultured in the
presence of the immunosuppressant cyclosporine-A (Cy-A), or (2) their TW are co-
cultured with susceptible EBV-negative cord blood mononuclear cells (Yao et al,
1985a). Circulating EBV-infected B cells are antigen-selected small, CD19+ve,
CD23-ve, CD27+ve, CD80-ve, surface immunoglobulin (slg) M+ve, sfgD-ve resting
memory B cells (Pope et al, 1968; Tosato et al, 1985; Miyashita et al, 1995, 1997;
Babcock et al, 1998; Hochberg et al, 2004a).
EBV gene expression (transcriptional) patterns displayed by PBLs from
healthy virus carriers have been analyzed by reverse transcriptase (RT)-PCR
amplification of whole cell, or enriched B cell, population RNA extracts. Thus, Qu
and Rowe (1992) reported LMP2a transcription in vivo, and Tierney el al (1994)
described EBNA1, LMP2a and EBERs expression without detectable lytic BZLF1
transcripts. Similarly, Chen et al (1995) reported EBNA1 and LMP2a expression
whereas Gonnella et al (1997) amplified EBNA1 and LMP1 only. In contrast, Prang
et al (1997) detected lytic BZLF1 and BALF2 transcripts in 72% and 16%,
respectively, of enriched peripheral blood B cell extracts from virus carriers.
Taken together, the only consistently expressed latent virus gene in peripheral
blood of healthy virus carriers is LMP2a ('latency programme'). Furthermore, cells
showing full viral latent gene expression ("growth programme') have never been
observed in peripheral blood in healthy virus carriers although such an expression
profile has been detected during IM (Tierney et al, 1994). Thus, the LMP2a-only
'latency programme' has been proposed as the mechanism of in vivo latency with
LMP2a providing the EBV-infected memory B cell with survival signals similar to
those that maintain the long-term memory B cell pool (Babcock et al, 1998). In line
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with this is the observation by Miller et al (1994) that LMP2a inhibits the switch
from latency to lytic infection in EBV-infected B cells in vitro. According to current
thinking, LMP2a and LMP1 provide infected B cells with B cell receptor (BCR: slg)
and CD40 co-stimulatoty signals, respectively, and thus mimic both survival signals
required to maintain the infected B cell pool (Caldwell et al, 1998; Thorley-Lawson
& Babcock, 1999; Bechtel et al, 2005; Mancao et al, 2005).
Recently, Thorley-Lawson et al examined the EBV expression profile of
tonsils from healthy EBV carriers. The group demonstrated latently infected naive B
cells in tonsils and their presence was associated with viral replication (Babcock et
al, 1998). Furthermore, in contrast to the studies above on peripheral blood, they
showed full latent viral gene expression (including EBNA2; 'growth programme*) in
purified naive (slgD+ve) tonsillar B cells (Joseph et al, 2000). These cells were
activated CD80+ve (B7.1+ve) lymphocytes. Based on their findings, the group
suggested that infectious virus is restricted to regions of the tonsil that harbour only
naive B cells (for example, the mantle zone). Thus, latently infected memory B cells
from the periphery could extravasate in the tonsillar marginal zones and reactivate
EBV in response to signals in the mantle zone. The EBV-infected naive B cells
would either be killed by virus-specific T lymphocytes, or differentiate within the
tonsil to become resting memory B cells that would then leave the tonsil to circulate
in peripheral blood whilst virus gene expression became restricted (Thorley-Lawson
& Babcock, 1999).
Model Of EBV Persistence
Thorley-Lawson et al have proposed a model of EBV persistence in vivo
based on the observation that EBV persists in resting memory B lymphocytes that do
not express any viral proteins (Miyashita et al, 1997; Babcock et al, 1998; Babcock
et al, 2000; Babcock & Thorley-Lawson, 2000; Thorley-Lawson, 2001; Hochberg et
al, 2004b; Thorley-Lawson & Gross, 2004), and that this situation arises despite the
virus's clear ability to drive proliferation of its host cells. Further support for the
pivotal role of B cells in both primary and persistent infection comes from studies by
Faulkner et al (1999) demonstrating that patients lacking Bruton's tyrosine kinase
38
and, thus, suffering from X-Iinked agammaglobulinaemia and absence of functional
B cells, can not be infected by EBV.
In their model, Thorley-Lawson et al propose that EBV promotes formation
of long-lived virus-infected memory B cells using normal pathways of B cell
response to antigen (Thorley-Lawson, 2005). The oral lymphoepithelium of the
tonsil (tonsillar crypts; part of Waldeyer's ring) is exposed to environmental antigens
that are sampled by naive B lymphocytes (Perry & Whyte, 1998; Brandtzaeg et al,
1999a). When encountering specific antigen, naive B lymphocytes are activated via
their BCR and migrate as blast cells into tonsillar follicles to produce germinal
centres (GC) where B cell maturation occurs (Liu & Arpin, 1997). Differentiation
[involving antigen-specific T helper (Th) cells] entails rounds of proliferation
associated with isotype switching and mutation of Ig genes followed by competitive
selection for B cells that bind the antigen most avidely and their release as long-lived
antigen-specific memory B cells. Non-selected B cells die by apoptosis. Paralleling
this scenario, EBV expresses all of its growth-promoting latent antigens ('growth
programme') following primary virus infection of naive B cells in tonsillar
epithelium (Joseph et al, 2000). Thus, the virus promotes B cell activation, blast
formation, proliferation and formation of tonsillar follicles without specific antigen-
mediated BCR triggering. In the tonsillar follicle, the transcription programme
changes to the more restricted 'default programme' (EBNA1, LMP1 and 2 only;
Babcock et al, 2000). At this stage, LMP2 drives Ig isotype switching (He et al,
2003; Casola et al, 2004) whilst LMP1 promotes Ig gene mutation and down-
regulates bcl-6 expression thus retaining memory B cells in the germinal centre
(Calame et al, 2003; Casola et al, 2004; Panagopoulos et al, 2004). Thus, the
importance of the 'default programme' may be to offer virus-infected B cells a
selective advantage in the germinal centre (Thorley-Lawson, 2005). For an overview
of this model of EBV persistence, see Figure 1 below.
Once they leave the germinal centre, latently infected B cells switch off virus
protein expression ('latency programme') and are maintained as normal memory B
cells (Hochberg et al, 2004b). Thus, EBV-infected memory B cells are thought to
express virus proteins only rarely in the peripheral circulation (Hochberg et al,
2004b). Whilst the numbers of such virus-infected cells can form over half of the
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memory B cell pool during the acute stages of IM (Hochberg et al, 2004a), a steady-
state of approximately 1-10 EBV-infected cells per 106 circulating memory B cells is
detected within a year of IM reflecting a dynamic balance between cell proliferation
and cell loss through lytic infection (Khan et al, 1996; Hochberg et al, 2004b).
However, the role of either EBV re-infection of B cells, or direct virus infection of
memory B cells, in maintenance of the virus-infected B cell pool is unclear (Arpin et
al, 1997). Equally, Conacher et al (2005) have shown short-term EBV persistence in
the absence of a germinal centre reaction and a typical B cell memory pool in X-
linked hyper-IgM syndrome patients who (due to a mutation in the CD40 ligand
gene) do not harbour such cells.
FIGURE 1
A Model Of How EBV May Establish Persistent Infection
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In the model, EBV infects naive resting B cells in the lymphoid tissue of Waldeyer's ring. The
'growth programme' activates the cells to become proliferating blasts and, thus, parallels antigen-
driven activation of a naive B cell. A switch to the 'default programme' provides rescue signals akin
to those delivered by antigen and antigen-specific T helper cells resulting in entry into the memory B
cell pool. Upon entry into the peripheral circulation, virus-infected cells switch to the 'latency
programme' which entails a shutdown of all protein-encoding genes. As part of memory B cell
homeostasis, these cells divide occacionally and express EBNA1 only (if infected with virus). This
permits replication of the virus genome and equal partitioning between daughter cells. Upon
differentiation into plasma cells, virus-infected memory B cells reactivate EBV resulting in production
of virions. EBNA: EBV nuclear antigen; GC: Germinal centre [Reprinted from Thorley-Lawson &
Gross (2004) with permission from the New England Journal of Medicine. Copyright © 2004
Massachusetts Medical Society. Alt rights reserved.]
Virus reactivation in mucosal sites leads to virus transmission. Thus, as a
result of antigen-mediated BCR triggering and homing of antibody-producing
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memory B cells to mucosal sites, an infected memory B cell activates EBV to lytic
infection (Brandtzaeg et al, 1999a,b; Laichalk & Thorley-Lawson, 2005). Studies in
vitro by Crawford and Ando (1986), and in vivo by Laichalk and Thorley-Lawson
(2005), have demonstrated such a link between B cell differentiation and lytic
infection. In tonsil, this results in egress of infectious virus into saliva. The
importance in transmission of reactivation of virus in genital sites is still unclear
although virus is detected in samples from the male and female genito-urinary tract
(Sixbey et al, 1986; Israele et al, 1991; Thomas et al, 2006) suggesting the
possibility of sexual transmission.
The above model centres on memory B cells as site of virus persistence, but
oropharyngeal epithelium may support virus replication and, thus, amplify virus in
the oropharynx (Gratama et al, 1988; Laulkner et al, 1999). However, epithelial cells
are not considered to support persistent EBV infection.
2.2 Immunity
2.2.1 Primary Infection
Our knowledge of the host immune response to primary EBV infection is
modelled on immune responses observed during 1M (the model for primary
infection). IgA, IgM and IgG antibodies to VCA are usually detected by onset of IM
together with anti-EA and -MA IgG (Henle & Henle, 1979). A range of (mostly
IgM) heterophile and auto-antibodies also appear transiently. During convalescence,
anti-EBNAl IgG antibodies arise whilst IgA and IgM antibodies to VCA as well as
the anti-EA IgG antibodies (and heterophile antibodies) decline to undetectable
levels (Moss et al, 2001).
Cellular immunity to primary EBV infection is manifest by lymphocytosis in
peripheral blood that consists mainly of 'atypical' activated CD8+ve T cells (Callan
et al, 1996; Khanna & Burrows, 2000; Vetsika & Callan, 2004). Over 70% of
lymphocytes in IM have been shown to be antigen-driven mono- or oligoclonal
MHC DR+ve, CD45RO+ve, CD8+ve, CD38+ve CTLs when analyzed using PCR
amplification of, and monoclonal antibodies (mab) to, the TCR V(3rchain
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(Tomkinson et al, 1987; Callan et al, 1996; Hoshino et al, 1999). A role for
superantigen (sAg)-driven expansion has not been demonstrated despite earlier
reports (Sutkowski et al, 1996). The transiently expanded T cell clones recognize
primarily early (IE and EA) lytic EBV antigens (for example, BZLF1 and BRLF1)
with up to 40% of circulating CD8+ve CTLs being directed against a single virus
epitope as evidenced by tetramer analysis (Steven et al, 1997; Callan et al, 1998). In
contrast, only a minor component of the CTL response in IM is directed against the
latent virus antigens. As the primary infection progresses, the vastly expanded
CD8+ve T cells against lytic antigens reduce in number and may even become
undetectable (Callan et al, 2000; Hislop et al, 2002; Callan, 2004).
Whilst CD4+ve T lymphocytes form a minor part of the observed
lymphocytosis of IM, the cells display an activated phenotype and respond to lytic
and latent viral epitopes (Precopio et al, 2003; Williams et al, 2004). In particular,
CD4+ve T cell responses have been described against the early lytic (BZLF1 and
BMLF1) and latent EBNA1 and EBNA3a antigens in IM patients (Amyes et al,
2003; Precopio et al, 2003). However, such CD4+ve T cell-mediated responses
decline rapidly during the disease and are at a low (or undetectable) level 1 year after
diagnosis.
The massive CTL response observed in IM is thought to cause its
characteristic symptoms through excessive cytokine release such as raised Th 1 -type
cytokine levels [for example, IL2 and interferon (IFN)y; Foss et al, 1994; Biglino et
al, 1996]. Furthermore, recent studies have also demonstrated a correlation between
the severity of IM symptoms and the level of activated T lymphocytes (Williams et
al, 2004). Thus, signaling lymphocytic activation molecule (SLAM; CD 150),
SLAM-associated protein (SAP), and CD244 (2B4) were significantly up-regulated
on CD4+ve and CD8+ve T cells at time of IM diagnosis. At that time, natural killer
(NK) cell levels were also significantly elevated suggesting a role for NK cells in
immune control of primary EBV infection. Thus, the same group showed higher NK
cell numbers at IM diagnosis to correlate with significantly lower circulating EBV
VL (Williams et al, 2005).
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2.2.2 Persistent infection
Stable levels of circulating anti-VCA, anti-MA and anti-EBNAl IgG
antibodies are detected in healthy virus carriers and low levels of anti-EA antibodies
may also be present (Henle & Henle, 1979). Antibodies against gp350/220 of the MA
complex are retained and neutralizing. Additionally, 21-30% of virus carriers have
anti-gp350 IgA in serum, and these antibodies are found in saliva of 12-19% of virus
carriers (Yao etal, 1991a,b).
Immune control of EBV infection is mediated primarily by CD8+ve MHC1-
restricted EBV-specific CTLs against all the latent viral proteins [CTL precursor
(CTLp) frequency ranges from 1:400 to 1:42,000 of the total T cell population]
although the role of T cell responses to EBNA1 is still unclear (Rickinson & Moss,
1997; for an overview of immunodominant CTL epitopes and their MHC restriction,
see Moss et al, 2001). In particular, CTL responses to the EBNA3 antigens are
immunodominant (Murray et al, 1990, 1992; Rickinson & Moss, 1997), and
cytolysis of the CD8+ve T cells is mediated by granule exocytosis mechanisms
(perforin, granzyme). EBNA1 contains glycine-alaninine repeats that interfere with
proteosomal proteolysis necessary for MHC 1-restricted epitope presentation to CTLs
(Levitskaya et al, 1995, 1997) and inhibit translation of EBNA1 (Yin et al, 2003)
although recent evidence suggests that EBNA1-specific CD8+ve CTLs can be
generated in vitro (Lee et al, 2004; Voo et al, 2004). Such EBNA1-specific CTLs
could play a future role in adoptive immunotherapy against EBV-associated
malignancies - all of which express EBNA1. Collectively, up to 5% of circulating
CD8+ve CTLs are committed to EBV immune control (Hislop et al, 2002).
In addition to immunosurveillance mediated by CD8+ve T cells, CD4+ve T
cells also have a role to play. Thus, EBNA1-reactive CD4+ve T cells have been
detected in healthy seropositive individuals. In particular, Munz et al (2000) and
Bickham et al (2001) have shown such T cells to lyse EBNAl+ve cells, and EBNA1
is now considered highly immunogenic for CD4+ve T cells (Leen et al, 2001;
Nikiforow et al, 2001). In contrast to CD8+ve CTL, such CD4+ve T cells mediate
their effector mechanisms via IFNy secretion and Fas/Fas ligand (FasL) interactions
rather than granule exocytosis (Nikiforow et al, 2003). The role of IFNy in mediating
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CTL defences against EBV is further highlighted by studies of the severe
immunodeficiency X-linked lymphoproliferative disease (XLP) which results from a
defect in the signalling adaptor SAP gene that signals through SLAM (and other Ig
superfamily receptors including 2B4). Thus, using autologous BLCLs as stimulators,
Sharifi et al (2004) demonstrated that EBV-specific T cell lines generated in vitro
from XLP patients showed markedly reduced IFNy production and cytotoxic
capacity compared to healthy controls.
During persistent infection, CTLs also control lytic infection and recognize
specific IE (BZLF1, BRLF1) and EA (BMLF1, BMRF1, BALF2) antigens
(Bogedain et al, 1995; Steven et al, 1997).
Immunosuppression reduces EBV-specific CTL activity, and this can lead to
EBV-driven proliferation of B cells that may culminate in B cell lymphoproliferative
disease (BLPD). BLPD encompasses a spectrum of B cell proliferations arising in
immunocompromised patients ranging from a diffuse polymorphic ('viral
lymphadenitis-like') proliferation with polyclonal Ig expression to a malignant
monoclonal Ig lymphoma. EBV is aetiologically associated with BLPD in most cases
and the disease is characterized by rapid onset, aggressive behaviour, and high
mortality despite treatment. In the organ transplant recipient, iatrogenic
immunosuppression may result in BLPD which is then referred to as PTLD. EBV is
associated with around 90% of PTLD.
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3. Post-Transplant Lymphoproliferative Disease (PTLD)
PTLD develops in up to 10% of organ graft patients and is characterized by
rapid onset, aggressive behaviour, and high mortality despite treatment. The disease
encompasses a spectrum of primarily B cell proliferations (BLPD) although T and
NK cell tumours have also been described (Nalesnik, 2001). Whilst EBV is
aetiologically associated with PTLD in most cases, EBV-negative lesions are well
recognized and constitute up to 10% of PTLD (Newstead, 2005).
3.1 Incidence And Risk Factors
The 2 major risk factors for PTLD formation are (1) the degree and duration
of immunosuppression required for graft maintenance, and (2) primary EBV
infection following transplantation (Thomas et al, 1995).
(1) Immunosuppression predisposes to the development of de novo cancers
(Penn, 1991a,b). The degree of immunosuppression required to facilitate organ
transplantation correlates with PTLD formation which in turn depends on the type of
organ graft. Generally, immunosuppression is heaviest during the first year post-
transplant when the risk of rejection is greatest and, thus, the risk of PTLD is high
during this period (Opelz & Henderson, 1993). However, PTLD incidence at 1 year
post-graft amounts to only a fifth of the 10 year cumulative incidence, and the
median time to PTLD is 5 years following transplantation surgery (Opelz & Dohler,
2004). Current immunosuppressive regimes used in organ transplantation include the
T cell suppressants Cy-A, azathioprine, prednisone, tacrolimus and mycophenolate
mofetil (Newstead, 2005). Additionally, mab against T cell surface antigens (anti-
CD3: OKT3; anti-CD25: basiliximab and daclizumab) that result in T cell depletion
are in clinical use. Furthermore, anti-lymphocyte and anti-thymocyte globulin (ALG,
ATG) are available for T cell depletion and graft-verms-host disease (GVHD)
prophylaxis (Dey et al, 2005).
Overall, <1-33% transplant patients develop PTLD (Williams & Crawford,
2006). However, the incidence of PTLD shows marked variation in different
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transplant groups with reports of between 0.2-1.6% in bone marrow (Beveridge el
al, 1984; Shapiro et al, 1988), 0.4-2.5% in kidney (Birkeland, 1983; Starzl et al,
1984), 1.8-3.4% in heart (Nalesnik et al, 1988; Armitage et al, 1991), 1.8-7.9% in
lung (Armitage et al, 1991; Levine et al, 1999), 2.3-13.7% in liver (Renard et al,
1991; Cox et al, 1995), 4.6-9.4% in heart/lung (Nalesnik et al, 1988; Randhawa et al,
1989), 7-11% in intestinal (Abu-Elmagd et al, 1998; Grant, 1999), and 13-33%
(Abu-Elmagd et al, 1998; Grant, 1999) in multi-organ transplant recipients. The
observed differences in incidence in the various organ transplant groups reflect the
use of different immunosuppressive therapeutic regimens. Triple therapy consisting
of Cy-A, azathioprine, and prednisone has been associated with an increased
frequency of PTLD in kidney and heart recipients (Wilkinson et al, 1989) although
high-dose Cy-A on its own correlates with increased PTLD incidence in heart/lung
recipients (Gao et al, 2003). The risk of PTLD is also significantly increased in
patients who have multiple allotransplants reflecting the higher cumulative dose of
immunosuppressive agents required for retransplants (Swerdlow et al, 2000).
(2) Primary EBV infection in the seronegative organ transplant population is
a major risk factor for development of EBV-associated PTLD. Compared to EBV-
seropositive organ graft recipients, seronegative patients receiving a seropositive
organ graft are at a 10-75 fold increased risk of PTLD (Cockfield, 2001).
Furthermore, several serological studies have demonstrated that approximately 50%
of organ transplant recipients who develop PTLD had a primary EBV infection
within the previous 6 months (Ho et al, 1985, 1988; Thomas et al, 1995)
demonstrating inherent risks of primary virus infection at a time when immune
defences are suppressed. It follows that PTLD is more common in children than
adults since children are more likely not to harbour the virus, and studies have shown
that EBV can be transmitted with grafted bone marrow or transplanted solid organs
from seropositive donors to seronegative graft recipients (Gratama et al, 1988; Cen et
al, 1991). Thus, in a study by Haque et al in 1996, 2 EBV-seronegative heart/lung
transplant recipients seroconverted shortly after transplantation and developed
EBV+ve PTLD that contained the donor virus isolate. In contrast, EBV+ve PTLD
from 2 previously seropositive heart/lung recipients contained the original recipient
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virus isolate. The studies underline the significance of EBV transmission via the
grafted organ as a risk factor for PTLD in seronegative recipients. Generally, PTLD
derives from recipient or donor B cells in solid organ or bone marrow transplant
recipients, respectively.
3.2 Presentation And Pathology
Clinically, PTLD presentation can be non-specific due to possible
concomitant infection and graft rejection. However, a viral lymphadenitis (IM)-like
picture is often observed when lesions arise within the first year following organ
transplantation. The disease can also present as a tumour of the lymph node, or as an
extranodal lesion. An extranodal lesion occurs in 69% of PTLD, and 51% of lesions
have been found in multiple organs (Penn, 1993). Commonly, extranodal tumours
involve lungs, liver, gastrointestinal tract, and, in one third of patients with
disseminated disease, the grafted organ (Thomas et al, 1995). Such disseminated
disease usually arises more than 1 year after organ grafting. Twelve % of PTLD are
confined to the central nervous system (CNS) in contrast to 1-2% of lymphomas that
arise in the general population (Penn & Porat, 1995).
PTLD shows marked morphological heterogeneity that can present as a
mono-, oligo- or polyclonal Ig tumour. Originally, Lrizzera et al (1981) described
two histological types of PTLD in renal graft recipients: polymorphic B cell
hyperplasia (PBH) and polymorphic B cell lymphoma (PBL). Histologically, PBH
and PBL are both characterized by polymorphic cells, nodal effacement and invasion
of normal architecture. PBH is further characterized by single-cell necrosis but lack
of cellular atypia. In contrast, PBL shows extensive necrosis and cellular atypia.
Subsequent classification schemes by Nalesnik et al (1988), Knowles et al (1995)
and Swerdlow (1997) subdivided PTLD further based on detailed
immunophenotyping and genotyping as well as morphology. Thus, PTLD phenotype
is usually one of B lymphoblastoid cells (BLPD) with expression of cell activation
markers and CAMs. Current World Health Organization (WHO) histopathological
PTLD classification includes "hyperplastic' (early, IM-like, reactive plasma cell
hyperplastic lesions), 'polymorphic' (polyclonal or monoclonal tumours), and
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'lymphomatous' or 'monomorphic' (of diffuse large B cell lymphoma, or BL, type)
categories whilst a fourth group is often used to include 'other' lesions such as HL,
plasmacytoma and myeloma (Nalesnik, 2001; Williams & Crawford, 2006).
Although no single cytogenetic abnormality is characteristic of PTLD, several
inconsistent cytogenetic abnormalities have been described. These include
chromosomal trisomy, deletions, c-myc gene rearrangements, t8:14 translocations, or
mutations in the p53, N-ras, c-myc, or bcl-6 genes which are often found in
monomorphic PTLD (Gottschalk et al, 2005).
3.3 Seroepidemiology And Viral Load Monitoring
The serological profile of primary EBV infection in organ graft recipients
often differs from that seen in healthy immunocompetent individuals. Specifically,
IgM antibody responses to VCA or heterophile antigens are not always detected
(Henle & Henle, 1981). In contrast, immunosuppressed virus carriers often have a
'reactivated' serological profile characterized by raised levels of IgG antibodies to
VCA and EA but not to EBNA (Ho et al, 1985). Furthermore, in seropositive
patients, suppressed EBV-specific CTL activity is associated with increased
oropharyngeal virus shedding and raised numbers of circulating EBV+ve B cells
(Crawford et al, 1981 b; Yao et al, 1985b).
PCR analysis of EBV DNA VL in blood is used to assess PTLD risk and
monitor response to PTLD treatment (Niesters et al, 2000; Leung et al, 2002;
Gottschalk et al, 2005). In the UK, its use is recommended by the Health Protection
Agency (HPA) as part of the HPA's National Standard Method's minimum testing
algorithm for EBV serology (www.hpa-standardmethods.org.uk). However, there is
as yet no consensus between laboratories as to how best to use EBV PCR as part of
current management of transplant recipients. Therefore, its use as a diagnostic and
monitoring tool varies between centres. Equally, interpretation depends on type of
samples analyzed although plasma is generally accepted as being a suitable specimen
for EBV PCR assessment. Furthermore, it is clear that a single VL assessment can
not be used to predict the likelihood of PTLD since lesions may arise in patients with
unremarkable VL (Straathof et al, 2002; Axelrod et al, 2003), and serial sampling is
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indicated. Thus, a rapid increase in VL in serial samples obtained following
transplantation may indicate increased risk of PTLD development (Gottschalk et al,
2005), and prompt reduction in immunosuppression may be indicated in such
circumstances (Lee et al, 2005). However, the role of EBV VL measurements in
assessing treatment response to PTLD therapy, and in predicting risk of PTLD
relapse, is still unclear since recent studies have not shown a clear correlation
between EBV VL and clinical course (Hopwood et al, 2002; Oertel et al, 2006).
3.4 EBV-Association And Pathogenesis
EBV is found in around 90% of PTLD. EBV DNA, mRNA and (mostly
latent) viral proteins have been demonstrated in PTLD tumour cells (reviewed in
Williams & Crawford, 2006), and this full latent viral gene expression strongly
suggests that the virus plays a major role in EBV+ve PTLD pathogenesis. Indeed, it
may be the only driving force behind outgrowth of early, hyperplastic lesions
observed shortly following primary virus infection that express all EBV latent genes.
Typically, PTLDs show such unrestricted latent viral gene expression (Young et al,
1989a; Thomas et al, 1990) although a more restricted phenotype reminiscent of HL
(absence of EBNA2 and 3 proteins), or BL (EBNA1 only phenotype), has also been
described (Cen et al, 1993; Timms et al, 2003). Equally, viral antigen expression
may be variable within (and between) tumours in the same patient.
In a minority of cells, lytic infection is evident by the finding of linear EBV
DNA and IE and, less commonly, EA and late (VCA, MA) viral proteins (Tanner &
Alfieri, 2001). Thus, viral gene expression may be heterogeneous between PTLD
lesions as well as within individual tumours. In such tumours, the role of EBV is not
entirely clear although the virus may be sufficient to drive early lesions that may
acquire genetic abnormalities and progress towards more malignant phenotype such
as the one observed in aggressive monomorphic tumours. Furthermore, in contrast to
the healthy state, EBV may infect both naive and memory B cells to give rise to
PTLD with evidence of infection of an abnormal cell. Thus, analysis of BCR Ig
heavy (IgH) chain genes showed PTLD tumour cells to consist of either naTve or
memory B cells as evident by the absence of somatic hypermutations in the former
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but not the latter malignant cell type (Timms et al, 2003). Furthermore, non¬
functional BCR mutations were detected in PTLD tumour cells that would result in
cell apoptosis of non-EBV-infected cells and immune recognition in the
immunocompetent individual. Studies by Lam et al (1997) have also described BCR-
deficient PTLD tumour cells.
PTLD cells express cell activation markers and CAMs typical of B
lymphoblasts and BLCLs. Since the majority of PTLD shows unrestricted viral gene
expression, the tumour is (in theory at least) susceptible to EBV-specific CTL
destruction. In vitro, the immunosuppressants Cy-A, FK506 and OKT3 are powerful
inhibitors of EBV-specific CTLs, and CTL activity often becomes undetectable in
peripheral blood from organ transplant recipients receiving immunosuppressive
therapy (Crawford et al, 1981b; Haque et al, 1997). Thus, immunosuppression
promotes survival of EBV+ve B cells which may lead to their unchecked
proliferation and, ultimately, PTLD. Studies by Patton et al (1990) demonstrating
clonal EBV in monoclonal PTLD suggests that virus infection occurs at an early
stage of tumorigenesis before expansion of the malignant clone. Expression of the
viral oncogenes EBNA2 and LMP1 further supports an essential role for EBV in
PTLD pathogenesis.
PTLD only develops in a minority of transplant patients and lesions are often
single and clonal in nature. Equally, late onset (often single nodal or extranodal)
PTLD is more often an EBV-negative lesion (Leblond et al, 1998; Swerdlow et al,
2000). Thus, genetic and/or epigenetic factors must play a role in PTLD pathogenesis
in addition to EBV. The microenvironment in which PTLD arises is thought to
favour EBV-driven B cell proliferation, and chronic low-grade antigen stimulation
resulting from host-verxws-graft disease in the grafted organ may cause expansion of
the EBV-infected B cell pool following virus reactivation from latently infected
cells. The non-neoplastic component in PTLD from solid organ graft recipients
consists primarily of mature CD4+ve (helper) CD45RO+ve (memory) T cells which
could act as a source of soluble growth factors that facilitate tumour growth (Thomas
et al, 1990; Perera et al, 1998). The role of CD4+ve T cells is further underlined by
studies in SC1D mice demonstrating that these cells are required for development of
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PTLD-like tumours in vivo from seropositive peripheral blood B lymphocytes (see
section 5.4.3; Johannessen et al, 2000).
3.5 Treatment
In spite of current treatment, PTLD carries a high mortality of up to 60% and
80% in solid organ and bone marrow transplant recipients, respectively (Armitage et
al, 1991; Opelz & Dohler, 2004; Svoboda et al, 2006). Adverse predictive factors
include number of anatomical sites involved, tumour monoclonality, and primary
CNS location (Leblond et al, 2001). Current treatment options for PTLD are
summarized in Table 4.
TABLE 4
Therapy Options For PTLD
First Line Treatment:
Reduction Of Tumour Mass
1. Reduction in immunosuppression with/without
nucleoside analogues (aciclovir/ganciclovir)
2. Combination of chemotherapy, radiotherapy,
surgery, and anti-CD20 mab treatment
Promotion Of CTL Activity 1. Reduction in immunosuppression






Eradication Of EBV Infection
1. Nucleoside analogues (aciclovir/ganciclovir)
2. Hydroxyurea
3. Induction of EBV lytic cycle
CTL: Cytotoxic T lymphocytes; mab: Monoclonal antibody (Adapted from Williams & Crawford,
2006)
3.5.1 Reduction Of Immunosuppression And Antivirals
Originally, PTLD treatment entailed the use of a combination of surgical
removal, irradiation and chemotherapy (Hanto et al, 1983). In 1984, however, Starzl
et al described the resolution of PTLD in 9 out of 12 (75%) kidney or liver recipients
by partial or complete withdrawal of immunosuppression alone. Reduction of
immunosuppression [alone or together with the nucleoside analogues aciclovir
(ACV) or ganciclovir (GCV) that inhibit EBV DNA polymerase and lytic replication
in vitro] is the current mainstay of primary therapeutic intervention in PTLD
although it may be accompanied by rejection of the grafted organ (Nalesnik, 1991).
This potentially life-threatening complication is of less concern in renal
transplantation where patients can be returned to dialysis. Presumably, reduction in
immunosuppression achieves reactivation of virus-specific CD8+ve T lymphocytes.
However, the effect of simultaneous use of ACV and GCV remains to be clarified
since PTLD consists largely of latently infected cells (Hanto et al, 1982; Pirsch et al,
1989).
ACV and GCV are used as prophylaxis in EBV-seronegative organ graft
recipients that receive an organ transplant from a seropositive donor. Thus,
prophylactic use of GCV to combat EBV-driven B cell proliferation in seronegative
paediatric organ graft recipients following liver transplantation has been shown to
decrease PTLD incidence (McDiarmid et al, 1998), and similar observations have
been made in heart and/or lung transplant recipients (Malouf et al, 2002). However,
it may perhaps be counterproductive to use antivirals in PTLD patients when one
considers that using valproic acid (VPA; used alongside the chemotherapeutic agent
gemcitabine) to induce lytic cycle in BLCL-inoculated SCID mice inhibited growth
of PTLD-Iike lesions in vivo. The effect of VPA was dependent on the presence of an
intact BZLF1 gene (Feng & Kenney, 2006). In line with this is a recent study by
Opelz et al (2007) demonstrating no prophylactic effect of antiviral treatment on the
incidence of PTLD development in renal transplant recipients. In contrast, however,
in their study of 44,828 recipients of cadaveric kidney transplants, Opelz et al
showed that prophylactic administration of anti-CMV Ig (used to protect CMV
seronegative recipients of seropositive organs from CMV infection) resulted in
complete protection against PTLD development during the first year (period of Ig
administration) post-transplant. Since most available anti-CMV Ig preparations
contain antibodies against EBV proteins, such prophylactic Ig use may be directed
against EBV infection although non-specific immunomodulatory effects may also
have a role to play.
Whilst reduction of immunosuppression has been of most benefit in the
treatment of polyclonal, polymorphic lesions, it may also result in regression of
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tumours containing oligo- or monoclonal tumour cell populations (Nalesnik et al.,
1992). On the whole, 40-86% of paediatric, and 25-63% of adult, organ graft
recipients experience remission following reduction in immunosuppression but
mortality is high (up to 90%) if patients do not respond to this treatment form
(Gottschalk et al, 2005; Taylor et al, 2005). Equally, relapsed PTLD is difficult to
treat with reduction of immunosuppression alone.
3.5.2 Conventional Therapy
Chemotherapy, radiotherapy and surgery still have a role in PTLD
management. Thus, a combination of these treatment forms may be used alongside
reduction in immunosuppression, or when tumours either fail to respond to such an
approach or relapse occurs (McCarthy et al, 1997; Koffman et al, 2000; Bollard et
al, 2003). Inclusion of low-dose chemotherapy to minimize its inherent toxicity may
then be appropriate (Gross et al, 2005). Equally, a combination of conventional
therapeutic options may be employed when reduction in immunosuppression may
result in loss of a life-saving organ graft such as a heart (Webber et al, 2006). Thus,
radiotherapy and surgical resection have been used successfully in patients with
localized PTLD lesions (Newstead, 2005: Foroncewicz et al, 2006).
3.5.3 Cytokines
The immunomodulatory effects of cytokines have been used against PTLD.
For example, Shapiro et al (1988) successfully used recombinant IFNa (a CTL and
NK cell stimulant) with intravenous (iv) Ig to treat a monoclonal and a polyclonal
EBV-positive PTLD lesion in 2 bone marrow recipients, respectively. Furthermore,
Davis et al (1998, 2001) showed that 8 of 14 (57%) PTLD patients responded to
IFNa although 4 (29%) of them developed graft rejection. Whilst IFNa treatment
has considerable side effects (including flu-like illness), this is not the case when
anti-IL6 antibodies have been employed in PTLD management with a view to
neutralizing the B cell growth-promoting effects of 1L6. Using such murine anti-IL6
mab, Haddad et al (2001) obtained partial or complete PTLD regression in 8 of 12
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(67%) solid organ transplant recipients (that were refractory to reduction in
immunosuppression) at up to 27 months' follow-up without serious side effects.
3.5.4 Adoptive Immunotherapy
Increasingly, novel PTLD treatment strategy has focused on development of
adoptive immunotherapy with a view to providing rapid, targeted treatment that is
well tolerated. Such an approach entails the use of either adoptive (1) humoral or (2)
cellular immunotherapy.
(1) Adoptive humoral immunotherapy centres on the use of mabs directed
against surface markers of B cells. Thus, Fischer et al (1991) and Benkerrou et al
(1993, 1998) used a combination of anti-CD21 and anti-CD24 mabs to treat PTLD in
bone marrow and solid organ recipients. Whilst oligoclonal lesions responded well to
therapy, monoclonal tumours were resistant to this treatment form. However, these
murine mabs are no longer available commercially. More recently, the anti-CD20
mab 'rituximab' has been licensed for PTLD treatment (Cook et al, 1999). One
mechanism of action of rituximab is activation of antibody-directed cell cytotoxicity
(ADCC; van der Kolk et al, 2002). Whilst this humanized mouse mab (with murine
antibody variable regions) has shown great promise with up to 100% response rate in
some studies, these studies have used rituximab in therapeutic protocols that also
include reduction in immunosuppression and/or conventional treatment approaches
(for example, chemotherapy; Milpied et al, 2000; Berney et al, 2002; Gianni et al,
2003; Gottschalk et al, 2005; Oertel et al, 2005). In contrast, in a (prospective) phase
2 trial to examine the safety and efficacy of rituximab in PTLD following solid organ
transplantation, Choquet et al (2006) treated 43 patients that did not respond to
reduction in immunosuppression with 4 weekly mab injections. At day 80, 37 (86%)
patients were alive with a response rate of 44% including 12 cases of complete
response. At day 360, 56% of patients were alive and the response rate was
maintained in 68% of patients. The overall survival rate at 1 year was 67%. Based on
their results, the group suggested a role for rituximab in a therapeutic approach that
combined different modalities (for example, reduction in immunosuppression).
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Further support for such a strategy derives from a retrospective study by Elstrom et
al (2006) who examined the clinical course of 35 PTLD patients (34 solid organ graft
and 1 bone marrow recipients) that failed to respond to reduction in
immunosuppression and received further therapy using rituximab. Patients that failed
rituximab treatment received chemotherapy. Overall, 22 patients underwent
rituximab treatment whilst 23 patients received further chemotherapy with an overall
response rate of 68% and 74%, respectively. Whilst rituximab and chemotherapy
were both effective, rituximab was well tolerated but chemotherapy was associated
with considerable toxicity resulting in death of 6 (26%) patients. The study result
suggested that rituximab is a suitable choice for management of PTLD patients who
do not respond fully to reduction in immunosuppression alone. Chemotherapy may
be reserved for patients who fail rituximab, need rapid response to treatment, or
develop EBV-ve PTLD.
Despite the overall encouraging results obtained in different studies
evaluating rituximab in PTLD therapy, tumour relapse can occur (Savoldo et al,
2005). The emergence of CD20-negative escape tumour variants has also been
observed in NHL out with the transplant setting rendering such lesions refractory to
rituximab (Davis et al, 1999).
(2) Adoptive cellular immunotherapy focuses on the use of lymphoid cells.
Our detailed understanding of immune control of EBV infection has led to
development of novel immunotherapeutic approaches to PTLD treatment based on
tumour expression of viral antigens that can be targeted by T lymphocytes. Such
novel strategies aim to restore EBV-specific T cell immune defences, and to mediate
PTLD regression without the side effects that accompany other approaches. Initial
results by Riddell et al (1992) demonstrated the potential effectiveness of adoptive
immunotherapy when they prevented CMV-induced pneumonitis in 3 bone marrow
transplant recipients using CMV-specific T cells from the seropositive donors.
Adoptive cellular immunotherapy has been shown to be very effective in
preventing and treating PTLD (Rooney et al, 1995, 1998a; Straathof et al, 2002;
Haque et al, 1998, 2002, 2007). Similarly, such an approach using autologous or
allogeneic EBV-specific CTLs has been shown to mediate regression of other EBV-
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associated malignancies such as HL (Rooney et al, 1998b; Lucas et al, 2004), and
NPC (Straathof et al, 2005). Generation of CTLs relies on stimulation (and
expansion) of the circulating EBV-infected memory donor B cell pool in vitro using
either BLCL, or virus gene-transfected dendritic cells (DCs), as antigen presenters
(Gottschalk et al, 2003; Wilkie et al, 2004).
In 1994, Papadopoulos et al described the infusion of unirradiated donor
leukocytes to treat EBV-associated PTLD in 5 recipients of T-cell depleted
allogeneic bone marrow transplants. Whilst 3 patients experienced long-term
remissions, they developed GVHD. The remaining 2 patients succumbed to
respiratory failure of unknown causes. Furthermore, Nalesnik et al (1997)
demonstrated regression of EBV+ve PTLD in 4 solid organ graft recipients following
treatment with autologous PBLs which had been depleted of monocytes and
stimulated in vitro with IL2 for 10-11 days prior to their infusion (lymphokine-
activated killer cells, LAK cells). Whilst 2 patients developed controllable graft
rejection, 3 patients remained disease-free for up to 16 months post-infusion, and 1
patient died of unrelated pneumonia. 3 graft recipients with EBV-ve PTLD failed to
respond to this treatment form. The group has also shown LAK cells to be effective
in a SCID mouse model of PTLD (Randhawa et al, 1998).
EBV-specific CTLs have been expanded in vitro for use in PTLD patients. In
1995, Rooney et al reported the use of neoR-marked autologous EBV-specific
CD4+ve/CD8+ve polyclonal CTL lines produced ex vivo from donor leukocytes to
prevent PTLD in 10 bone marrow recipients without GVHD. It was possible to
regenerate marker gene neoR+ve CTLs from peripheral blood of recipients in vitro
for up to 18 months after infusion (Heslop et al, 1996; Bollard et al, 2004). The
group also demonstrated curative effects of CTL infusions in 2 bone marrow
recipients with established PTLD (Rooney et al, 1998a). These initial studies also
uncovered evidence of CTL selection of tumour escape (EBNA-3b deletion) mutants
in a third PTLD patient who succumbed to the disease despite CTL therapy
(Gottschalk et al, 2001) raising the possibility of such treatment resistance. An
overview of studies employing CTL immunotherapy against EBV-associated PTLD
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The situation for CTL therapy is somewhat more complex in solid organ
transplant patients since donors of such organs are often not available, or suitable, to
donate T cells for in vitro expansion. In contrast, the use of polyclonal autologous
patient-derived CTLs has proven to be of some benefit in prevention (Haque et al,
1998; Comoli et al, 2002) and treatment (Khanna et al, 1999; Sherritt et al, 2003) of
PTLD. In a pilot dose escalation study in solid organ graft recipients, ex vivo-
expanded autologous EBV-specific CTLs were infused into 3 adult seropositive
recipients (2 liver and 1 kidney; Haque et al, 1998). Peripheral blood CTLp
frequency (as measured by limiting dilution analysis) increased above pre-infusion
levels and remained high for up to 3 months post-infusion concomitant with a
significant fall in EBV DNA VL during that period as measured by PCR. Similar
observations were made by Comoli et al (2002) in 7 solid organ transplant recipients,
and PTLD did not develop in either study. In further studies by Khanna et al (1999)
and Sherritt et al (2003) on 2 solid organ transplant recipients suffering from PTLD
demonstrated the effectiveness of autologous CTLs in mediating tumour regression.
Despite an immunosuppressive drug regime, it has been possible to generate such
CTLs from seronegative organ graft recipients that experienced a primary EBV
infection post-transplant (Khanna et al, 1999).
The use of autologous CTLs remains a challenge since in vitro expansion of
the cells is labour intensive, costly, and takes up to 12 weeks. The last point is
particularly poignant since such a delay means that specific therapy may come too
late for PTLD sufferers. In order to circumvent the technical difficulties of using
autologous T lymphocytes, Haque et al set up and characterized a frozen tissue bank
of around 100 EBV-specific CTLs expanded in vitro from healthy blood donors
(Wilkie et al, 2004). Initial studies using CTLs from this tissue bank on a 'best MHC
match' basis demonstrated PTLD regression in a liver/intestine transplant recipient
(Haque et al, 2001). Using the same approach in a phase I/II clinical trial, Haque et
al (2002) infused allogeneic CTLs into 7 solid organ (2 liver, 3 liver/small bowel, 2
kidney) and 1 bone marrow transplant patients with EBV+ve PTLD. Of the 5
patients that completed the treatment course of 1-6 (106 CTL per kg) iv infusions of
partly MHC-matched allogeneic EBV-specific CTLs, 3 individuals experienced
complete remission whilst 2 had no clinical response. The responders showed no
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evidence of disease for up to 28 months after completion of the CTL treatment
course. Organ graft function improved in responders with no evidence of GVHD or
other side effects. Of the 3 patients that did not complete the CTL course, 1 patient
showed partial response whilst 2 patients died rapidly of causes unrelated to CTL
infusion.
A direct role for infused CTLs in mediating EBV+ve tumour destruction has
been obtained in a study demonstrating complete regression of a primary cerebral
EBV+ve B cell lymphoma in a child with primary immunodeficiency and, thus, no
functional EBV-specific CTLs of her own (Wynn et al, 2005). The infused
allogeneic CTLs were able to access CNS which is in line with previous studies
showing that B and T lymphocytes can access the brain (Hickey et al, 1991; Anthony
et al, 2003). Furthermore, Gandhi et al (2007) have recently shown homing of
infused allogeneic CTLs generated in vitro from a healthy male blood donor to
pulmonary PTLD arising in a female lung transplant recipient. The PTLD was of
recipient origin. Using fluorescent in situ hybridisation and immunostaining, the
group demonstrated XY (male) chromosomes in CD8+ve T cells within the tumour
mass.
Recently, Haque et al (2007) reported the overall results at 6 months post-
transplant of the first phase II multi-centre clinical trial using allogeneic CTLs
against EBV+ve PTLD. Using their EBV-specific CTL bank, allogeneic CTLs were
selected based on (1) a ' best MHC-match', and (2) the results of EBV-specific
cytotoxicity in vitro as measured by 51Cr-release assays. At the time of receiving
CTL lines, PTLD patients had already failed a regime of conventional PTLD
treatment (see Table 4 above). Overall, 33 PTLD patients received weekly CTL
(2x106 per kg) infusions for 4 weeks and were monitored for between 6 months and 2
years with no adverse effects of CTL infusions observed. At 6 months, 14 patients
had experienced complete remission of disease, and a further 3 patients were in
partial remission. 16 patients showed no response to immunotherapy. Thus, 17 (52%)
of patients treated with CTLs showed complete or partial remission 6 months after
receiving the last CTL dose. There was a significant trend towards a better
therapeutic response with higher numbers of CD4+ve T cells in the transferred CTL
populations. Equally, a significant correlation was found between the level of MHC
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matching and therapeutic success. Using such a well-characterized CTL tissue bank
on a 'best MHC match' basis circumvents lengthy and labour-intensive in vitro
expansion of autologous CTLs for individual patients and offers instead a ready
source of effective PTLD therapy in a poor prognosis patient group.
In light of the above studies, adoptive immunotherapy using CTLs targeted
against virus-derived antigens on a 'best MHC match' basis appears to be effective,
safe, rapid, and potentially applicable to other systems where a suitable tumour-
specific target antigen is known. Thus, any tumour-specific antigen can potentially
be targeted in this manner. Furthermore, genetically engineering CTLs to express
TCRs that specifically recognize antigens on the surface of malignant cells using an
antibody construct (or single variable chain antibody fragment, scFv) circumvents
MHC restrictions. The use of scFv to recognize target antigens on a tumour cell
surface has shown great promise (see General Discussion). However, it is important
to study such new treatment strategy in vitro and in vivo prior to introduction into
clinical practice.
3.5.5 Testing Of Novel PTLD Treatment
PTLD biopsy material available for research is limited, and the few
established biopsy-derived cell lines available differ phenotypically from the tumour
cell type and are, therefore, not an accurate in vitro model for the disease (Cen et al,
1993). Consequently, PTLD has been modelled in various animals including severe
combined immunodeficient (SCID) mice which offer valuable insight into PTLD
development. Equally, SCID mice can be used to trial new PTLD prophylaxis and
treatment such as novel adoptive immunotherapy.
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4. Use Of Animals In Research
In order to answer a scientific question of paramount importance, animals can
be employed provided a suitable in vivo model is available and no in vitro systems
can be used [for alternative model systems, see the 'Fund for the Replacement of
Animals in Medical Experiments' (FRAME) website: www.frame.org.uk].
Furthermore, it must be ensured that the most appropriate animal model, animal
procedures, and animal numbers are used in order to obtain meaningful results whilst
guarding animal welfare.
In the UK, use of animals in research is strictly controlled by the Home
Office 'Animals (Scientific Procedures) Act 1986' (for further information, see the
website: www.homeoffice.gov.uk/animalsinsp/). This entails that all research work
involving animals must have met with the approval of local Ethical Review
Committees as well as being specifically licensed ('Project Licence'; PPL) by the
Home Office. Furthermore, all staff carrying out animal procedures must be
specifically licensed ('Personal Licence'; PIL) by the Home Office. The Act is
enforced by Home Office Inspectors with additional support from Named Veterinary
Surgeons who oversee animal welfare. As part of any in vivo experimental work,
constant efforts are made to (1) reduce the number of animals used (Reduction), (2)
refine the experimental approach (Refinement), and (3) replace animals with in vitro
models whenever possible (Replacement) - the so-called '3 Rs' that Home Office
guidance requires PIL and PPL Holders to address continuously throughout any
project/licensing period.
61
5. Animal Models For EBV-lnduced Diseases
Non-human primates have traditionally been used to model EBV-associated
diseases (for an overview of animals used for this purpose, see Table 6). However,
Old World species are naturally infected with related simian herpesviruses in the
same lymphocryptovirus (LCV) genus as EBV and are, thus, immune to EBV
infection due to cross-reacting antibodies (Gerber & Birch, 1967; Landon & Malan,
1971; Frank et al, 1976; Deinhardt & Deinhardt, 1979). Over 95% of adult Old
World non-human primates harbour LCV whether in the wild or held in captive
colonies (Landon & Malan, 1971; Jenson el al, 2000; Rao et al, 2000), and the
biology of LCV infection appears to parallel closely that of EBV in humans (Wang
et al, 2001).
In light of the above, and the observation that there was (until recently) no
solid evidence to suggest that LCV infected New World non-human primates,
experimentally EBV infected New World species became widely used in vivo models
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5.1 New World Non-Human Primates:
Common Marmoset And Cottontop Tamarin
New World non-human primates are susceptible to EBV infection. The (1)
common marmoset (Callithrix jacchus) and the (2) cottontop tamarin (Saguinus oedipus
oedipus) have been used to model EBV-associated diseases.
(1) The common marmoset is a model for primary and persistent EBV
infection. Following experimental intramuscular (im) or intraperitoneal (ip) infection of
the animals, an IM-like lymphocytosis is observed in some animals together with anti-
VCA and anti-EA antibody-like responses similar to IM (Falk et al, 1976; de The et al,
1980). EBV DNA is detected in lymphoid tissues (Cox et al, 1996). Furthermore,
regular detection of salivary EBV DNA (buccal fluid) and long term detection of EBER
transcripts (by RT-PCR) in PBLs indicates persistent EBV infection (Cox et al, 1996;
Farrell et al, 1997). The animal has been used for vaccine studies. However,
immunization of the common marmoset using the envelope gp350 antigen does not
prevent EBV infection although reduced virus is detected in buccal fluid (Cox et al,
1998). EBV-associated lymphomas do not develop in virus-infected common
marmosets.
(2) The cottontop tamarin is a model for persistent EBV infection and
lymphomagenesis. The tamarin consistently develops multifocal EBV+ve large cell
lymphomas following im and/or ip EBV inoculation (Shope et al, 1973; Cleary et al,
1985). Since the tumours express all the viral latent genes (Young et al, 1989b) and
mirror PTLD, the cottontop tamarin has played an important role as a model in which to
study candidate EBV vaccines. Since the original suggestion by Epstein in 1976 that
EBV vaccination would not only control EBV-associated malignancies but also establish
the role of EBV in oncogenicity in man, these efforts have been based on the gp350/220
envelope protein (Epstein, 1976). Although immunization of cottontop tamarins with a
subunit vaccine does not afford sterile immunity since EBER transcripts continue to be
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detected in lymphoid tissue of immunized animals (Niedobitek et al, 1994), gp350/220
vaccines provide protection against EBV-induced lymphomas (Epstein et al, 1985).
New World primates are endangered (but bred in captivity), rare and costly.
Furthermore, recent studies have shown that New World species are naturally infected
with LCV, further undermining their use to model EBV infection and disease. Thus, Cho
et al (2001) isolated a B cell-immortalizing LCV from a B cell lymphoma arising
spontaneously in a common marmoset. Additionally, PCR studies detected this
marmoset LCV (mLCV) in three different marmoset colonies and a similar LCV was
also found in (New World) squirrel monkeys suggesting widespread infection.
Additional studies have confirmed that LCV can be found in a number of New World
species (Jenson et al, 2002; Ehlers et al, 2003). The mLCV genome has been sequenced
(Rivailler et al, 2002a,b) and is strikingly different from that of EBV as it lacks a
number of EBV (and Old World rhesus LCV, rLCV) homologue genes (for example,
EBERs and BARTs) suggesting that mLCV is a primitive relative of EBV, and that EBV
evolved in higher order primates. The resulting biological differences between the two
viruses are not yet known. The genomic sequence divergence between mLCV and EBV
does explain, however, why New World species can be infected with EBV and why
mLCV went undetected for so long since previous studies used EBV-derived antigens in
their screening assays. Only around 40-60% of captive marmosets tested harbour mLCV
(Fogg et al, 2005) which is in sharp contrast to rLCV and EBV which ubiquitously
infect Old World rhesus macaques and humans, respectively.
5.2 Old World Non-Human Primates:
Rhesus And Cynomolgus Monkeys
The best studied LCV are those detected in the (1) rhesus (Macaca mulatta) and
(2) cynomolgus (Macaca fascicularis) monkeys.
(1) Rhesus monkeys are naturally immune to EBV infection which is similar to
other Old World non-human primates. In an attempt to create a new model for EBV
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infection, Moghaddam et al {1997) orally infected 2 nai've rhesus monkeys with a rLCV
(see 5.1 above) naturally endemic in rhesus monkeys. The animals developed an IM-like
response with T cell lymphocytosis and activated CD23+ve B cells in peripheral blood
together with cross-reacting antibodies to EBV latent (EBNA2) and lytic (VCA) viral
proteins. Intermittent oropharyngeal shedding of virus and outgrowth of spontaneous
rLCV+ve BLCL in vitro confirmed persistent rLCV infection during a 1.5 year
observation period. Persistent infection conferred protection against re-challenge with
virus in 1 animal tested. The rLCV genome has been sequenced demonstrating a high
degree of sequence homology to EBV as well as an identical repertoire of viral genes
(Rivailler et al, 2002a,b). Based on EBNA2 homologue gene polymorphism, two
different rLCV types ('type 1' and 'type 2') have been delineated suggesting similar
selective pressures for human and non-human primate hosts in terms of rLCV evolution
(Cho et al, 1999). In further studies, Moghaddam et al (1998) found that rLCV and EBV
failed to immortalize human and rhesus B cells in vitro, respectively, despite
conservation of the CD21 (EBV receptor) binding domain of the rhesus major
membrane glycoprotein suggesting species-specific restrictions to infection occurring
beyond virus binding and penetration. The rhesus model has also been used to study
CTL-mediated immune control of rLCV infection (Fogg et al, 2005, 2006).
(2) Cynomolgus monkeys have been considered for EBV research. Whilst
spontaneous lymphomas are uncommon in Old World monkeys, concomitant infection
with simian immunodeficiency virus (SIV) markedly increases their occurrence (Hunt et
al, 1983; Baskin et al, 1986). Thus, up to 40% of cynomolgus monkeys develop high-
grade B cell lymphomas when infected with SIV but the requirement for SIV-induced
immunosuppression prevents the use of the model for PTLD studies. In an effort to
create a non-human primate model of PTLD, Schmidtko et al (2002) carried out 160
renal allograft transplants in cynomolgus monkeys over a 5 year period under an
immunosuppressive regime that included Cy-A. 9 (5.6%) animals developed
cynomolgus LCV-associated (cLCV; Feichtinger et al, 1992) B cell (predominantly
polymorphic) PTLD-like lesions 28-103 days post-transplant. Of the 9 PTLD cases, 6
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animals succumbed to multiorgan failure secondary to PTLD whilst the remaining 3
monkeys died of GVHD as well as acute and chronic rejection. The potential effect of
PTLD treatment (for example, reduction of immunosuppression) was not investigated
nor was adoptive immunotherapy considered. Similar studies in SIV-infected rLCV-
infected rhesus monkeys have demonstrated outgrowth of rLCV-associated B cell
lymphomas (Rivailler et al, 2004).
5.3 Murine Herpesvirus 68 (MHV68)
Many aspects of murine herpesvirus 68 (MHV68), a y-herpesvirus originally
isolated from the bank vole (Clethrionomys glareolus) in Slovakia (Blaskovic el al,
1980), parallel that observed during EBV infection, and MHV68 has provided insight
into y-herpesvirus infection in vivo.
Primary MHV68 infection occurs in the lung, and experimental intranasal
infection of Balb/c mice with MHV68 results in lytic virus infection of lung alveolar
epithelium. Persistent infection is established in murine B cells although lung
epithelium, macrophages and DCs can also support persistent infection (reviewed in
Nash et al, 2001; Olivadoti et al, 2007). An IM-like syndrome occurs 3 weeks after
primary infection with a major expansion of Vp4+ve CD8+ve T cells (Tripp et al, 1997)
although the exact manner in which the T cell proliferation is driven remains to be
elucidated (a putative MHV68-encoded sAg was proposed at the time). Whilst CD8+ve
T cells control both lytic and latent in vivo infection (Braaten et al, 2005), CD4+ve T
cells are important in inhibiting reactivation of replicative infection in lung epithelium.
During primary MHV68 infection, large amounts of IFNy are produced by
lymphoid tissue. In their study of mice lacking the IFNy cell surface receptor (IFNy R-/-
mice), Dutia et al (1997) failed to detect any differences in virus titres in lung (or rate of
clearance of lung infection) in IFNy R-/- mice compared to wild type animals. In
contrast, splenic tissue from IFNy R-/- mice showed marked fibrotic changes
accompanied by increase in latently infected B cells. Additionally, fibrosis was observed
67
in the lung (Ebrahimi et al, 2001). These changes were dependent on the presence of
CD8+ve T cells and (to a certain extent) CD4+ve T lymphocytes. Further studies by
Mora et al (2005) have demonstrated progressive deposition of interstitial collagen in
lungs of MHV68-infected IFNy R-/- mice which can be used to model idiopathic
pulmonary fibrosis (IPF). IPF is a progressive, fibrotic lung disease of unknown etiology
in humans that is associated with chronic lung infection with one or more herpesviruses
(including EBV). Lytic MFIV68 infection is associated with IPF in mice, and antiviral
treatment is of benefit in vivo (Mora et al, 2007).
Vaccination studies using gpl50 (EBV gp350/200 homologue) have been unable
to prevent lytic or latent MHV68 infection in vivo although infection following
vaccination does not result in an IM-like syndrome (Stewart et al, 1999).
MHV68+ve lymphoproliferative disease (LPD) develops in a few MHV68-
infected mice. Thus, in a study of 220 persistently infected animals, 20 (9%) mice
monitored for up to 3 years developed MHV68+ve LPD, and immunosuppression with
Cy-A increased the incidence to 60% (Sunil-Chandra et al, 1994). Although the exact
role of the virus in LPD outgrowth remains to be clarified, a LPD-derived MHV68+ve
cell line gives rise to tumours in nude (athymic; devoid of T cells) mice (Usherwood et
al, 1996).
5.4 Severe Combined Immunodeficient (SCID) Mouse
The SCID mouse readily accepts human xenografts due to a lack of functional B
and T cells. The animal has become a valuable tool to study PTLD pathogenesis and
novel treatment strategy since the discovery that EBV+ve PBL engraft in SCID mice
('hu-PBL-SCID') and give rise to EBV+ve PTLD-like tumours (Mosier et al, 1988).
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5.4.1 Biology
The murine SCID mutation was originally described in inbred CB.17 mice by
Bosma et al in 1983. The mutation, which is heritable as a single autosomal recessive
(SCID) gene on mouse chromosome 16, leads to impaired function of the 'protein
kinase, DNA activated, catalytic polypeptide' ('Prkdc') enzyme which is essential in
repairing dsDNA breaks and in recombining the variable (V), diversity (D) and joining
(J) genes of functional BCRs and TCRs (Fulop & Phillips, 1990; Bosma & Carroll,
1991). Since V(D)J gene recombination does not proceed, differentiation of mature B
and T cells is severely impaired, and mice homozygous for the mutant gene
(SCID/SCID) are profoundly deficient in functional B and T lymphocytes. Therefore, the
animals are unable to mount humoral or cellular adaptive immune responses, and can
not reject allogeneic or xenogeneic tissue grafts. Since the animals have little or no
immunity, they readily succumb to infections if they are not kept within a specific
pathogen free (SPF) environment such as the one that is afforded by individually
ventilated (microisolator) cages (IVCs) and handled using aseptic technique. However,
erythroid, myeloid and NK cell differentiation is normal (reviewed in Ansell &
Bancroft, 1989).
In maturing lymphocytes of SCID mice, appropriate V(D)J BCR and TCR
coding sequences are not joined together properly such that a non-productive antigen-
receptor gene rearrangement leads to abortive lymphocyte differentiation and deletion of
B and T cell clones. However, this recombinase defect is not complete and around 2-
23% of 3-9 months' old ('leaky') SCID mice develop a small number of functional B
and T cells with a few B cell clones secreting Ig (Bosma et al, 1988). Although
spontaneous thymic T cell lymphomas develop in up to 15% of SCID mice (Custer et al,
1985), spontaneous B cell tumours have not been described.
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5.4.2 Xenoreactivity
Tary-Lehmann et al (1994) demonstrated in a study on the human T cell
repertoire in PBL-injected SCID mice that the mouse-derived human cells were in a
state of anergy when harvested from mice after 30-90 days' in vivo growth. Cell lines
established from these T cells regained their antigen-responsiveness after in vitro
culture, and the CD4+ve T cell subset displayed reactivity only against murine MHC2
antigens. Thus, the results suggested that only xenoreactive human T cell clones survive
long-term in vivo. Based on their observations, Tary-Lehmann et al (1995) proposed that
GVH reactivity determined long-term human T cell survival in SCID mice. However,
the impact of GVH reactivity on human PBL engraftment in vivo varies between
different laboratories and depends, for example, on numbers of transferred cells and the
health status of the SCID mouse colony (Dick, 1994; Huppes et al, 1994). Thus,
different investigators report subclinical to lethal GVH reaction (Mosier, 1991; Murphy
et al, 1992; Hoffmann-Fezer et al, 1993). Current thinking is that a GVH reaction occurs
during xenograftment of SCID mice but that it is generally asymptomatic (Murphy et al,
1996).
5.4.3 Modelling PTLD
Studies on EBV tumorigenesis in SCID mice have generally employed 3
methods of xenograft implantation: (1) ip inoculation of EBV+ve human PBLs ('hu-
PBL-SCID' model; reviewed in Bankert et al, 2001); (2) inoculation/implantation of
patient tumour biopsy material (for example, ip implantation of PTLD biopsy material:
'hu-Bx-SCID' model); and (3) inoculation of human tumour cell lines [for example,
subcutaneous (sc) or ip inoculation of BLCLs: 'hu-BLCL-SCID' model].
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Hu-PBL-SCID Mouse Model
As part of efforts to establish a small animal model for research on human
immunodeficiency virus (HIV), Mosier et al reported in 1988 the engraftment of human
leukocytes in SCID mice that had been inoculated ip with human PBLs (hu-PBL-SCID).
Transfer of PBL resulted in a functional human immune system (as evidenced by tetanus
toxoid-specific human antibody responses following immunization) in mice whose
peripheral blood and lymphoid tissues were populated with human leukocytes long-term.
Thus, the animals were 'humanized' in terms of their immune system. Furthermore, the
group described outgrowth of EBV+ve human B cell lymphomas in their hu-PBL-SCID
mice. Specifically, PBLs from 80% of their EBV-seropositive donors gave rise to ip
tumours when each animal was inoculated with >5x107 leukocytes although subsequent
studies showed seropositive donors to differ markedly in their cells' ability to give rise
to ip tumours in vivo (Picchio et al, 1992). Thus, our laboratory has observed that PBLs
from 64% of an EBV-seropositive donor panel gave rise to EBV+ve B cell lymphomas
in the hu-PBL-SCID mouse model with a median tumour incidence of 67%
(Johannessen et al, 2000). Tumours developed after a median time of 62 days (range:
33-102 days). The panel varied in the ability of PBLs to cause tumours in SCID mice
although leukocytes from each donor gave reproducible results. Based on the results, our
donor panel could be classified according to tumour incidence in SCID mice into (1)
'high' (71-100% of mice), (2) 'intermediate' (31-70%), (3) 'low' (1-30%), and (4) 'no'
(0%) incidence donors (Picchio et al., 1992; Johannessen et al., 2000). Such
classification reflects some as yet unclear qualitative differences between healthy virus
carriers in terms of the ability of their EBV+ve B cells to give rise to PTLD-like tumours
in vivo. Around 25% of the donor panel were high and no incidence donors each
whereas approximately 50% of the panel were intermediate/low incidence donors.
Transfer of human PBLs ip into SCID mice triggers influx of murine neutrophils
into the peritoneal cavity with concomitant production of the murine cytokines IL4, 6,
10, 12 and IFNy (Santini et al, 1995). Of these growth factors, only murine IL12 has an
effect on human cells and, thus, the influence of these factors on tumour development in
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vivo must be limited. Murine IL12 is produced by peritoneal macrophages and promotes
differentiation of human and murine Thl cells and production of IFNy. This may explain
preferential survival of human Thl cells in vivo (Tripp et al, 1993; Amadori et al, 1996)
which may influence any observed cytokine interactions in SCID mice. Thus,
conclusions based on the relative importance of a Thl versus Th2 cytokine expression
profile may need to be transferred with caution from the hu-PBL-SCID model to the
human setting.
The experimental design for the hu-PBL-SCID mouse model has not yet been
standardized between laboratories which makes study comparisons difficult because of
variables such as cell numbers injected and qualitative differences between PBL donors.
Equally, pre-conditioning of mice to facilitate engraftment of transferred PBLs (defined
as total human Ig >1 pg/mL of murine serum; Hesselton et al, 1993) can be employed
using methods such as depletion of murine NK cells with rabbit anti-murine asialo GM1
(ASGM1) antiserum and/or x-irradiation of mice. Again, there is no consensus
agreement as to the use of such techniques and they have produced variable results. An
alternative to SCID mice are non-obese diabetic (NOD)/SCID mice that are also
deficient in endogenous NK cell activity (Shultz et al, 1995), and the animals have been
used for modelling PTLD in vivo. In contrast to hu-PBL-SCID mice, hu-PBL-
NOD/SCID animals are resistant to ip outgrowth of human PTLD-like tumours unless
CD8+ve T cells are depleted in vivo using anti-human CDS mab (Wagar et al, 2000)
which is a situation reminiscent of the organ transplant recipient. Transfer of autologous
CD8+ve T cells into such CD8-depleted animals restores resistance to ip tumour
development. In the hu-PBL-NOD/SCID model, long-term systemic human B cell, T
cell, monocyte and DC homeostasis is achieved in vivo following transfer of human
bone marrow CD34+ve progenitor cells into pre-conditioned (sublethally y-irradiated)
animals implanted previously with autologous human fetal liver and thymic tissues
('BLT mice'; Melkus et al, 2006). Furthermore, the human T cells can mount an MHC-
restricted immune response to EBV in vivo following virus challenge as manifest by (1)
expansion of CD45RA-ve, CD27+ve memory T cells in vivo, and (2) T cell IFNy
production in vitro in the presence of autologous BLCLs.
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EBV+ve B cell tumours that arise in the hu-PBL-SCID model are immunoblastic
lesions that express B cell activation markers and CAMs akin to that observed in BLCLs
and PTLD (Rowe et al, 1991). In contrast to PTLD, however, established lesions show a
paucity of human T cells. Tumours present as solitary or multifocal masses (or as
leukaemic-type infiltrates) in lymphoid tissue of the murine hepatic porta and within
liver parenchyma or, less frequently, in lung, mesentery, spleen or thymus. Similar to
PTLD, EBV DNA is detected in tumour cells which express all (unrestricted) virus
latent genes with a small number of cells expressing lytic viral proteins. The lesions,
which have a normal karyotype, are mono-, oligo- or polyclonal, and Ig clonally distinct
tumours can arise in mice harbouring multifocal masses.
Analysis of EBV clonality has demonstrated that PBLs from high incidence
donors give rise to tumours containing multiple viral episomes, linear DNA, and
immortalizing virus reflecting lytic infection in vivo (Picchio et al, 1992). Conversely,
lesions from intermediate-low incidence donors (and BLCL) often contain clonal EBV,
and linear DNA is infrequently found. In 1995, Rochford and Mosier further highlighted
qualitative differences in tumours in hu-PBL-SCID mice. In their studies, lesions were
found to consist of two B cell subsets: intermediate levels of the B cell activation marker
CD23 and the plasma B cell marker CD38 on one B cell subset correlated with latent
viral gene expression, whereas lytic cycle and infectious virus was found in B cell
populations expressing low levels of CD23 and high levels of CD38. Based on their
results, the group proposed a step-wise model of lymphomagenesis in hu-PBL-SCID
mice that entailed (1) proliferation of latently infected B cell blasts, (2) their
differentiation into plasma cells concomitant with lytic EBV infection, and (3) virus
infection and recruitment of uninfected B cells leading to tumour outgrowth.
Somewhat in contrast to the above 3-step model, a study of 10 EBV-seropositive
(4 high, 4 intermediate, 1 low and 1 no incidence) healthy blood donors from our
laboratory aimed at addressing qualitative differences in their EBV infection failed to
demonstrate a correlation between tumour formation in SCID mice and (1) spontaneous
in vitro outgrowth of BLCLs from PBLs, (2) PBL EBV DNA VL by PCR detection, and
(3) in vitro regression assay as a measure of host CTL immunity to EBV (Johannessen et
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al, 1998). Since each assay tested gave consistent results, the study suggested that each
assay measures a different aspect of EBV infection of B cells. This may reflect
heterogeneity of circulating EBV-infected B cells, or different behaviour of such cells
under different experimental conditions. Our results suggest, therefore, that tumour
formation in the hu-PBL-SCID mouse is not a direct function of direct B cell outgrowth,
EBV VL, or CTL activity. However, an interplay of all these factors may be
instrumental in tumour development in vivo. In light of the results, it was important to
delineate which factors are required for tumour formation in vivo.
Cell Populations Required For PTLD Development
Tumour incidence in the hu-PBL-SCID mouse model is significantly reduced
when B cells are inoculated without T cells. Thus, Veronese et al showed in 1992 that
EBV+ve B cells from seropositive PBL donors do not give rise to ip tumours in SCID
mice unless CD4+ve or CD8+ve T cells are transferred together with B cells. Studies
from our laboratory confirm the requirement for T cells in the inoculum for tumour
development. Our results showed that tumour incidence was dramatically reduced from
76% to only 7% (representing only 1 tumour) when CD4+ve T helper cells were
removed from the inoculum (Johannessen et al, 2000). Furthermore, removal of CD8+ve
cytotoxic, CD30+ve activated, CD45RA+ve nai've, or CD45RO+ve memory T cells
resulted in less, but significant reduction of tumour incidence. The results of the
CD45RA- and CD45RO-depletion experiments probably reflect a reduction in numbers
of inoculated CD4+ve and CD8+ve T cell subsets since CD45RA or CD45RO antigens
are expressed on both T cell subsets. Our data contrast with those of Veronese et al
(1992) who found only minor (not significant) changes in tumour incidence in hu-PBL-
SCID mice inoculated with B cells together with either CD4- or CD8-depleted
leukocytes when compared with PBL-injected animals.
In light of the above results, we concluded that T cell-B cell contact and/or
soluble T cell growth factors promote in vivo B cell proliferation and tumorigenesis.
Furthermore, when we treated T cells in vitro with the mitogen phytohaemagglutinin
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(PHA) prior to transfer ip into SCID mice, PBLs from high/intermediate donors gave
rise to ip tumours more rapidly in vivo whereas cells from low/no incidence donors were
not affected (Johannessen et al, 2000). The results suggest that T cells from the 2 donor
groups differ qualitatively in their ability to provide EBV+ve B cells with either
necessary soluble growth factors or growth-promoting signals through cell-to-cell
contact necessary for tumour formation in hu-PBL-SCID mice. Support for this
conclusion comes from a study by Coppola et al {1998) who noted that PBL from atopic
individuals are less likely to give rise to ip tumours in SCID mice than healthy controls.
The group suggested that qualitative differences in Thl/Th2 cell subset profiles
contributed to the observed inter-donor variability in tumour development in vivo.
Further studies on such qualitative differences between T cell subsets have focused on
the role of growth factors (cytokines) in tumour formation in the hu-PBL-SCID model
since antibody-stimulation of the B cell CD40 costimulatory molecule (mediated via
cell-to-cell contact) inhibits rather than promotes tumour development in vivo
(Funakoshi et al, 1997).
Human Cytokines And The SCID Mouse
Based on results from our laboratory, we have proposed that EBV+ve B cells
require T cell help in the form of soluble growth factors at an initial stage of
lymphomagenesis in the hu-PBL-SCID model. Such a hypothesis explains the need for
T cell subsets to be included together with EBV+ve B cells in the inoculum at the time
of mouse injection. We also postulate that malignant B cells acquire the ability to
produce necessary growth factors in an autocrine manner as part of the malignant
process. Therefore, established tumours become independent of T cell help in vivo
which could explain why T cells are conspicuously absent from such lesions. To test our
hypothesis, we have analyzed (by RT-PCR) the human cytokine expression profile of
human PBL-derived tumours obtained in the hu-PBL-SCID model. All tumours
examined were found to express human IL10 and IFNy, and the majority also expressed
IL2, 4 and 6. IL5, a B cell and eosinophil growth factor, was not detected in any tumour
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tested. The observed cytokine profile is similar to that seen in activated T cells (and
BLCLs), and all of these cytokines can stimulate growth and/or differentiation of B
cells. Furthermore, in situ hybridisation studies using EBER and cytokine probes on
serial tumour sections have confirmed the RT-PCR results. Elowever, in preliminary
experiments in our laboratory in which either human 1L4 or IFNy were neutralized in
vivo in hu-PBL-SCID mice using sc transferred x-irradiated hybridoma cells producing
mabs to these cytokines, we did not observe a significant difference in tumour outgrowth
between test and control mice. These results suggest that neither IL4 nor IFNy on their
own are essential in tumour formation in vivo thus highlighting overlap in function
between different cytokines.
The above results suggest that in hu-PBL-SCID mice, malignant cells supply
themselves with B cell growth factors in an autocrine-stimulated fashion suggesting a
direct role for the tumour cells in their own cytokine production. IL6 and IL10 are both
found in serum from tumour-bearing hu-PBL-SCID mice (Veronesi et al, 1994;
Baiocchi et al, 1995), and IL6 confers a malignant phenotype on BLCL in T cell-
deficient athymic (nude) mice (Scala et al, 1990). However, inhibiting IL6 in vivo with a
view to hinder tumour development has given inconclusive results. LMP1 induces
human IL10, and this cytokine is found at high levels in serum from tumour-bearing
SCID mice (Nakagomi et al, 1994; Baiocchi et al, 1995). Therefore, a direct role for
EBV in induction and maintenance of autocrine growth factor production in vivo is
likely.
Hu-PBL-SCID Mouse: Model Of PTLD Formation
Based on our results obtained in the hu-PBL-SCID mouse model, we have
suggested a 2-step model of PTLD formation in vivo (Johannessen et al, 2000). In our
model, (1) initial outgrowth of EBV+ve tumorigenic B cells is promoted by T cells, and
(2) the malignant B cells become independent of T cell help as the tumour cells establish
an autocrine, cytokine-mediated stimulatory loop that maintains tumour growth in vivo.
This model is supported by the findings that (a) tumour formation in vivo is dependent
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on T cell subset-derived help as shown by cell depletion experiments; (b) T cells are
scant in established lesions as demonstrated by immunostaining analysis; (c) tumours
portray a cytokine gene expression profile (as shown by RT-PCR studies) that includes
B cell growth factors; (d) the B cell growth factors are expressed by the malignant cells
themselves as demonstrated by in situ hybridisation analysis. In line with this model are
studies on primary PTLD biopsy material. Thus, Thomas et al (1990) and Perera el al
(1998) have shown that PTLD tumours arising in organ transplant recipients often
contain a large non-malignant component that consists mainly of CD4+ve T cells. Such
CD4+ve T helper cells may supply the malignant cells with necessary growth factors
and act as a 'feeder' population. Further studies in our laboratory have shown that
patient-derived PTLD biopsy material rich in non-neoplastic CD4+ve helper,
CD45RO+ve memory T cells give rise to biopsy-derived tumours in the SCID mouse
model (hu-Bx-SCID; Perera et al, 1996). In line with the hu-PBL-SCID model, the
biopsy-derived SCID tumours contain few T cells. Recently, we have also demonstrated
(by RT-PCR analysis) human IL2, 6, 10 and IFNy transcripts in the patient-derived
PTLD biopsy material and the biopsy-derived SCID tumours (see section 1 in Results;
Johannessen et al, 2002). Taken together, our studies in the hu-Bx-SCID mouse model
are in line with our results obtained in the hu-PBL-SCID mouse model and suggest that
the hu-PBL-SCID model reflects PTLD pathogenesis in the organ transplant recipient.
Our proposed model of tumour formation in the hu-PBL-SCID mouse is shown in
Figure 2 (Johannessen et al, 2000).
In line with the above model are studies by Baiocchi et al (1995) who detected
human IL10 and its receptor in tumours from hu-PBL-SCID mice and demonstrated that
human IL6 or 10 maintain fresh SCID tumour material in vitro. The group suggested
that human IL6 and 10 may play roles in an autocrine stimulatory loop promoting
tumour outgrowth in the animals.
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FIGURE 2
A Model Of Tumour Development In The Hu-PBL-SCID Mouse
EBV+ve PBL
u
Ip Transfer Into SCED Mice
U
Autologous T Cells Promote Outgrowth Of Tumorigenic EBV+ve B Cells
u
Tumour Cells Are Sustained By An Autocrine Cytokine-Mediated Loop
u
Tumour Cell Proliferation Becomes Independent Of T Cell-Mediated Help
Additionally, reduction in tumour incidence has been observed in hu-PBL-SCID mice
following administration of a neutralizing antibody against IL6 (Mauray et al, 2000),
and clinical studies by Haddad et al (2001) have demonstrated a therapeutic effect of
using neutralizing anti-IL6 antibodies in PTLD patients refractory to reduction in
immunosuppression (see section 3.5.3 above). Further support comes from analysis of
EBV+ve acquired immunodeficiency syndrome (AIDS)-related BLPD (ARE) showing
that IL6 is expressed by ARL-derived reactive lymphocytes, and from studies of PTLD
demonstrating that circulating IL6 is found at high levels in solid organ graft recipients
with EBV+ve PTLD (Emilie et al, 1992a; Tosato et al, 1993). Equally, IL10 is
expressed in EBV+ve ARL and high circulating IL10 levels are found in ARL patients
(Emilie et al, 1992b). PBL from renal allograft recipients suffering acute rejection
express high levels of numerous cytokines (for example, IL4, 10, IFNy) which decline
following treatment with the murine anti-human CD3 mab OKT3 (Platzer et al, 1994)
leading to sequestration of antibody-coated T lymphocytes in liver and spleen.
In addition to the importance of T cell subsets in tumour development in vivo,
recent studies have highlighted the role played by plasmacytoid dendritic cells (PDCs).
Thus, Lim et al (2007) have shown that EBV+ve PBLs depleted of PDC develop
tumours more rapidly in NOD/SCID mice than PBL-injected control mice. Thus, EBV-
activated PDC produced IFNa and stimulated NK cells and IFNy-producing CD3+ve T
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cells. PDC-stimulation of CD3+ve T cells was mediated by cell-to-cell contact, partly
through toll-like receptor (TLR)-9 signalling.
Cytokine gene polymorphism and individual differences in cytokine production
can influence susceptibility to certain human diseases such as cerebral malaria (McGuire
et al, 1994). Therefore, it is conceivable that inter-donor variability in tumour
development observed in the hu-PBL-SCID model may relate to cytokine gene
polymorphism involving any of the B cell growth factors expressed by the malignant
cells (for example, IL4, 6, 10, or IFNy). Based on their results, Helminen et al (1999,
2001) suggested that IL10 gene promoter polymorphism correlates with susceptibility to
primary EBV infection, and that low IL10 production resulting from such mechanisms
renders individuals more susceptible to primary EBV infection. Therefore, IL10 gene
polymorphism could perhaps increase PTLD risk in seronegative organ graft recipients
by increasing their risk of primary EBV infection post-transplant. Recent studies by Lee
et al (2006) show that using genotyping to detect the adenosine/adenosine (A/A) IFNy
cytokine gene polymorphism at base +874 added predictive value to EBV VL PCR
measurements in paediatric liver transplant recipients. Thus, cytokine genotyping
(together with EBV VL) was helpful in identifying organ transplant patients at high risk
of PTLD. These results are supported by studies in the SCID mouse demonstrating that
the IFNy A/A genotype correlates significantly with rapid and consistent tumour
formation in the hu-PBL-SCID model (Dierksheide et al, 2005). Neutralization of
transforming growth factor (TGF)(3 in mice injected with IFNy A/A PBLs led to
expansion of CD8+ve T cells in vivo and reduced tumour development suggesting that
TGFp promotes tumour outgrowth by inhibiting CTL activation in hu-PBL-SCID mice.
Novel PTLD Therapy: Hu-BLCL-SCID Mouse Model
In 1987, Reddy et al described the successful implantation of a human lung
tumour-derived cell line in SCID mice. Since this first report of successful establishment
of a human tumour in the animals, around 4,000 papers have appeared to date in the
scientific literature citing their use for studies of human tumorigenesis.
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SCID mice inoculated ip with PBLs from EBV-seronegative healthy donors
followed by inoculation of concentrated virus preparations experience EBV infection of
the transferred B cells in vivo and development of PTLD-like lesions (Cannon et al,
1990; Boyle et al, 1992). Therefore, it is possible to mimic EBV infection in a
seronegative organ transplant recipient using a SCID mouse that has been humanized
with seronegative PBL. Such modelling can be used to test the efficacy of novel
measures aimed at preventing EBV infection using tumour formation as an experimental
read-out.
SCID mice inoculated sc or ip with BLCL (hu-BLCL-SCID) regularly give rise
to PTLD-like tumours (Rowe et al, 1991; Boyle et al, 1992). In sc-injected animals, the
tumours can be visualized under the skin and directly measured. Thus, the sc hu-BLCL-
SCID mouse can be used as a preclinical tool to assess novel PTLD therapy in vivo prior
to introduction into the clinical (patient) setting. Recording changes in tumour mass over
time, the effect of treatment can be assessed by serial tumour sampling and analysis of
tumour material by such techniques as PCR, microarrays, immunostaining and flow
cytometry.
When the hu-BLCL-SCID model has been used to address the effect of antiviral
therapy on PTLD, ACV has not shown an inhibitory effect on tumour formation in vivo
whereas GCV has been found to be effective in SCID mice (Boyle et al, 1992;
Unpublished observations from our laboratory). Additionally, studies of adoptive CTL
immunotherapy in hu-BLCL-SCID mice have provided data which support the use of
EBV-specific CTL against PTLD (see section 3 in Results).
An alternative therapeutic strategy entails the use of suicide genes in EBV+ve
malignant cells that renders them susceptible to pro-drug killing. In a study in 1996,
Franken et al inoculated SCID mice with BLCL that had been transfected with a
construct that included a thymidine kinase (TK) suicide gene under the control of an
EBNA2-responsive promoter. In the presence of EBNA2, activation of the promoter led
to TK production. In the animals, development of EBV+ve tumours resulted in EBNA2
expression and, therefore, production of TK by the tumour cells. When the animals were
treated with GCV, TK-mediated phosphorylation of the pro-drug led to formation of the
80
active anti-viral drug and complete tumour regression. Further studies by Rogers et al
(1996) have shown similar results when transfecting EBV+ve tumour cells with the
enzyme cytosine deaminase (CyD). CyD converts the pro-drug 5-fluorocytosine (5-FC)
into its active form, 5-fluorouracil. Following administration of 5-FC, CyD-transfected
SCID mouse tumors regressed as a result of formation of the active anti-tumour
compound.
The effectiveness of rituximab and bcl-2 has been studied in the hu-BLCL-SCID
model. Thus, Guinness et al (2000) and Loomis et al (2003) demonstrated that
combining a bcl-2 antisense oligonucleotide with rituximab in vivo was curative in 11
out of 14 (79%) tumour-bearing animals treated whereas 14 out of 14 (100%) control
mice died of LPD. Bcl-2 or rituximab monotherapy did not achieve the therapeutic effect
of combination treatment since initial monotherapy-induced delay in tumour outgrowth
in vivo was followed by subsequent neoplastic disease. Thus, a bcl-2 antisense
oligonucleotide potentiated the antitumor effect of rituximab suggesting that bcl-2
antisense oligonucleotide therapy in combination with rituximab may represent a non¬
toxic and effective (targeted) therapy for PTLD.
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AIM
The aim of this study was to set up an established in vivo model of Epstein-Barr
virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) in which to
investigate adoptive immunotherapy for PTLD.
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MATERIALS AND METHODS
1. Abbreviations And Symbols
A Amp
ACIF Anti-complement immunofluorescence
ACPL Anti-complement peroxidase labelling
AP Alkaline phosphatase
APAAP Alkaline phosphatase anti-alkaline phosphatase
BPB Bromophenol blue
Bq Becquerel
BSA Bovine serum albumin
CaCl2 Calcium chloride
cDNA Complementary DNA




















ECACC European Collection of Animal Cell Cultures
EDTA Ethylene diamine-tetraacetic acid
ELISA Enzyme-linked immunoabsorbent assay
EtBr Ethidium bromide
FACS Fluorescent activated cell scanning










KH2P04 Potassium dihydrogen orthophosphate
L Liter
LCMV Laboratory for Clinical & Molecular Virology
LSHTM London School of Hygiene & Tropical Medicine
P Micro (10*6)
m Milli (10"3)/meter
M Molar (moles per liter)/Mega (106)
MgCl2 Magnesium chloride
MMLV-RT Moloney Murine Leukemia Virus reverse transcriptase
MRI Magnetic resonance imaging
mRNA Messenger RNA
n Nano (10"9)




NBF Neutral buffered formalin
NHS Normal human serum
NRS Normal rabbit serum












rpm Revolutions per minute
RPMI Roswell Park Memorial Institute
SDS Sodium dodecyl sulphate
SDW Sterile distilled water
SSC Standard saline citrate
















Anachem, Luton, Bedforshire, UK
Applied Biosystems, Warrington, Cheshire, UK
Arnold R Horwell, London, UK
Atta, Genetic Research Instrumentation, Dunmow, Essex, UK
Barloworld Scientific Ltd, Stone, Staffordshire, UK
BD PharMingen, Oxford, Oxfordshire, UK
Beckman Coulter, High Wycombe, Buckinghamshire, UK
Beckton-Dickinson (UK) Ltd, Oxford, Oxfordshire UK
Biometra GmbH, Goettingen, Germany
Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK
BOC Cryospeed, Manchester, UK
Caltag Medsystems Ltd, Towcester, Northamptonshire, UK
Capell (Precision Medical Ltd), Pickering, Yorkshire, UK
Cinna/Tel-Test Inc, Friendswood, Texas, USA
Clay Adams, Parsippany, New Jersey, USA
Clontech Laboratories Inc, Saint-Germain-en-Laye, France
Cryotechnics, Edinburgh, UK
Cymbus Bioscience, Southampton, Hampshire, UK
DakoCytomation Ltd, High Wycombe, Buckinghamshire, UK
Denley Instruments, Billinghurst, Sussex, UK
Distillers MG, Reigate, Surrey, UK
ECACC, Salisbury, Wiltshire, UK
Electrolux Domestic Appliances, Luton, Bedfordshire, UK
Eppendorf, Hamburg, Germany
Eurogentec Ltd, Southampton, Hampshire, UK
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK
Flowgen, Lichfield, Staffordshire, UK
Flow-ICN (UK), Thame, Oxfordshire, UK
FMC BioProducts, Rockland, Maine, USA
Fuji Photo Film Company, Omoya, Japan
GE Healthcare, Chalfont St Giles, Buckinghamshire, UK
Genetic Research Instrumentation, Dunmow, Essex, UK
Grant Instruments, Cambridge, Cambridgeshire, UK
GraphPad Software, Inc., San Diego, CA, USA
Greiner Bio-One Inc, Stonehouse, Gloucestershire, UK
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Hanna Instruments Ltd, Leighton Buzzard, Bedfordshire, UK
Harlan Sera-Lab, Loughborough, Leicestershire, UK
Heraeus, Brentwood, Essex, UK
Hybaid Ltd, Teddington, Middlesex, UK
IBI/Eastman Kodak Company, New Haven, Connecticut, USA
International Equipment Company, Damon, Dunstable, Bedfordshire, UK
Invitrogen, Paisley, Renfrewshire, UK
ISP Europe, Tadworth, Surrey, UK
Jencons, Leighton Buzzard, Bedfordshire, UK
Johnson & Johnson Medical Inc, Arlington, Texas, USA
Jouan, Tring, Hertfordshire, UK
Leitz, Wild Leitz UK Ltd, Knowlhill, Milton Keynes, Buckinghamshire, UK
Macarthy Medical, Romford, Essex, UK
MDS Nordion. Ottawa. Ontario. Canada
Medical Air Technology Ltd, Oldham, Lancashire, UK
Millipore (UK) Ltd, Croxley Green, Hampshire, UK
Miltenyi Biotec Ltd, Bisley, Surrey, UK
Mini-Instruments Ltd, Burnham on Crouch, Essex, UK
MP Biomedicals, LLC, London, UK
Nordic Immunological Laboratories, Maidenhead, Berkshire, UK
Nordion International Inc, Ontario, Canada
Novartis Ltd, Oxford, Oxfordshire, UK
Nunc, Nalge (Europe) Ltd, Hereford, Herefordshire, UK
Ohaus Europe, Cambridge, Cambridgeshire, UK
Olympus, Gallenkamp, London, UK
Oxoid Limited, Basingstoke, Hampshire, UK
Painse and Byrne, Greenford, Middlesex, UK
Patterson Scientific, Dunstable, Bedfordshire, UK
Perkin Elmer Life Sciences, Beaconsfield, Buckinghamshire, UK
Photosol, Basildon, Essex, UK
Polybags Ltd, Lyon Way, Greenford, Middlesex, UK
Promega UK, Southampton, UK
Qiagen Ltd, Crawley, Sussex, UK
RA Lamb, London, UK
R&D Systems, Abingdon, Berkshire, UK
Roche Diagnostics Ltd, Lewes, Sussex, UK
Sandoz Ltd, Bordon, Hampshire, UK
Sanyo Gallenkamp (MSE), Loughborough, Leicestershire, UK
Sarstedt Ltd, Beaumont Leys, Leicester, UK
Scientific Industries, Bohemia, New York, USA
Scientific Laboratory Supplies (SLS), Nottingham, UK
Scottish National Blood Transfusion Centre, Edinburgh, UK
Sera Lab, Crawley Down, Sussex, UK
Serotec Ltd, Kidlington, Oxford, UK
Sharp Corporation, Abeno-Ku, Osaka, Japan
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Sigma-Aldrich Ltd, Gillingham, Dorset, UK
Sigma-Genosys Ltd, Haverhill, Suffolk, UK
Skatron, Newmarket, Suffolk, UK
Starlab (UK) Ltd, Milton Keynes, Buckinghamshire, UK
StemCell Technologies, Vancouver, British Columbia, Canada
Stratagene, La Jolla, California, USA
Stuart Scientific, Barloworld Scientific Ltd, Stone, Staffordshire, UK
Thermo, Basingstoke, Hampshire, UK
Tissue Culture Services, Claydon, Buckinghamshire, UK
Ultra-Violet Products Ltd, Cambridge, Cambridgeshire, UK
Varian Ltd, Oxford, Oxfordshire, UK
Vision BioSystems (Europe) Ltd, Newcastle Upon Tyne, UK
VWR International Ltd, Poole, Dorset, UK
Wako Chemicals GmbH, Neuss, Germany
Whatman, Maidstone, Kent, UK
3. Reagents
All cell culture reagents were supplied by Invitrogen and Harlan Sera-Lab unless
otherwise stated. General chemical reagents, other than those listed below, were
supplied by Sigma. Tissue culture (TC) flasks, 48- and 96-well plates as well as
cryovials were supplied by Nunc. All other plasticware was supplied by Barloworld
Scientific, Greiner Bio-One, SLS, or Thermo.
Reagent


































Ficoll™ 400 GE Healthcare
Formamide Invitrogen
(J)Xl 74 DNAIHae III markers Promega
<j)Xl74 DNA///mf I dephosphorylated markers Promega
Glycerol Sigma
Histopaque® Sigma




Mixed bed resin Sigma
Naphthol ASBI phosphonic acid Sigma
New Fuchsin Substrate System Dako
NICK™ column GE Healthcare
NuSieve® 3:1 agarose FMC BioProducts
Oligonucleotides Eurogentec
Omniscan™ (Gadodiamide) GE Healthcare
PHA Sigma
Preservative free heparin Painse and Byrne
Proteinase K Promega
PVP Sigma
RNAzol™ B Cinna/Tel Test Inc.
RT-PCR Kit Stratagene
Sheared salmon sperm DNA 5.'->3' Inc.
Silane Sigma
Sodium azide Sigma
T4 Polynucleotide kinase Promega





X Ray Developer Photosol







Microfuge tubes (0.5/1.5 rnL)





4.2 Tissue Culture Plasticware
Item
Cell culture flasks (50mL)
Cryotubes
Filter units (0.45 pm, 0.60 pm)
Micropipette tips
Plastic universal tubes (25 mL)
Polypropylene conical centrifuge tubes (50 mL)
12x75 mm round bottom tube
Syringes 1-60 mLs
24 wells cell culture plates (15 mm)
96 wells flat bottom microtitre plates









































































'Laboratory counter', Clay Adams











Fuji Photo Film Company





'Mini-Monitor 900 GM Type E',
Mini-Instruments
'JX300', Sharp
'New improved Neubauer', BDH
Skatron
Invitrogen































'Varian 7T Scanner, Magnex
115/60 Gradient', Varian
'Digital PW9', Integra Biosciences
'Pipet-Boy', Integra Biosciences
'R301', Arnold R Horwell








'GeneQuant II', GE Healthcare

















































6.2 Magnetic Resonance Imaging (MR!)
Omniscan™ (Gadodiamide) 10 nM
6.3 Immunohistochemicai Techniques
Neutral Buffered Formalin (NBF)
NaH2P04xH20 0.4% w/v
Na2HP04 (anhydrous) 0.7% w/v
40%w/v formaldehyde 10% v/v
Made up in dH20, pH7.2-7.4.
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Made up in dH20.






Made up in dH20.
Complement Fixation Buffer (CFB)




Made up in dH20.
Dulbecco's B: CaCl2x2H20 0.53% w/v
Made up in dH20.
Dulbecco's C: MgCl2x6H20 0.4% w/v
Made up in dH20.
For CFB: Dulbecco's B 2.5% v/v
Dulbecco's C 2.5% v/v
Made up in Dulbecco's A.
lxTris Buffered Saline (TBS)
Tris-HCl, pH7.6 0.05 M
NaCl 0.15 M





Made up in dH20, pH9.2.
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Levamisole




Made up in ddH20 and autoclaved overnight.
lOxProteinase-K (PRK) Buffer
Tris-HCl, pH7.6 0.50 M
Made up in DEPC water.
20xTris Buffered Saline (TBS)
Tris-HCl, pH7.6 1.0 M
NaCl 3.0 M
Made up in DEPC water.
l%Triton® X-100
Triton® X-100 l%v/v
Made up in DEPC water.
Substrate Buffer
Tris-HCl, pH8.2 2.5 M
Made up in DEPC water.
Proteinase-K 3 mg/mL
(from the fungus Tritirachium album)




Boric acid 5.5% w/v
0.5M EDTA, pH8 4% v/v























20xStandard saline citrate (SSC)
NaCl
Naacitrate









Made up in dFEO.
10% w/v Sodium Dodecyl Suphate (SDS)
Made up in dFEO.
Formamide
Deionised in 10%w/v Mixed-bed resin.




EDTA, pH8 1 mM
Made up in dHaO.





Made up in lxTBE buffer.
1 % w/v
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cDNA Synthesis: 'RT-PCR Kit'
Random primers 0.1 mg/mL
First-strand buffer lOx
RNase block ribonuclease inhibitor 40 U/mL
1 OOmM dNTPs 25 mM each
MMLV-RT 50 U/mL
Taq DNA Polymerase 5 U/mL
(from the Thermus aquaticus bacterium strain YT1)
Enzyme storage buffer A
Glycerol 50% v/v








Triton®X-100 1 % v/v
MgCl2 25 mM
DNA Polymerization Mix
dATP, dCTP, dGTP, dTTP 20 mM each
Made up in water, pH7.5
Gel Electrophoresis
NuSieve® 3:1 agarose 2.5% w/v




50xDenhardt"s solution 10% v/v
10%w/v SDS 5% w/v
Sheared Salmon Sperm DNA 1 % v/v
Made up in dH20.
Hybridization Solution
Prehybridization solution with 32P-labelled probe and fresh











(from a recombinant E. coli bacterium strain)




lKbp DNA ladder 200pg/mL
(in 1 OmM Tris-HCl, pH7.5, 50 mM NaCl, 0.1 mM EDTA)
<|>Xl74 DNAJHae III markers 1.0mg/mL
(in 10 mM Tris-HCl, pH7.5, 1 mM EDTA)
(J>Xl74 DNA////nf I dephosphorylated markers 50pg/mL
(in 10 mM Tris-HCl, pH7.5, 1 mM EDTA)
7. Antibodies
The antibody and serum reagents used in this study are shown in Tables A1 to
A3 in Appendix 1.
8. Cell And Tissue Samples
8.1 Organ Graft Recipients
Primary biopsy material obtained from PTLD arising in organ transplant
recipients was transported promptly in sterile medium from UK organ transplant centres
to our laboratory for diagnostic and research purposes. The biopsy material was divided
upon arrival using aseptic technique, and a small piece was teased out into a single cell
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suspension in WM. Once the cells had been washed in WM, they were counted and their
viability was assessed. Tumour cells were then transferred in CM ip into SCID mice.
8.2 Healthy Blood Donors
Once an informed written consent was obtained, 50-100 mL of heparinized blood
was collected from healthy staff in our laboratory. Furthermore, 'buffy coats' (blood
bags containing PBLs in small volume of plasma) were obtained from the Scottish
National Blood Transfusion Service in Edinburgh.
8.3 Serological Analysis
EBV serostatus was determined by analysis of anti-VCA IgG antibody titer using
an indirect immunofluorescence method (Henle & Henle, 1966). Test slides were
prepared using standard methods. Briefly, 5x104 cells of the EBV genome-positive cell
line P3HR1 (Hinuma et al, 1967), routinely grown in our laboratory, were washed in
PBS and plated out into each of 12 wells on microscope slides. Once cells had dried onto
the slides at room temperature, they were fixed in acetone for 5 minutes. The slides were
then dried in air again at room temperature followed by storage at -20°C. For VCA
testing, slides were thawed out from storage and test samples together with known VCA-
positive (KAM) and EBV-negative (WDA) control sera applied to the fixed cells. Thus,
10 pL of test sera, diluted 1:5 and 1:10 in PBS, were added separately to designated slide
wells, and the slides incubated at 37°C for 1 hour. Slides were washed in PBS at room
temperature followed by the addition to each well of 10 pL of FITC-conjugated rabbit
anti-human IgG diluted 1:50 in PBS. The slides were incubated at room temperature for
1 hour, washed in PBS, and mounted in 1:1 PBS:glycerol. Slides were viewed under an
epifluorescent microscope, and the antibody titre was determined as the higher of the
two test dilutions that gave positive VCA staining. A consistent titre of <1:5 was
considered to indicate an EBV-seronegative blood donor.
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9. Cell Culture Techniques
Using aseptic technique, all cell culture techniques were carried out inside
microbiological class 2 safety cabinets using sterile equipment and solutions.
9.1 Control Cell Lines
A viably frozen store of control cell lines was kept under liquid nitrogen in our
laboratory. These cell lines were routinely grown in vitro, and are shown in Table A4 in
Appendix 1.
9.2 Cell Culture
Cells were grown in vitro as suspension cultures and kept at a concentration of
between lxlO5 and lxlO6 cells (depending on the nature of the culture) per mL of CM in
a humidified incubator containing 5% CO2 at 37°C. Cells were fed with CM as required
(usually every 2-3 days). In order to ensure adequate humidification, sterile distilled
water (SDW) was added to the outermost wells of 24, 48 and 96 wells plates, and the
plates were kept in sandwich boxes containing water-filled bijoux tubes.
9.3 Cell Wash
In order to 'wash' cells, they were spun at 160 g for 7 minutes in a bench top
centrifuge, resuspended in WM, and spun again. The g-number was calculated as
follows:
2 6
g-number =11.2xrxn x 10"
(r: centrifugal radius in cm from axis to middle of tube;
n: speed in revolutions per minute, rpm)
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The cell wash was was repeated as often as deemed necessary in fresh WM
which was discarded after each wash cycle. Once complete, the cells were resuspended
in an appropriate medium.
9.4 Viable Storage Of Cells
In order to store cells viably, 1x107-2x107 cells were spun at 160 g for 7 minutes
in a bench top centrifuge, resuspended in 1 mL of FM, and transferred into a 1.5 mL
cryovial. The cryovials were kept at -70°C overnight, and then transferred into
specialized tanks where they were stored under liquid nitrogen as frozen viable stock.
9.5 Recovery Of Frozen Cells
Following a quick thaw in a waterbath at 37°C, cells that had been stored viably
frozen in a cryovial under liquid nitrogen were transferred as a thawed cell suspension
into a sterile 20 mL plastic tube. Next, 9 mLs of WM were added drop-wise slowly to
the suspension. Once a further 10 mLs of WM had been added more rapidly, the
suspension was spun at 160 g for 7 minutes. The supernatant was discarded and the cells
were washed again in fresh WM. Once complete, the cells were resuspended in 5-7 mLs
of CM and placed in a 25 cm2 TC flask for in vitro culture. Initially, fastidious cells were
cultured in a 24-wells plate using 20% v/v FCS/CM until it was deemed safe to transfer
the cells into flasks for bulk culture.
9.6 Viability Assay/Cell Counts
Cell viability was assessed using trypan blue. To this end, 10 pL of 0.5% w/v
trypan blue (in PBS) was mixed with 10 pL of the cell suspension. 10 pL of the
resulting mixture were placed on a haemocytometer and a cell count was performed
visually on a graticule under a light microscope. Whilst live cells exclude the dye, it can
access dead cells and turn them blue. Viability was expressed as the number of viable
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cells out of the total number of counted cells multiplied by a factor of 100 (ie, a
percentage was obtained). A viability of >70% was considered acceptable.
9.7 T Cell Fractionation Using Antibody-Coated Magnetic Beads
In order to select out T cell subpopulations, CD4+ve or CD8+ve T cells were
positively selected from fresh or frozen cell samples using EasySep® (StemCell
Technologies) kits. The manufacturer's instructions were followed and the composure of
cell fractions generated was assessed by flow cytometry (see section 9.14). Briefly, cell
samples were suspended in EasySep® buffer (2% v/v FCS/lmM EDTA in PBS) at a
concentration of 1x10s cells/mL. Next, 100pL of CD4+ve, or CD8+ve, T cell EasySep®
positive selection mixture (contains tetramer complexes of bi-specific antibodies
directed against the CD4, or CD8, cell surface markers and dextran) was added per 1 mL
of the whole cell suspension. Having given the resulting suspension a gentle mix, it was
incubated for 15 minutes at room temperature. Next, 50pi EasySep® magnetic dextran
iron nanoparticles were added per 1 mL of cell suspension, and the mixuture incubated
for 10 minutes at room temperature. Following a gentle mix, the final volume per
sample was increased to 2.5 mLs using EasySep® buffer. Each such sample was then
placed in a magnet for 5 minutes at room temperature. With the sample still in the
magnet, the supernatant was poured out in one movement. The following next 3 steps
were then repeated twice: (1) the sample was removed from the magnet and 2.5 mLs of
EasySep® buffer added to the positively selected cell population followed by gentle
mixing; (2) a further magnetic separation of 5 minutes at room temperature; (3)
decanting of supernatant. The positively-selected cells were resuspended in CM,
counted, assessed by viability assay, and used in subsequent experiments.
101
9.8 y-lrradiation Of Cells
Cellular chromosomal damage to prevent cell proliferation was incurred using y—
• ••*137*irradiation. To this end, cell suspensions were exposed to y-irradiation from a Cesium
source. Exposure time (ET, in minutes) was calculated as follows:
ET = Y x 60 minutes/hour
x 1.10
4.07x104rad/hour x DF
(Y: value of the desired irradiation dose in rads;
137 •
DF: decay factor as tabulated by the manufacturer of the Cesium source)
9.9 EBV Virus Preparation
Using standard methods, an EBV virus preparation was generated from the B95-
8 EBV genome-positive marmoset cell line (Miller el al, 1972). Following expansion of
the B95-8 cells in vitro, cells were left unfed for 1 week and then centrifuged at 800 g for
20 minutes. Whilst the supernatant was collected and kept (see below), the cell pellets
were resuspended in 10 mLs of cold CM and subjected to 3 rounds of alternate quick
freeze-thawing cycles to induce cell lysis and virus particle release. In order to pellet cell
debris, samples were spun at 450 g for 20 minutes. The supernatant that was harvested in
this manner was mixed with the supernatant collected previously (see above), and the
combined supernatant mixture ultracentrifuged at 24,000 g at 4°C for 2 hours. The virus
pellet obtained in this fashion was resuspended (concentrated x200) in cold CM and
passed through a pre-wet (in PBS) sterile 0.6 pm filter. Finally, 100 pL aliquots were
stored in cryovials at -70 C.
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9.10 EBV Virus Preparation Immortalizing Capacity (EBV Titration)
Serial dilutions (1:10, 1:102, 1:103, 1:104, 1:105, 1:106) of a concentrated EBV
virus preparation generated as described above were each used to infect 10A PBLs
obtained from EBV-seronegative healthy individuals in a total volume of 1 mL (in CM)
at 37°C for 1 hour in a humidified incubator containing 5% CO2. Cells were then washed
twice in WM to remove excess virus and cells resuspended in CM. For each EBV
dilution, infected PBLs were plated out in 5 replicate flat-bottom wells of a 96-wells
microtiter plate. Each well contained 2xl05 cells in 200 pL of CM. Following 4 weeks of
in vitro culture, cells were assessed directly under a light microscope for signs of
immortalization. The transforming titer of the virus preparation was determined as the
reciprocal of the virus dilution which gave rise to BLCLs in >3 wells. Only virus
preparations with a transforming titer of >10"4 were used in subsequent studies.
9.11 Cyclosporin-A
A stock solution of 100 pg/mL Cy-A was prepared in injectable grade alcohol.
For in vitro culture, 0.5-1 pL (50-100 ng) were used per 1 mL of CM.
9.12 Establishment Of In Vitro EBV-lnfected BLCLs
PBLs to be infected were pelleted at 160 g for 7 minutes and resuspended in 100
pL of concentrated EBV virus preparation to which CM was added to give a final 1 mL
volume. The cell/virus suspension was incubated at 37°C for 1 hour in a humidified
incubator containing 5% CO2. Cells were washed twice in WM (to remove excess virus),
and resuspended at a concentration of 106 cells per 1 mL of CM together with Cy-A (see
9.11 above). Next, 2 mLs aliquots were plated out per well in a 24-wells plate.
Following 4 weeks of in vitro culture, cells were assessed directly under a light
microscope for signs of immortalization. BLCLs were immunophenotyped and
transferred into TC flasks for bulk culture.
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9.13 Establishment And Maintenance Of EBV-Specific CTLs
Using fresh, or cryopreserved, PBLs separated from buffy coats, EBV-specific
CTLs were established as described previously (Wilkie et al, 2004). Briefly, y-irradiated
(4.000 rads) BLCLs were used to stimulate autologous PBLs in vitro. Initially, a cell
mixture containing a 40:1 PBL:BLCL ratio was suspended at a concentration of lxlO6
cells per mL of 20% v/v FCS/CM in 25 cm2 TC flasks and kept at 37°C in a humidified
incubator containing 5% CO2. The expanding T cells were restimulated 10 days later
(denoted stimulation 1, or 'stim 1') with a ratio of 4:1 T cells:y-irradiated autologous
BLCL. Four days later, 20 IU/mL of recombinant IL2 (rIL2) were added to the in vitro
cultures. From this timepoint (14 days) onwards, the T cell cultures were restimulated
weekly with y-irradiated autologous (4:1 ratio) BLCLs together with a thrice weekly
dose of rIL2. At time of weekly stimulation, the T cell concentration was adjusted to
lxlO6 cells per mL to ensure optimum growth conditions.
On occasion, aliquots of viably frozen BLCL and T cell sets at very early
stimulation points were kindly donated by Ms G Wilkie (CRUK Study Group,
Laboratory for Clinical & Molecular Virology, The University of Edinburgh). Following
thawing of these cells, they were expanded in exactly the same manner as described
above.
9.14 Flow Cytometry (Fluorescent-Activated Cell Scanning, FACS)
Flow cytometry (fluorescent-activated cell scanning, FACS) was carried out
using standard methods. Briefly, FACS buffer (FB) [1% w/v bovine serum albumin
(BSA), 5mM EDTA and 0.1% w/v sodium azide in PBS] was generated, and lOx
concentrated CellFIX™ (BD Biosciences) was diluted 1:10 with distilled water prior to
use. For each cell sample, 100 pL aliquots of a lxl06 cells per mL suspension were
established in FB in LP5 tubes and spun at 200 g for 5 minutes. Once resuspended in 50
pL of FB, directly-conjugated mabs shown in Table A 1.2 in Appendix 1 were added to
obtain a routine working dilution (as previously determined in our laboratory) for
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immunostaining of each cell surface marker. For each mab, an unstained (no antibody)
control and an Ig isotype-only mab control was included in every experiment. Following
gentle mixing of the cell/mab mixtures, they were incubated at 4°C for 20 minutes in the
dark. Next, the cell suspensions were washed twice in 1 mL of FB and spun at 200 g for
5 minutes. Cell pellets were resuspended in 200 pL of a 1:10 dilution of CellFIX™ and
stored at 4°C in the dark until flow cytometric analysis. FACS acquisition (and analysis
of 1,000-10,000 acquired events per sample) was performed using the 'CellQuest
Software' on a FACSCalibur machine (Becton Dickinson).
9.15 51Chromium-Release Assay
A standard 4 hour 5lCr-release assay was carried out as described previously
(Wilkie et al, 2004). Briefly, target cells (autologous and mismatched BLCLs as well as
NK target K562 cells) were incubated with 50 pCi of 5lCr at 37°C for 1 hour in a
humidified incubator containing 5% CO2, washed twice in HBSS, resuspended in 20%
v/v FCS/CM (to give a final concentration of 1x10s cells/mL), and plated out in 3
replicate U-bottom wells of a 96-wells microtiter plate. Each well contained 10x10 cells
in 100 pL of CM. In parallel, a 2xl06 cells/mL effector T cell suspension was prepared
in 20% v/v FCS/CM. Using 100 pL aliquots per well, 50xl03-200xl03 T cells were
added to target cell wells to generate a 5:1, 10:1 and 20:1 effector-to-target ratio in
triplicate wells. In order to gauge spontaneous 5lCr release by target cells, 100 pL of
20% v/v FCS/CM only were added to each target cell well in triplicate. Similarly,
addition of 100 pL of 1% v/v Triton® X-100 only served to establish maximum 51Cr
release by target cells. Once all the cell combinations had been plated out, the cell
mixtures were incubated at 37°C for 4 hours in a humidified incubator containing 5%
CO2. Following centrifugation at 300 g for 5 minutes, 100 pL of supernatant was
collected from each well, transferred into scintillation tubes, loaded into racks, and 5lCr
release measured in a y-counter. The % specific cell lysis was calculated as follows
(results were expressed as an average of readings from triplicate wells):
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% Specific Lysis = cpm test release - cpm spontaneous release
x 100
cpm maximum release - cpm spontaneous release
(cpm: Counts per minute)
9.16 Proliferation Assay
Cells were grown in CM at a concentration of 106 cells per mL in a 24-wells
plate. On the day of pulsing, cells were plated out at a concentration of 2x105 cells per
200 pL per well in 3 replicate wells of a 96-wells round bottom microtiter plate. The
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proliferative response was assessed by pulsing the cells with 1 pCi per well of [ H]-
thymidine at 37°C for 4 hours in a humidified incubator containing 5% CO2 (Taylor et
al, 1957; Rubini et al, 1960). A cell harvester was used to lyse the pulsed cells in water,
and the DNA-incorporated [ H]-thymidine was harvested onto filter mats. The mats
were immersed in scintillation solvent. The radioactivity, as a parameter of cell
proliferation, was measured in a scintillation p-counter. The results were expressed as
average counts per minute (cpm).
10. SCID Mice
We have a breeding colony of CB.17 SCID mice at the University of Edinburgh.
The colony is kept in an SPF environment in microisolator (IVC) cages and handled in
microbiological class 2 safety cabinets. The animals are fed autoclaved feed and water
without antibiotics. All animal work was carried out under relevant Home Office Project
and Personal Licences in accordance with the Home Office 'Animals' (Scientific
Procedures) Act 1986', and monitored by Home Office Inspectors and University
Named Veterinary Surgeons.
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10.1 Inoculation Of Scid Mice
Cells were washed in WM and injected sc or iv in a volume of 100 pL of sterile
CM into a test mouse. For ip inoculation, a volume of up to 500 pL was used per test
animal.
10.2 Collection Of Murine Blood Samples
Blood samples were collected by superficial venesection as laid out in the
relevant Project Licence. No more than 10% of the total blood volume (TBV) was
collected in any 24 hours, and no more than 15% of the TBV was collected in any 28
days period. Samples were left to clot at 4°C for 1 hour, given a microfuge pulse, and
serum collected and frozen at -20°C until testing.
10.3 Sc Tumour Measurements
Using callipers, macroscopic sc tumours were measured in 2 planes 90° on each
3 2other and tumour volume (mm ) calculated using the formula ab /2 (tumour mass in
mm3; a: length; b: width).
10.4 Health Monitoring And Culling Procedure
Mice were observed daily for signs of sickness (for example, disinterest in their
surroundings, hunched back, respiratory distress and ruffled fur). Upon showing signs of
illness, or after a pre-set time limit (based on past experience), mice were culled by
cervical dislocation (Schedule 1 procedure) in accordance with Home Office instructions
and then submitted for necropsy. At necropsy, a macroscopic assessment was carried out
and the following organs removed: lung, liver, spleen, and any tumour tissue. Each
tissue sample was divided into 2 pieces which were either (1) fixed in neutral buffered
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formalin (NBF) for histological and immunohistochemical analysis, or (2) preserved in
RNALater™ (Qiagen) for molecular studies involving analysis of DNA and RNA.
10.5 Magnetic Resonance Imaging (MRI)
For MRI imaging, animals underwent inhalation anaesthesia as outlined in the
relevant Project Licence. Once unconscious, mice were scanned using a small animal
'Varian 7T MRI Scanner' ('Magnex 115/60 gradient') housed at the University of
Edinburgh. For imaging, a 'Rapid 39/59 mm Quad Coil' was used. In order to enhance
image contrast, 20-30 pL of 10 nM gadolinium were iv inoculated. Scan time was gated
on the animal's respiratory cycle and amounted to approximately 8.5 mins for 4
averages to give a resultant image.
11. Histopathology And Immunohistochemistry
11.1 Snap-Freezing Of Tissues
Frozen tissue blocks were prepared by placing an excised tissue piece on a cork
plate, covering it with 'Optimum Tissue Cutting' (OCT) compound, snap-freezing the
block in iso-pentane pre-cooled in liquid nitrogen, and transferring the frozen tissue
blocks to pre-cooled cryovials for storage under liquid nitrogen. For snap-freezing of
tissues for molecular analysis only, small tissue pieces were transferred into 1.5 mL
cryovials that were snap-frozen in, and stored under, liquid nitrogen.
11.2 Preparation Of Cytospins
For cell sample of interest, a suspension of 5xl05-10xl05 cells/mL was prepared
in PBS, and 100 pL/sample was spun in a cytocentrifuge onto microscopy slides. The
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samples were dried in air, fixed in acetone for 5 minutes, and allowed to dry in air again
prior to storage at -20°C.
11.3 Preparation Of Cryo-Sections
Snap-frozen tissues were processed to 6 pm sections on polysine-coated slides,
fixed in acetone for 5 minutes, dried in air at room temperature, individually wrapped in
cling film (to prevent condensation upon thawing) and stored at -20°C. At time of use,
slides were left to warm up at room temperature, unwrapped, and placed in a humid
chamber for immunohistological analysis.
11.4 Preparation Of Paraffin Wax-Embedded Sections
Tissues fixed in NBF were paraffin wax-embedded and processed to 5 pm
sections on polysine-coated slides.
11.5 Preparations For Use Of Paraffin Wax-Embedded Sections
(Rehydration Of Sections)
In order to dewax paraffin wax-embedded sections, they were immersed in
xylene for 5 minutes followed by 5 minutes in 100% v/v ethanol. The sections were
rehydrated by sequential immersion for 3 minutes in each of 90% v/v, 70% v/v and 30%
v/v ethanol which was followed by rinsing in tap water and drying in air. Sections were
demarcated using a hydrophobic marker pen.
11.6 Retrieval Of Antigen
In order to ensure antigen exposure during immunostaining, slides were
immersed either in a 1:10 dilution of a citrate-based (pH 6) 'Target Retrieval Solution'
(DakoCytomation) at 95 °C for 20 minutes, or an EDTA-based (pH 8) 'Antigen Retrieval
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Solution' (DakoCytomation) at 100°C in a pressure cooker for 10 minutes. The former
approach was used prior to immunostaining human cell surface markers (CD3, CD4,
CD8, CD20, CD45) and EBV antigens (EBNA2, LMP1, BZLF1), whereas the latter
procedure was employed prior to immunostaining cytotoxic granule molecules (perforin,
granzyme B).
11.7 Section Mounting For Preservation
In order to preserve immunostained sections, they were mounted in either water-
or solvent-based solutions. Thus, antibody labels that were insoluble in organic solvents
were dehydrated (see section 11.9) and mounted in di-butyl-polystyrene-xylene (DPX),
whereas labels insoluble in water-based solutions were mounted in either 1:1
PBS:glycerol or 'Faramount Aqueous Mounting Medium' (DakoCytomation). Lastly,
sections were covered with coverslips for preservation.
11.8 Counterstaining Of Sections
Sections were counterstained by immersing them either in 0.1% w/v Evan's Blue
(red cytoplasmic staining under UV-light) for 30 minutes, or Mayer's Haemalum (blue
nuclear staining under light microscope) for 3 minutes at room temperature followed by
rinses in tap water.
11.9 Dehydration Of Sections For Mounting In DPX
Prior to mounting antibody labels insoluble in organic solvents, sections were
dehydrated by sequential immersion for 3 minutes into each of 30% v/v, 70% v/v, 90%
v/v and 100% v/v ethanol followed by 3 minutes in each of acetone and xylene. Next,
the sections were mounted in DPX and covered with a coverslip for preservation.
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11.10 Hematoxylin And Eosin (H&E) Staining
Sections were first immersed in Mayer's Haemalum (blue nuclear staining) for 5
minutes, rinsed in tap water, and flooded with 1% w/v eosin for 15 minutes (pink
cytoplasmic staining). Slides were rinsed in tap water, left to dry in air, mounted and
covered with a coverslip for preservation.
11.11 Indirect Immunofluorescence (IIF) Immunostaining
Frozen test sections together with positive and negative control slides were
incubated with 10 pL of primary antibody at 37°C for 1 hour in a humid chamber
followed by two washes in PBS for 5 minutes each. Sections were incubated with 10 pL
of either a fluorescein isothiocyanate (FITC)- or tetramethylrhodamine isothiocyanate
(TRITC)-conjugated secondary antibody at room temperature for 1 hour. The slides
were washed twice in PBS again and rinsed with distilled water. When an FITC-label
was used, the sections were counterstained with Evan's Blue. Sections were mounted in
1:1 PBS:glycerol (or 'Faramount Aqueous Mounting Medium') and viewed under an
epifluorescent microscope.
11.12 Peroxidase Anti-Peroxidase (PAP) Test
Standard methods were used (van Noorden, 1986) that involved inclusion of
positive and negative control slides. Whilst paraffin wax-embedded sections were
dewaxed and rehydrated, frozen sections were used directly. Antibody dilutions were
made up in PBS, and incubations took place in a humid chamber.
Briefly, 10 pL of a primary murine mab were applied to sections at room
temperature for 1 hour followed by two washes (for 5 minutes each) in PBS. Next, 10
pL of a secondary 1:25 rabbit anti-mouse Ig antibody/1:25 normal human serum (NHS)
was applied to sections and they incubated at room temperature for 1 hour followed by
further washes in PBS. Lastly, 10 pL of a 1:100 monoclonal mouse peroxidase anti-
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peroxidase (PAP) complex-conjugated antibody was applied to sections at room
temperature for 1 hour followed by washes in PBS. Bound antibody (PAP label) was
visualized using 0.5 mg/mL of 2,3-di-aminobenzidine (DAB) in PBS for 2 minutes
followed by application of 1 pL/mL of 30% w/v H2O2 for 3-5 minutes. Peroxidase
catalyses the formation of atomic oxygen from H2O2, which oxidizes DAB (a
chromogen) with formation of a brown end product. Following rinses in tap water,
sections were counterstained in Mayer's haemalum at room temperature for 3 minutes
followed by dehydration, mounting in DPX, and examination under a light microscope.
11.13 Alkaline Phosphatase Anti-Alkaline Phosphatase (APAAP) Test
Standard methods were used (van Noorden, 1986) that involved inclusion of
positive and negative control slides. Whilst paraffin wax-embedded sections were
dewaxed and rehydrated, frozen sections were used directly. Antibody dilutions were
made up in tris buffered saline (TBS), and incubations took place in a humid chamber.
Briefly, 10 pL of a primary murine mab were applied to sections at room
temperature for 1 hour followed by two washes (for 5 minutes each) in TBS. Next, 10
pL of a 1:25 secondary rabbit anti-mouse Ig antibody/1:25 NHS were applied to sections
at room temperature for 1 hour followed by further washes in TBS. Lastly, 10 pL of a
1:50 monoclonal mouse alkaline phosphatase anti-alkaline phosphatase (APAAP)
complex-conjugated antibody was applied to sections at room temperature for 1 hour
followed by washes in TBS. Bound antibody (APAAP label) was visualized by flooding




5 mg Fast Red TR salt/1 OmL veronal acetate buffer, pH9.6
5 mg Naphthol ASBI phosphonic acid/2 drops of DMF
Solutions A and B added together with 200pL of
levamisole
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Alkaline phosphatase (AP) hydrolizes naphthol phosphate to phenols which
couple to 'Fast Red', a colourless diazonium salt (chromogen), generating a red azo dye
(levamisole inhibits endogenous AP). Sections were incubated with Solution C at 37°C
for 15-45 minutes whilst being monitored for the intensity of staining of control
sections. Following washes in TBS, counterstaining in Mayer's haemalum for 3 minutes,
and rinses in tap water, sections were mounted in an aqueous mountant.
11.14 Indirect EBNA Detection:
Anti-Complement Immunofluorescence (ACIF)/
Anti-Complement Peroxidase Labelling (ACPL)
Standard methods were used (Reedman & Klein, 1973; Klein et al, 1976;
Guohua et al, 1981) that involved inclusion of positive and negative control slides.
Frozen sections were used directly. Antibody dilutions were made up in complement
fixation buffer (CFB), and incubations took place in a humid chamber.
Indirect EBNA detection entailed immunostaining of the C3 component of
complement by (anti-complement) indirect immunofluorescence (ACIF), or indirect
(anti-complement) peroxidase labelling (ACPL), using the complement-fixing properties
of anti-EBNA IgG antibodies. As a source of complement, the EBV negative human
serum WDA (stored at -70°C) was used.
Briefly, 10 pL of either an EBNA-positive or -negative human serum diluted
1:10 in CFB containing 10% v/v complement were applied to sections at 37°C for 1 hour
followed by two washes (for 5 minutes each) in CFB.
(1) ACIF: Ten pL of 10% v/v complement in CFB were applied to sections at
37°C for 30 minutes followed by washes in CFB. This step served as a complement
enhancement step (Klein et al, 1976). Next, 10 pL of FITC-conjugated goat anti-human
C3c secondary antibody diluted 1:20 in CFB was applied to sections at room
temperature for 1 hour followed by washes in CFB, rinsing in distilled water,
counterstaining in Evan's Blue, further PBS washes, and mounting in aqueous mountant.
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(2) ACPL: Ten pL of a peroxidase (Px)-labelled rabbit anti-human C3c
secondary antibody at a dilution of 1:25 in CFB was applied to sections at 37°C for 1
hour followed by washes in CFB and PBS. The Px label was developed as described
above for the PAP test (see section 11.12). Sections were dehydrated and mounted in
DPX.
11.15 EnVision™ And NovoLink™ Polymer Dectection Systems
Standard methods were used that involved inclusion of positive and negative
control slides. Paraffin wax-embedded sections were dewaxed and rehydrated. Antibody
dilutions were carried out in 'Antibody Diluent, Background Reducing'
(DakoCytomation), and incubations took place in a humid chamber at room temperature.
Each wash was carried out in TBS for 5 minutes. Both the (1) 'EnVision™'
(DakoCytomation) and (2) 'NovoLink™ Polymer Detection System'
(VisionBioSystems) approaches use polymeric labelling to increase sensitivity of the
secondary detection reagent (directed against mouse and rabbit primary antibodies).
(1) EnVision™: Each section was incubated with 10 pi of primary antibody for
30 minutes followed by two washes and the application of 10 pi of the 'Rabbit/Mouse
LINK' polymer reagent for 30 minutes. After further washes, sections were incubated
with 10 pi of the 'AP Enzyme Enhancer' (AP-labelled amplification polymer) for 30
minutes followed by two washes. In order to visualize the AP label (red precipitate at the
antigen site under the light microscope), an AP substrate working solution was prepared
by mixing 100 parts of'Permanent Red Substrate Buffer' with 1 part of'Permanent Red
Chromogen'. The AP label was developed as described above for the APAAP test (see
section 11.13) followed by rinses in distilled water. Lastly, sections were counterstained
with haematoxylin, rinsed in distilled water, dehydrated, mounted in DPX, and covered
with coverslips for preservation.
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(2) NovoLink™: Initially, in order to neutralize endogenous peroxidase, 10 pi.
of 'Peroxidase Block' were applied to each section for 5 minutes followed by two
washes. Next, sections were incubated with 10 pL of 'Protein Block' for 5 minutes (to
prevent non-specific antibody binding) followed by two washes and incubation with 10
pi of primary antibody for 30 minutes. Sections were washed again. In order to enhance
binding of the polymer reagent to the primary antibody, 10 pL of 'Post Primary Block'
were applied to each section for 30 minutes followed by two washes. Sections were
incubated with 10 pL of the Px-labelled 'NovoLink™ Polymer' for 30 minutes followed
by two washes. In order to visualize the Px label (brown precipitate at the antigen site
under the light microscope), a DAB working solution (see the PAP test above; section
11.12) was prepared by adding 50 pL of 'DAB Chromogen' to 1 mL of 'NovoLink™
DAB Substrate Buffer (Polymer)' followed by rinses in distilled water. The Px label was
developed as described above for the PAP test. Lastly, sections were counterstained with
haematoxylin, rinsed in distilled water, dehydrated, mounted in DPX, and covered with
coverslips for preservation.
11.16 Detection Of EBER1 And 2
(EBER In Situ Hybridization, ISH)
EBER ISH was carried out in accordance with the standard method (Howe &
Steitz, 1986). Paraffin wax-embedded sections (with positive and negative control
slides) were dewaxed by immersion in xylene for 3 minutes, and rehydrated by
immersion in 99% v/v and 95% v/v ethanol for 3 minutes each. Sections were then left
to dry in air. The 'Epstein-Barr Virus (EBER) PNA Probe/Fluorescein' and 'PNA ISH
Detection Kit' from DakoCytomation were used in accordance with the manufacturer's
instructions. All incubations were performed at room temperature (unless otherwise
stated) in a humid chamber.
Slides were washed twice in autoclaved di-ethyl-pyrocarbonate (DEPC)-treated
double distilled water for 3 minutes and each section then incubated with 20 pL of 0.1
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mg/mL proteinase-K (PRK) in PRK buffer for 30 minutes followed by two 3 minutes
washes in DEPC-treated water and dehydration by immersion in 95% v/v and 99% v/v
ethanol for 3 minutes each. Sections were left to air dry followed by the application of 5-
10 pL of a 5-carboxy-fluorescein (FITC)-labelled peptide nucleic acid (PNA) probe
complimentary to EBER1 and 2 [sections were covered with pre-treated (in methanol)
coverslips] at 55°C for 1.5 hours (positive and negative 'Control PNA Probe/FITC' were
included in each run). Cover slips were removed and sections immersed in a pre-heated
(55°C) working solution (1:60 in pure water) of 'Stringent Wash' for 25 minutes
followed by a brief immersion in TBS to bring the tissue samples down to room
temperature. Sections were then incubated with 10 pL of an 'Anti-FITC/AP' (AP-
conjugated antibody to FITC) for 30 minutes followed by two washes in TBS and a 1
minute immersion in double-distilled water. In order to visualize bound probe
(blue/black precipitate at the RNA site under light microscopy), the AP 'Substrate'
containing 5-bromo-4-chloro-3-indolylphosphate (BCIP) and nitroblue tetrazolium
(NBT) was applied to sections for 30-60 minutes followed by rinses in distilled water
and counterstaining in hematoxylin. Following further rinses in distilled water, sections
were mounted in 'Faramount Aqueous Mounting Medium' and covered with coverslips
for preservation.
11.17 Viewing Slides/Photomicrography
Slides were viewed under a light microscope at a magnification of xlOO and
x400 (or at x 1,000 under oil), and photographed when appropriate.
11.18 Cell Counts
In order to quantify labelled cells, the numbers of labelled and unlabelled
(counterstained background) cells were counted in 5 high power (x 1,000 under oil)
fields. The results were expressed as the number of marker-positive cells out of the total
counted cell population (multiplied by a factor of 100 to give % marker+ve cells).
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12. Reverse-Transcriptase Polymerase Chain Reaction
(RT-PCR)
RT-PCR was carried out essentially as described by Saiki et al (1985, 1988) and
Hart et al (1988).
12.1 Methods Involving Ribonucleic Acids (RNA)
In order to preserve the integrity of RNA transcripts, precautions were taken
throughout the following procedures. In particular, emphasis was placed on preventing
contamination with RNases and gloves were worn at all times. To this end, only
disposable plasticware was used, and all glassware was autoclaved prior to use. Only
ultrapure (molecular biology grade) distilled water was used during the preparation of
buffer solutions, all of which (except SDS) were autoclaved prior to use. RNA samples
were suspended in RNase-free ultrapure sterile water.
12.2 Preparation Of Complementary Deoxyribonucleic Acid
(cDNA) Template
Total RNA was extracted from PHA-treated PBMCs, Balb/c splenocytes,
BLCLs, and tumour tissues. From each sample, 5 pg of RNA were used to generate
complementary DNA (cDNA) by reverse transcription using reverse transcriptase (RT).
12.2.1 Extraction Of Total RNA
'RNAzol™B', which contains the RNase inhibitor guanidinium and the
denaturing agent phenol, was used in accordance with the manufacturer's (Cinna/Tel
Test) protocol to extract total RNA. RNAzol1MB promotes the formation of
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RNA/guanidinium/water complexes in an aqueous phase whilst eliminating DNA and
proteins from this phase.
12.2.2 Homogenization
Vials containing snap-frozen cell pellets or tumour tissue, and stored under liquid
nitrogen, were transferred onto dry ice to prevent thawing of sample. Whilst still frozen,
cell pellets were solubilized in their vials in RNAzolIMB (200 pL RNAzol[MB per 106
cells) by passing the lysate a few times through a pipette tip. Frozen tumour samples
were removed from vials and promptly dissected into small tissue fragments with sterile
scalpel blades followed by an immediate transfer into sterile vials containing
RNAzol™B (200 pL RNAzol™B per 10 mg of tissue) and homogenization using sterile
plastic plungers.
12.2.3 Extraction Of RNA
Chloroform was used to extract RNA from samples by adding 200 pL per 2 mL
of homogenate in their vials followed by vigorous shaking, a 5 minute incubation on ice,
and 12,000 g centrifugation at 4°C for 15 minutes. The spin promotes the separation of
an upper aqueous phase from a lower organic phenol/chloroform phase. Whilst RNA is
contained in the upper aqueous phase, the interface and lower organic phase contains
DNA and protein.
12.2.4 Precipitation Of RNA
The RNA-containing upper aqueous phase was harvested and transferred into a
sterile vial containing an equal volume of isopropanol on ice. RNA precipitation was
carried out in this manner for 15 minutes followed by 12,000 g centrifugation at 4°C and
the formation of a visible RNA pellet.
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12.2.5 Washing Of RNA
The supernatant was carefully harvested by a pipette so not to disturb the RNA
pellet which was washed once with 70% v/v ethanol at 7,500 g. The resulting pellet was
then resuspended carefully in pure water.
12.2.6 RNA Handling
Since RNA has its maximum absorbance at 260 nm, its concentration was
determined spectrophotometrically (optical density, OD) at this wavelength. In order to
assess protein contamination, further readings were taken at 280 nm. A 260/280
absorbance ratio of 1.8-2.0 indicated pure RNA. Next, the suspensions were divided into
2 aliquots. Whilst one was kept at -20°C as a working solution, the other sample was
kept at -70°C as stock (suspended in 75% v/v ethanol to preserve RNA integrity).
RNA integrity was checked by running samples out on 1% w/v NuSieve®
agarose gels. Under UV light, distinct bands corresponding to the 18S and 28S
ribosomal RNA subunits indicated a sample containing undegraded RNA whereas
sample smears suggested RNA degradation.
12.2.7 First-Strand cDNA Synthesis
cDNA synthesis was carried out using an 'RT-PCR Kit' from Stratagene in
accordance with the manufacturer's protocol using reverse transcription from random
primers by RT. The resulting heterogenous RNA-derived cDNA template population
was subsequently used as starting material for PCR (see section 12.3).
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All reagents were supplied by the manufacturer and included the following:
Random primers
First-strand buffer
RNase block ribonuclease inhibitor
1 OOmM deoxynucleotide-
triphosphates (dNTPs)







For each sample, a starting solution containing 5 pg of total RNA was made up
in pure water to a final volume of 38 pL to which 3 pL (100 mg/mL) of random primers
were added followed by gentle mixing. In order to denature the RNA, the sample
solutions were heated at 65°C for 5 minutes followed by quenching on ice. The random
primers were allowed to anneal to the cDNA templates at room temperature. Next, 5 pL
of lOx first-strand buffer and 2 pL of 100 mM dNTPs were simultaneously added to the
samples followed by 0.5 pL of each of a (40 U/pL) RNase block ribonuclease inhibitor
and the (50 U/pL) MMLV-RT. In order to allow first-trand cDNA synthesis by the
MMLV-RT, the sample solution was incubated in a waterbath at 37°C for 1 hour, and
then either used directly, or stored at -20°C.
In order to amplify/generate a homogenous population of a particular target
sequence of interest, PCR was carried out using sequence-specific primers.
12.3 PCR
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12.3.1 Methods Involving cDNA
Precautions were taken to avoid contamination with foreign DNA. To this end,
gloves were worn at all times and only sterile disposable plasticware was used. Only
molecular-grade, contamination-free reagents were used including ultrapure water. Pre-
amplification procedures took place in a designated clean room containing all necessary
laboratory equipment including designated pipettes and aerosol-resistant pipette tips.
PCR amplification was carried out in a general-purpose laboratory. cDNA samples were
tested on at least 2 occasions alongside positive and negative controls. In each run,
sterile distilled water (SDW) was included as a DNA template-free negative control.
12.3.2 Primer Pairs And Reaction Conditions
The sequences of the published oligonucleotide primer pairs used in this study
are shown in Table A5 in Appendix 1. Primers were synthesized by Eurogentec and
stored at -20°C. Although published reaction conditions were used as reference points,
all reaction conditions were optimized in our laboratory.
(1) Reaction Mixture
For each sample, 5 pL of cDNA were used as template in each reaction, and
transcript amplification was carried out in a total reaction volume of 100 pL. Each
reaction mixture consisted of 50 mM KC1, 10 mM Tris-HCl (pH9.0), 0.1% v/v Triton
XI00, and 200 pM of each of dATP, dCTP, dGTP, and dTTP as well as 2.5 U of Taq
DNA polymerase (from Thermus uquaticus strain YT1; the IL2 and 4 primers were used
with 3.5 and 2.0 units of enzyme, respectively). Additionally, 1.5 mM MgCE was
included in each reaction (the IL6 and IFNy primers were used with 2.5 mM MgCE).
The concentration of each primer was 1 pM per reaction.




A thermal cycler was used for PCR amplification. Amplification of the (3-actin,
1L5 and 6 transcripts consisted of 40 cycles of a 1 minute long denaturing step at 94°C
followed by 2 minutes of annealing/extension at 65°C. The IL2 and IFNy transcripts
were amplified using 40 cycles of 1 minute at 94°C and 2 minutes at 55°C. In order to
amplify the IL4 and IL10 transcripts, a 35 cycle reaction consisted of 45 seconds at 94°,
45 seconds at 60°C (annealment), and 2 minutes at 72°C followed by a final extension
step for 7 minutes. A summary of the PCR amplification cycles used is shown in Table
A6 in Appendix 1.
For visualization of amplified products under UV light, 20 pL of amplified
sample in 4 pL of loading buffer (6:1) were run out on 2.5% w/v NuSieve® agarose gels
containing 1 pg/mL ethidium bromide (EtBr).
12.4 Gel Electrophoresis
In order to use fragment size to separate and identify amplified DNA products,
they were run out on agarose gels in accordance with the protocols of Sambrook, Fritsch
and Maniatis (1989). To this end, low viscosity NuSieve® 3:1 agarose (3 parts NuSieve®
agarose, 1 part SeaKem® agarose) was dissolved by microwave heat treatment in lxTBE
buffer followed by cooling under running cold water and the addition of 1 pg/mL EtBr.
Horizontal gels were cast in plastic gel trays incorporating plastic combs for the creation
of sample wells and left to set. Once set, the gels were covered with lxTBE buffer and
the plastic combs gently removed (avoiding rupturing the wells). Next, a 1:6 v/v mixture
of PCR products and loading buffer was carefully loaded into wells. Each gel included
32P-end-labelled Hin/'I-digested bacteriophage <j)Xl74 DNA as DNA size markers and a
non-radiolabelled 1 Kbp DNA ladder. Electrophoresis of the PCR products was carried
out at 60 mA, and separated product bands were visulized at 365 nm under a UV
transilluminator followed by gel photographing for reference purposes.
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12.5 Southern Transfer
In accordance with the method of Southern (1975), PCR products were blotted
onto nylon membranes following electrophoretic separation on NuSieve® agarose gels.
First, the gels were immersed in alkaline denaturing solution for 30 minutes to denature
the DNA followed by neutralization at pH7.2 in neutralizing solution for 30 minutes.
Next, the Southern blot proper involved inverting the gels on top of glass plates sitting
on plastic trays filled with 20xSSC solution. The gels were placed on top of a single
large sheet of pre-wet (in 20xSSC solution) 3MM paper, the edges of which were
immersed in the 20xSSC solution of the underlying tray, and the undersurface of the gels
was rid of any air bubbles. A cut-to-size piece of positively charged nylon Hybond™-
N+ hybridization transfer membrane was then placed on top of the gels (avoiding the
formation of air bubbles) which was followed by arranging 3 cut-to-size pieces of 3MM
paper on top of the transfer membrane (the bottom sheet was pre-wet in 20xSSC
solution). In order to avoid evaporation, and to guide the direct transfer of the amplified
products onto the nylon membrane, the edges of the gels were sealed with cling film. To
create a flow of 20xSSC solution from the underlying tray and up through the gels, a
stack of dry paper towels was placed on top of the gels thus facilitating blotting of the
PCR products onto the transfer membrane. Southern transfer was further aided by
positioning a glass plate on top of the paper towels together with a 500 g weight, and
leaving the process overnight at room temperature. Following Southern transfer, gel
fragments were washed away in 2xSSC solution, and the transferred PCR DNA
fragments cross-linked to membranes by 120,000 pJ UV-irradiation in an UV
Stratalinker™.
12.6 Pre-Hybridization
Membranes were sealed in plastic bags containing pre-hybridization solution in
preparation of gene-specific probing with 32P-labelled oligonucleotide probes. In order
to minimize non-specific probe binding, 100 pL of sheared salmon sperm DNA that had
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been denatured by boiling in water for 5 minutes (followed by quenching on ice) was
added per 10 mL of pre-hybridization solution. The transfer membranes were soaked in
a waterbath at 42°C for at least 2 hours.
12.7 Radioactive Probes
Probes used in this study are shown in Table A7 in Appendix 1. Their sequences
were either designed, or obtained from published papers, as indicated. Probes were all
synthesized by Eurogentec, diluted in pure water to a concentration of 10 pmoles/pL (10
pM), and stored at -20°C.
Radiolabelling of probes was carried out using commercially available
(Promega) T4 polynucleotide kinase with the assay buffer provided. Probes were 5' end-
labelled by the enzyme by incubating 10 pmoles (1 pL) of the oligonucleotide together
with 5 pL of fresh (370 MBq/mL, 10 mCi/mL) 32P-labelled y-dATP in a reaction
solution containing 70 mM Tris-HCl (pH7.6), 10 mM MgCh, and 5 mM DTT in a
waterbath at 37°C for 30 minutes. The probe solution was run through a pre-wet (in
lxTE buffer) NICK™ column containing Sephadex® G-50 DNA grade in distilled water
to separate 32P-labelled probes from unincorporated oligonucleotides. The purified
radiolabeled probe was eluted off the column with lxTE buffer and effective
radiolabelling confirmed with a Geiger counter.
12.8 Hybridization Of 32P-Labelled Probe
Following pre-hybridization of transfer membrane (see section 12.6), bags
enclosing the membranes were opened and 32P-labelled probes were added to the pre-
hybridization solution together with fresh aliquots of denatured sheared salmon sperm
DNA. The bags were resealed and the radiolabelled probes left to hybridize with their
specific target sequences in a waterbath at 42°C overnight.
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12.9 Autoradiography
Following overnight's hybridization, the hybridization solution was discarded
and the membranes were rinsed to remove any probe bound to the membranes in a non¬
specific manner. Initially, two 10 minute rinses in 2xSSC/0.1% w/v SDS were carried
out at room temperature followed by a final 15 minute rinse in lxSSC/0.1% w/v SDS
solution. Excess moisture was removed from the membranes by blotting on 3MM paper
which was followed by sealing the membranes in cling film, and placing them in film
cassettes to expose Hyperfilm™-MP to the membranes. In order to magnify the signal
detected from bound radiolabelled probes, the cassettes contained intensifying screens
and were placed at -70°C. Exposure time varied from 1 to 7 days, and the autorads were
developed, annotated and kept as permanent records. A signal in a test sample lane was
scored as positive if the fragment was of the expected size (when compared with DNA
size markers included in each experiment) based on sequence alignment of primers with
the known gene sequence. Autorads were only analyzed further if (1) amplifiable DNA
was present as determined by p-actin cDNA amplification, and (2) all the positive and
negative controls (as well as the template-free SDW control) indicated successful, non-
contaminated RT-PCR amplification of target sequences.
12.10 Re-Probing
Transfer membranes could be re-used and re-probed with a freshly radiolabelled
probe by washing them in boiling hot 0.1% w/v SDS solution for 2 hours followed by
overnight autoradiography to confirm that all probe had been removed successfully.
Starting with immersion in pre-hybridization solution (see section 12.6 above), the
membranes were then re-probed by the usual method outlined above.
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13. Clonality
In order to ascertain whether SCID tumours represented the corresponding
biopsy, samples were assessed for (1) Ig and (2) EBV clonality.
(1) Ig clonality was analyzed by PCR using primers specific for a conserved
region of the V segment of framework (Fr) 3 and junction (J) segments of the Ig heavy
chain (IgH) gene locus (McCarthy et al, 1990; Stetler-Stevenson et al, 1990). The Fr3
PCR products were analyzed on ABI PRISM™ 310 Genetic Analyzer. Similar analysis
was performed using primers derived from Frl. Based on sequence analysis of
amplification products, a TaqMan™ PCR assay specific for specific rearrangements was
designed and performed using standard methodology when appropriate (Kuppers et al,
1995). Thus, PCR was performed with 1 pg of DNA using primers specific for a
conserved region of the V segment of Frl, or Fr3, and the J segments of the IgH gene
locus. Using QIAquick 8 PCR purification kit (Qiagen), 30 pL of PCR product were
purified, eluted in 60 pL of buffer, and 3 pL of purified product run on the ABI
PRISM™ 310 Genetic Analyzer with 0.5 pL of the GS350 marker and 10 pL of
formamide. Results were analyzed using GeneScan™ software.
(2) EBV clonality was assessed using standard Gardella gel technique (Gardella
et al, 1984; Raab-Traub & Flynn, 1986). For each tumour sample, lOxlO6 BamH\-
digested cell lysates were run on a Gardella gel (0.8% w/v agarose), Southern transferred
onto a nylon membrane, and probed with a P-labelled plasmid probe (Ecodhet).
Following EBV infection of a target B cell, the number of reiterated 500 bp virus
genome terminal direct repeats involved in generating the virus episome is characteristic
of any infection event. Since progeny EBV+ve cells retain the same EBV episome, a




The statistical tests used in this study were: (1) Fisher's exact test for comparison
of proportions; (2) Linear regression and Logrank test for comparison of survival of 2
(or more) groups of mice, and (3) non-parametric tests (Kruskall test, Mann-Whitney
test, Spearman's test) for analysis of association between 2 variables for comparison of 2
(or more) groups. Tumour incidence in different groups of SCID mice was compared by
the Fisher's exact test (with 2-tailed p value). The time to tumour in different groups of
animals was compared using the Kruskall test, Mann-Whitney test, and Spearman's test.
Statistical analysis was performed using 'GraphPad Prism' software (GraphPad
Software, Inc). Significance was determined using p values as follows: p>0.05 and
p<0.05 were considered to be non-significant and significant, respectively (Kirkwood,
1988).
Standard Error (SE) was calculated as: SE=SDn_)/Vn where SD is the standard
deviation and n denotes the number of samples analyzed. The value of SE was shown as
error bars on graphs.
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RESULTS
1. Expansion Of PTLD Biopsy Material
PTLD biopsy material is not readily available, is very difficult to expand in vitro,
and the few PTLD-derived cell lines available do not reflect accurately the initial tumour
phenotype (Cen et al, 1993). Furthermore, PTLD biopsy material generally contains
heavy infiltrates of non-malignant T cells (Perera et al, 1998) which can limit its use in
molecular studies. In light of these difficulties, the tumours have been modelled in vivo.
Our initial aim was to expand PTLD biopsies in SCID mice (hu-SCID-Bx model). Using
this approach, we wished to generate human PTLD-like lesions in the animals. To this
end, EBV+ve PTLD biopsy material was obtained from 5 solid organ transplant
recipients (denoted 'patient 1-5'; for patient details, see Table 7). We have previously
reported on successful in vivo expansion of PTLD biopsy samples from these patients




















1 5 M Kidney 72 Carrier Lymph
node
Myeloma
2 9 M Liver 343 Carrier1 Lymph
node
BLPD
3 0.1 F Liver 16 Primary infection Tonsil BLPD
4 7 M Heart 454 Carrier4 Lymph
node
HL




: At time of transplantation; : Time from organ graft to tumour; : Recurrence, original lesion arose 2 months post-
graft; 4: Recurrence, original lesion arose 29 months post-organ graft; HL: Hodgkin's lymphoma; BLPD: B celt
lymphoproliferative disease; M: Male; F: Female; Pt: Patient; No: Number
For each biopsy received, 25xl06-50xl06 biopsy cells (denoted 'biopsy') were
injected ip into one SCID mouse within 12 hours of patient sampling (material from
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patient 2 was inoculated into two animals). All samples gave rise to EBER+ve ip
tumours (denoted 'SCID tumour') in SCID mice. It was possible to passage material
from patient 3 only. Thus, our tissue panel consisted of 5 sets of PTLD biopsy and SCID
tumours. This panel was analyzed for (1) Ig and EBV clonality, (2) cell surface
phenotype, (3) in vitro proliferation, and (4) cytokine expression. Since sample material
was limited, a full complement of tests could not always be carried out.
1.1 Clonality
Initially, samples were assessed for (1) Ig and (2) EBV clonality to determine
whether SCID tumour cells represented the corresponding malignant cells in the PTLD
biopsy.
(1) Ig clonality was analyzed by PCR using primers specific for a conserved
region of the variable (V) segment of either framework (Fr) 1 (patient 2) or 3 (patients 1,
3, 4 and 5) and junction (J) segments of the Ig heavy chain (IgH) gene locus.
Representative results are shown in Figure 3.
Matching Ig clones were found in PTLD biopsy and SCID tumour sets from 4
out of 5 (80%) patients (number 1-3 and 5). Thus, 4 biopsies gave rise to identical
lesions in vivo which had expanded successfully in SCID mice. Additional sequence
analysis of material from patient 2 confirmed the identical Ig gene rearrangement in the
biopsy and SCID tumour (Figure 3A; Johannessen el al, 2002). The malignant Ig clone
was also detected in a PBL sample taken from patient 2 at time of PTLD. Biopsy and
SCID tumour from patient 3 were oligoclonal with an identical dominant rearrangement.
The passaged SCID tumours from patient 3 were clonal, one of which was identical to
the dominant biopsy and SCID tumour rearrangement (Figure 3B). Conversely, the
biopsy from patient 4 contained a dominant clone in a polyclonal Ig background (Figure
3C). Whilst the SCID tumour was clonal, it was not identical to the biopsy.
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FIGURE 3
Analysis Of Ig Gene Rearrangements
Samples were analyzed for Ig clonality using PCR in order to ascertain whether
SCID tumour cells represented the corresponding PTLD malignant cells. Figure 3A:
Electropherogram of Frl PCR from patient 2. Panel 1: PTLD biopsy result; Panels 2 and
3: Two SCID tumours. VH3 rearrangement of 328bp is indicated in each panel. Figure
3B: Electropherogram of Fr3 PCR from patient 3. Panel 1: PTLD biopsy showing
oligoclonal distribution; Panel 2: SCID tumour showing oligoclonal distribution with 3
dominant rearrangements; Panel 3: SCID tumour (passage 1) showing 1 dominant
rearrangement; Panel 4: SCID tumour (passage 2) showing a single rearrangement.
Figure 3C: Electropherogram of Fr3 PCR from patient 4. Panel 1: PTLD biopsy; Panel
2: SCID tumour. Dominant clones were detected at 109bp and 91 bp, respectively, as
indicated.
The symbol X denotes GeneScan™ 350 ROX-labelled size standard.














160 180 200 220 240 260 280 300 320
—i 1 1 1 1 1 1 1 1—
340 360
I i I L J
<—328bp
I X XI A A
□1 2B : A1-3V3S8I0PSY/VH3 / □□ 2R: A1-3/98BIQPSY/VH3 /
\ A A -- JL J
|«—328bp
L A A
□1 IB : A1-t07-tSCID / □□ 1R: A1-107-1SCID /
XXX X
A A A . i J
I*—328bp
L A A
□1 3B: A3-107-2SC® / □□ 3R:A3-107-2SCID/













□i SB :A9-12/96TUMOUR AS/ □□ 5R :A9-12/96TUMOUR AS/
W—91bp
AAA
□□ 6R: A11-114SCID AS/ □1 68 : A11-114 SCID AS /
131
(2) EBV clonality was assessed by standard Gardella gel technique (Gardella et
al, 1984). Biopsy and SCID tumour pairs from patients 2, 4 and 5 were analyzed. The
results are shown in Figure 4.
FIGURE 4
EBV Clonality Of PTLD Biopsy And SCID Mouse Tumours
Pt 5 Pt 2 Pt 4
I 1
M 1 2 3
i III
4 5 6 7 8
mm j EHHik Flf —►§p •••►
For each tumour sample, 10x10 ZJawtll-digested cell lysates were run on a 0.8% w/v agarose Gardella
gel, Southern hybridized onto a nylon membrane, and probed with a radiolabeled plasmid probe
(£codhet).
Lane 1: PTLD biopsy from patient 5. Lanes 2-3: SCID tumour (2 extracts from the same tumour material) from
patient 5. Lane 4: PTLD biopsy from patient 2. Lanes 5-6: Two SCID tumours from patient 2. Lane 7: PTLD biopsy
from patient 4. Lane 8: SCID tumour from patient 4. M: Non-radiolabelled lKbp DNA ladder as DNA size markers.
Pt: Patient; Clonal bands: —: Pt 5; ^ : Pt 2; "*► ; pt 4
All lesions tested contained a single band indicating virus clonality. Each PTLD
biopsy and SCID tumour set from patients 2 and 5 contained identical size bands
indicating that they were derived from the same infected cell in each case. Conversely,
the biopsy and SCID tumour pair from patient 4 contained different EBV clones
indicating that the SCID tumour arose from a non-malignant B cell in the biopsy sample.
1.2 Cell Phenotype
Next, PTLD biopsy and SCID tumour sets from patients 2-5 were
immunostained to determine the cellular phenotype. Bound antibody was detected using
PAP and APAAP techniques, and the proportion of specific antibody-positive cells in
tumour sections was assessed using the scheme shown in Table 8.
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TABLE 8
Quantification Scheme For Immunostained Tissue Sections
Score Percentage Of Antibody-Positive Cells









The results of the immunophenotyping studies are shown in Table 9.
TABLE 9
Immunophenotypic Comparison Of PTLD Biopsy




Pt 2 SCID 2 Pt 3 SCID 3 Pt 4 SCID 4 Pt 5 SCID 5
TCRct/|3 3+ OC 2+ - 4+ OC 3+ -
CD3 3+ OC 2+ - 4+ OC 3+ -
CD19 2+ 3+ 2+ 2+ 2+ 2+ 3+ 3+
CD23 2+ 2+ 2+ 2+ 2+ 2+ 2+ 3+
Polyclonal
EBV Serum1
3+ 3+ 3+ 3+ - 3+ 3+ 3+
EBNA1 3+ 3+ 3+ 3+ _ 2 3+ 3+ 3+
EBNA2 2+ 2+ 2+ 2+ - 2+ 2+ 2+
LMP1 1 + 1+ 1+ 1 + 1 + 1 + 1 + 1 +
BZLF1 +/- (+) +/- (+) - (+) +/- (+)
EA(D) +/- (+) +/- (+) - (+) +/- (+)
VCA +/- (+) +/- (+) - (+) +/- (+)
MA +/- (+) +/- (+) - (+) +/- (+)
Mouse
MHClDd
NT (+) NT (+) NT (+) NT (+)
NT: Not tested; TCR: T cell receptor; Pt: Patient; : Polyclonal EBV+ve human serum ('JAT'; London School of
Hygiene & Tropical Medicine, London); 2: EBNA1 -positive by RT-PCR
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PTLD biopsy and SCID tumour pairs from all patients (number 2-5) tested
expressed the B cell surface antigens CD 19 and CD23 indicating an activated, B
lymphoblastoid phenotype (Table 9). All biopsy material contained a substantial T cell
component (26->75%) whilst all SCID tumours contained no, or only the occasional, T
cell. Biopsy material from patients 2, 3 and 5 showed EBNA1 and 2 together with LMP1
suggestive of full EBV latent gene expression. All SCID tumours demonstrated similar
virus gene expression profile. In biopsy lesions, low level (<5% of cells) expression of
the lytic cycle antigens BZLF1, EA(D), VCA, and MA was detected. In the
corresponding SCID tumours, increased (5-10%) lytic cycle antigen expression was
observed. Conversely, biopsy from patient 4 showed restricted pattern of EBV gene
expression with only LMP1 detected by immunostaining (although EBNA1 transcripts
were detected by RT-PCR). No lytic cycle antigens were observed. The corresponding
SCID tumour showed EBNA1, EBNA2 and LMP1 expression with similar lytic antigen
expression [BZLF1, EA(D), VCA, MA] to other SCID tumours tested, further
emphasizing differences in tumour cell type between the biopsy and SCID tumour in this
case.
1.3 Expansion Of Tumour Material In Vitro
In vitro growth characteristics of PTLD biopsy and SCID tumour sets from
patients 1 and 3 were assessed using [ H]-thymidine incorporation into DNA as a
measure of proliferative capacity. Representative results are shown in Figure 5.
An initial growth spurt of biopsy-derived cells was observed during the first 24
hours followed by a low proliferation rate over the ensuing 13 days. The cells
subsequently died in culture. When culturing SCID tumour cells, an initial growth spurt
was observed during the first 24 hours followed by a low proliferation rate over the next
6 days. A high proliferation rate was then noted on day 14 in one case, and the cells




In Vitro Proliferation Of PTLD Biopsy And SCID Mouse Tumour
(Patient 3)


















Cells were pulsed with 1 jLtCi ['H]-thymidine for 4 hours, lysed, and the DNA-incorporated [3H]-
thymidine was measured in a scintillation (3-counter (expressed as average counts per minute).
E : PTLD biopsy; CJ : SCID tumour
1.4 Human Cytokine Gene Expression
In line with a previous report from our laboratory (Perera et al, 1998), extensive
T cell infiltrates (>26% of all cells; see Table 9) were apparent in all PTLD biopsy
material tested. Conversely, only the occasional (or no) T cells were detected in
corresponding SCID tumours. To address the possible role of T cell-derived growth
factors in tumour development, the human cytokine gene expression of all lesions (from
patients 1-5) were examined using RT-PCR. Representative results are shown in Figure
6.
All PTLD biopsy and SCID tumour sets demonstrated a similar cytokine profile
with expression of the B cell growth factors IL2, 4, 6, 10 and IFNy.
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FIGURE 6
Human Cytokine Gene Expression: IL10
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Using human ILiO primers, cDNA from 5(J.g of RNA was amplified in a 35 cycle RT-PCR reaction. The
PCR products were run on a 2.5% w/v agarose gel, Southern transferred onto a nylon membrane, and
hybridized using human ILlO-specific radiolabeled oligonucleotide probe.
Top panel: PTLD biopsy results; Lane 1: Radiolabeled size marker; Lane 2: Non-radiolabelled DNA ladder; Lane
3: PUA-treated human PBLs; Lane 4: PHA-treated Balb/c murine splenocytes; Lane 5: Sterile distilled water; Lanes
6-9: Four EBV in vitro immortalized BLCLs; Lanes 10-14: PTLD biopsy material from patients 1-5, respectively.
Bottom panel: SCID tumour results. Lanes 1-9: as above. Lanes 10-15: SCID tumours from patients 1-5,
respectively. Lanes 11-12: Two SCID tumours derived from patient 2. Bp: Base pairs; 1L: Interleukin. The size of the
1L10 RT-PCR product (328bp) is indicated.
1.5 Conclusions And Discussion
We transferred PTLD biopsy material from 5 organ graft recipients successfully
into SCID mice (hu-Bx-SCID model). Four (80%) of our PTLD biopsy and SCID
tumour sets arose from the same malignant cell (Figures 3A,B), whereas material from
one patient (number 4) that developed HL (Table 7) gave rise to a SCID lesion that did
not reflect the original malignant cell (Figure 3C). Rather, the SCID tumour probably
developed from a non-malignant EBV+ve 'bystander' B cell which is an observation
that has been reported by others. Thus, Meggetto et al (1996) inoculated cell suspensions
of 25 HL lymph node biopsy samples sc and ip into SCID mice. Whilst EBER
transcripts were detected in Hodgkin Reed-Sternberg (HRS) cells in 8 out of 25 (32%)
biopsies, 10 (40%) of these lymph node samples gave rise to EBER+ve, EBNA2+ve,
LMPl+ve sc and/or ip tumours in SCID mice. Of these 10 lymph node biopsies, (1) 4
(40%) derived from lymph node samples containing EBER+ve HRS and EBER+ve non-
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neoplastic small lymphocytes; (2) 5 (50%) originated from biopsies whose only EBV+ve
cells were non-neoplastic small lymphocytes; and (3) 1 (10%) arose from a lymph node
that contained EBER-ve cells only. Whilst there was a significant correlation between
the detection of EBV+ve non-neoplastic lymphocytes in biopsies and SCID tumour
outgrowth, no significant difference in SCID tumour formation was found between
transfer of lymph node samples with and without EBER+ve HRS cells.
The biopsy from patient 4 expressed EBNA1 and LMP1 only. In contrast, biopsy
material from the other patients, and all SCID tumours, expressed EBNA1, 2 and LMP1
antigens suggestive of unrestricted latency with a minor lytic [BZLF1, EA(D), VCA,
and MA] component (Table 9) further underlining differences in tumour cell type
between the biopsy and SCID tumour from patient 4.
It was only possible to passage SCID tumour material from one patient (number
3; see Figure 3B). Whilst the PTLD biopsy and SCID tumour from this patient were
oligoclonal with an identical dominant Ig rearrangement, the passaged SCID tumours
were clonal, one clone of which was identical to the dominant biopsy and SCID
rearrangement. Thus, these SCID lesions may reflect clonal progression in vivo whereby
an oligoclonal lesion (biopsy) gives rise to clonal tumours with increased malignant
potential. This is in line with what is known about the natural history of PTLD in organ
transplant recipients. It is generally agreed that PTLD represents a spectrum of lesions
where polyclonal hyperplastic reactive (viral lymphadenitis-like) B cell proliferations
may give rise in a step-wise manner to oligoclonal polymorphic and, ultimately,
monoclonal monomorphic lymphomas with increasing malignant potential and
resistance to therapy (Larratt et al, 2001).
All PTLD biopsy and SCID tumour sets demonstrated a similar cytokine profile
that included the expression of the B cell growth factors IL2, 4, 6, 10 and IFNy (Figure
6). Additional in situ hybridization studies in our laboratory have demonstrated that
these B cell growth factors were expressed by the PTLD tumour cells themselves rather
than the infiltrating T cells (Johannessen et al, 2000). The results obtained in the hu-
SCID-Bx model support our previous model of PTLD formation (see Figure 2 in
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Introduction) postulating that the malignant cells supply themselves with B cell growth
factors in an autocrine cytokine-mediated manner (Johannessen et al, 2000).
To our knowledge, the results showed for the first time the successful expansion
of a panel of PTLD biopsy material in SCID mice. Our findings contrast with an earlier
report by Randhawa et al (1997) suggesting that such material did not generally grow in
vivo. In their study, the group transferred 5 EBER+ve (2 polymorphic, 3 monomorphic)
PTLD biopsies sc into SCID mice. Whilst all 5 mice developed sc or thymic
monomorphic tumours, only 2 (40%) animals developed EBER+ve lesions (both were sc
tumours). Ig gene rearrangement and EBV clonality analysis showed a clonal
relationship of 1 of these 2 (50%) tumours to the corresponding biopsy sample.
Randhawa et al concluded that human PTLD was maintained in the patient setting by
host-derived growth stimuli that did not exist in the SCID mouse. Our findings do not
support that conclusion (see above). Rather, our results suggest autonomous PTLD
tumour development in SCID mice.
In the current study, analysis of the in vitro proliferation capacity of the tumour
panel demonstrated that PTLD biopsy and SCID tumour cells do not survive outside the
in vivo microenvironment (Figure 5) which is in line with previous (unpublished) results
from our laboratory as well as the experience of others. Not only is it difficult to obtain
adequate amount of lymphoma biopsy material for research purposes, but biopsy cells
do not generally grow in vitro, and the occasional biopsy-derived cell line does not
reflect the original tumour cell type. Thus, Cen et al (1993) examined EBV gene
expression in 23 PTLD biopsies and demonstrated that biopsy-derived BLCL outgrowth
in vitro reflected the selection of cell subpopulations that did not reflect the original
biopsy tumour cell type.
Whilst the above sets of experiments provided an adequate quantity of SCID
mouse-expanded homogenous PTLD material from 4 organ transplant recipients that
was uncontaminated with infiltrating non-malignant cells, we were unable to generate
PTLD biopsy-derived cell lines in vitro that could be used to generate further PTLD-like
tumours in SCID mice. Therefore, in order to model PTLD in vivo, we established a
SCID mouse model using in vitro EBV-infected BLCLs (Rowe et al, 1991).
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2. Establishment Of A SCID Mouse Model
The aim of these experiments was to establish SCID mouse models of PTLD
suitable for the testing of novel immunotherapies using inoculation of BLCLs. Thus, we
inoculated BLCL cells generated from a panel of healthy EBV-seropositive blood
donors either sc or ip to create hu-BLCL-SCID models in which to study (1) tumour
regression and (2) tumour prevention, respectively.
2.1 Sc Hu-BLCL-SCID Model: Tumour Regression
Initially, we assessed the sc tumorigenic potential of BLCL in SCID mice. The
aim was to establish an in vivo model in which tumour development could be visualized
and measured directly providing changes in tumour volume (ie, tumour regression) over
time as the read-out of the experiments. Using sc tumour development, therapeutic
intervention could be instigated at the time when small sc macroscopic lesions appeared
and treatment-induced tumour changes assessed.
2.1.1 Number Of BLCL Cells Required And Time To Tumour
To define the minimum cell number required for consistent BLCL-derived
tumour formation in vivo, we inoculated groups of 3 animals (2 sites per mouse) sc with
lxlO6, 2xl06or 4xl06 BLCL cells derived from a panel of 10 healthy EBV seropositie
donors (denoted 'donor A-J'). In parallel control experiments, PBL from 3 EBV-
seronegative healthy donors were used. These did not give rise to sc tumours. The
results are shown in Table 10.
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TABLE 10
Tumour Development In Sc Hu-BLCL-SCID Mice
Number Of BLCL Cells
Injected Sc Per Site
(Donor A-J)
Number Of Tumours/
Number Of Sc Sites Injected
(%)
Number Of Mice That
Developed Sc Tumours In
Both Flanks
(%)
1 xlO^ 11/20 (55) 3/10(30)
2xlOb 20/20(100) 10/10(100)
4xl0b 20/20(100) 10/10(100)
Twenty out of 20 (100%) sites injected sc with either 2xl06 or 4xl06 BLCL cells
showed macroscopic sc tumour outgrowth. In contrast, an inoculum of lxl06 BLCL
cells produced sc tumours in 11 out of 20 (55%) sites injected. In sc-inoculated mice,
tumours presented as sc macroscopic circumscribed masses at the site of sc inoculation.
The time to tumour development is shown in Table 11. It took a median time of 10, 5,
and 5 weeks for sc tumours to develop when an inoculum of lxlO6, 2xl06 and 4xl06
BLCL cells was used, respectively.
TABLE 11
Time To Tumour Formation In Sc Hu-BLCL-SCID Mice








A 10/9 4/7 3.5/5
B NTD/NTD 5/5 4/6
C 7/NTD 7/6 7/7
D 9/NTD 4/5 4/6
E 11/NTD 4.5/6 4.5/5
F 15/NTD 4.5/6 4/6
G 8.5/10 4/5 3.5/4.5
H 12/13 5/6.5 4.5/5
I NTD/NTD 7/8 5/6





NTD: No tumour developed
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Injection of 2xl06 BLCL cells per sc site was the minimum requirement for
consistent sc tumour outgrowth in 5 weeks. Therefore, we induced sc tumours in all our
animals with this standard BLCL does.
2.2 Ip Hu-BLCL-SCID Model: Tumour Prevention
Next, we assessed the ip tumorigenic potential of BLCL in SCID mice. The aim
was to establish an in vivo model in which the effects of novel preventative therapy on
tumour development could be ascertained using presence or absence of ip tumours as the
read-out of the experiments.
2.2.1 Number Of BLCL Cells Required And Time To Tumour
To define the minimum cell number required for consistent BLCL-driven ip
tumour formation in vivo, we inoculated groups of 3 animals with lxl06, 2xl06or 4xl06
BLCL cells derived from a donor panel of 5 healthy EBV-seropositive donors (denoted
'donor K-O'). In parallel control experiments, PBL from 3 EBV-seronegative healthy
donors were used. These did not give rise to ip tumours. The results are shown in Table
12.
TABLE 12
Tumour Development In Ip Hu-BLCL-SCID Mice
Number Of BLCL Cells Injected Ip
(Donor K-O)
Number Of Tumours/
Number Of SCID Mice Injected
(%)
1 xlOb 2/5 (40)
2 xlOb 5/5 (100)
4xl06 5/5(100)
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Five out of 5 (100%) mice injected ip with either 2xl06 or 4xl06 BLCL cells
developed macroscopic ip tumours. In contrast, an inoculum of lxlO6 BLCL cells
produced ip tumours in 2 out of 5 (40%) animals injected. In ip-injected animals, ip
tumours presented as macroscopic circumscribed masses in the upper or middle
abdominal cavity at the under surface of the liver at the porta hepatis or in the
mesentery. At times, the lesions extended into the liver. The time to tumour
development is shown in Table 13. It took a median time of 6, 6.5, and 6 weeks for ip
tumours to develop when an inoculum of lxl06, 2xl06 and 4xl06 BLCL cells was used,
respectively.
TABLE 13
Time To Tumour Formation In Ip Hu-BLCL-SCID Mice
Donor Number Of BLCL Cells Inoculated Ip
IxlO6 2xl06 4xl06
K NTD 6.5 6
L NTD 13 11
M 7 7 6
N NTD 6 4





NTD: No tumour developed; Ip: Intraperitoneally
Injection of 2x106 BLCL cells ip was the minimum requirement for consistent ip
tumour outgrowth in SCID mice in 6.5 weeks. Therefore, we induced ip tumours in all
our animals with this standard BLCL dose.
2.3 Factors Influencing/Predicting Tumour Development
Previously, we have examined the effect of (1) age of SCID mice at the time of
inoculation of EBV-infected B cells, (2) sex of mice, (3) murine serum Ig (mo-s-Ig)
levels, and (4) murine NK cell activity on PTLD-like tumour development in vivo and
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found none of these factors to adversely influence tumour outgrowth (Johannessen,
1997; Johannessen et al, 2000). Therefore, they were not studied further and 4-15
weeks' old SCID mice of both sexes used in all subsequent experiments without
depletion of endogenous (murine) NK cells or measurements of mo-s-Ig levels. Equally,
we have previously established that EBV-infected B cells do not give rise to PTLD-like
lesions in vivo beyond a period of 100 days after inoculation and, thus, all experiments
were terminated at this time point. Whilst we have also demonstrated previously that
fresh and frozen PBL stocks are equally able to give rise to ip tumours in the hu-PBL-
SCID model, we used freshly in vitro cultured BLCL, CTL and T cell subsets in all
subsequent experiments unless otherwise stated.
We have previously analyzed the usefulness of changes in mouse weight and
human serum Ig (hu-s-Ig) levels in predicting tumour outgrowth in SCID mice
inoculated with EBV-infected B cells, and not found these factors to be helpful in
forecasting tumour formation in vivo (Johannessen, 1997). Therefore, changes in murine
weight or hu-s-Ig were not used to predict tumour development in the animals.
2.4 Analysis Of Tissues And Tumours
The aim of these experiments was to determine the histology of BLCL-derived
tumours in SCID mice and to assess the tissue distribution of tumour cells in BLCL-
inoculated animals. Initially, paraffin wax-embedded tissue sections from lung, liver,
spleen and any tumour tissue from a panel of 10 sc and 10 ip mice inoculated with
BLCL from different donors were screened using (1) H&E staining, (2) anti-human
CD45 and CD20 immunostaining, (3) in situ hybridization for EBERs, and (4)
immunostaining for EBV latent (EBNA2, LMP1) and IE lytic (BZLF1) antigens. Tissue
sections from mice injected with saline only were used as species-specific controls for
all immunohistochemical analysis (for all other control tissues used, see Materials &
Methods). The results of analysis of serial tissue sections were as follows:
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(1) H&E: Sections were scored for distortion of normal tissue morphology and
cellular infiltrations. Large immunoblastic tumour cells were only consistently detected
in sc and ip tumour tissues (see Figures 7C-D).
(2) Human CD45 and CD20: Scattered or small foci of human CD45+ve,
CD20+ve cells were rarely found in lung and liver, occasionally in spleen, and
abundantly in sc and ip tumour tissues (see Figures 7E-H).
(3) EBERs: Scattered or small foci of EBER+ve cells were rarely found in lung
and liver, occasionally in spleen, and abundantly in sc and ip tumour tissues (see Figures
8A-B).
(4) EBV Antigens: EBER+ve cells in tumour tissue were found to express the
latent EBNA2 and LMP1 antigens with the occasional cell expressing the IE lytic
BZLF1 lytic antigen (see Figures 8C-H).
Macroscopic sc and ip BLCL-derived lesions were EBV+ve human B
immunoblastic tumours portraying full (unrestricted) latent virus gene expression with
the occasional tumour cell in lytic cycle. Immunostaining of the murine pan-nucleated
cell marker MHC1 on tumour sections showed no (or the very occasional) murine cell
underlining further that the lesions were human in origin. Taken together, tumours in sc
and ip hu-BLCL-SCID mice reflect PTLD in the organ transplant recipient.
In light of the above results as well as published reports (Rowe et al, 1991;
Picchio et al, 1992; Johannessen et al, 2000), further macroscopic sc and ip tumours
were not examined for their histological or EBV status, but were assumed to be
EBV+ve, PTLD-like lesions. Furthermore, microscopic tumours were assumed only to
develop in animals with macroscopic lesions.
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FIGURE 7
Immunophenotyping Of SCID Mouse Tumours:
Human Leukocyte Markers
(Paraffin Wax-Embedded Sections)
Figures 7A,B: Photographs of the peritoneal cavity of ip inoculated control (Figure 7A:
suspension medium only) and test (Figure 7B: BLCL) SCID mice taken at necropsy.
Arrow indicates ip BLCL-derived tumour in test mouse (Figure 7B). Figures 7C
(xlOO),D (x400): Photomicrographs of H&E staining of tumour sections showing large
lymphoblastoid tumour cells with large nuclei (blue haematoxylin staining) and scant
cytoplasm. Figures 7E,F (x400): Photomicrographs of immunostaining of the human
pan-leukocyte marker CD45 on tumour sections using an alkaline phosphatase (AP)
label. Figure 7E shows CD45+ve human cells (red membrane staining) counterstained
with Mayer's haemalum. Figure 7F shows the conjugate control with counterstained
cells only. Figures 7G,H (x400): Photomicrographs of immunostaining of the human
pan-B cell marker CD20 on tumour sections using a peroxidase (HRP) label. Figure 7G
shows CD20+ve human cells (brown membrane staining) counterstained with Mayer's
haemalum. Figure 7H shows the conjugate control with counterstained cells only.
The panels show a single mouse experiment but are representative of several
experiments.
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Immunophenotyping Of SCID Mouse Tumours:
EBV Transcripts/Antigens
(Paraffin Wax-Embedded Sections)
Figures 8A,B (x400): Photomicrographs of in situ hybridization for EBERs on tumour
sections using an alkaline phosphatase (AP) label. Figure 8A shows EBER+ve cells
(dark blue/black nuclear staining) on a probed tumour section which was counterstained
with Mayer's haemalum (blue nuclear staining). Figure 8B shows the counterstained
unprobed (negative) control tumour section. Figures 8C,D (x400): Photomicrographs of
immunostaining of EBNA2 on tumour sections using an alkaline phosphatase (AP)
label. Figure 8C shows EBNA2+ve cells (red nuclear staining) counterstained with
Mayer's haemalum (superimposed blue nuclear staining). Figure 8D shows the
conjugate control with counterstained cells only. Figures 8E,F (x400):
Photomicrographs of immunostaining of LMP1 on tumour sections using an alkaline
phosphatase (AP) label. Figure 8E shows LMPl+ve cells (red membrane staining)
counterstained with Mayer's haemalum (blue nuclear staining). Figure 8F shows the
conjugate control with counterstained cells only. Figures 8G,H (x400):
Photomicrographs of immunostaining of BZLF1 on tumour sections using an alkaline
phosphatase (AP) label. Figure 8G shows BZLFl+ve cells (red cytoplasmic staining)
counterstained with Mayer's haemalum (blue nuclear staining). Figure 8H shows the
conjugate control with counterstained cells only.
The panels show a single mouse experiment but are representative of several
experiments.
Arrows point to examples of specific transcript+ve/antibody+ve cells.
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2.5 Conclusions And Discussion
Based on the standardization experiments, the following points were established
regarding the sc and ip hu-BLCL-SCID mouse models:
(1) A minimum inoculum of 2x106 BLCL cells consistently gives rise to
macroscopic sc and ip tumours in SCID mice.
(2) BLCL-derived macroscopic sc and ip tumours in SCID mice are
immunoblastic human CD45+ve, CD20+ve B cell lesions.
(3) The SCID tumours are EBER+ve and show unrestricted latent EBV gene
expression with the occasional tumour cell in lytic cycle.
(4) Control mice injected with suspending medium alone, or PBLs from
EBV-seronegative donors, do not develop PTLD-like tumours in vivo.
In light of the above, we concluded that BLCL-derived SCID tumours mirror
PTLD in the organ transplant recipient and, therefore, BLCL-inoculated SCID mice can
be used to model the disease. Overall, the results agree with other published data by
Rowe et al (1991) and Lacerda et al (1996) who obtained consistent tumour growth
following sc or ip inoculation of BLCLs into SCID mice. The lesions that developed
were EBV+ve human B cell immunoblastic malignancies identical to PBL-derived
SCID tumours and PTLD. Whilst sc tumours developed locally, ip lesions formed at the
porta hepatis and in the mesentery.
The optimized experimental design used in subsequent experiments involved sc
or ip transfer of 2xl06 BLCL cells that consistently give rise to sc and ip tumours,
respectively, within a median time of 5-7 weeks (Tables 10-13) in experimental groups
of at least 3 SCID mice. Mice were sacrificed (1) when any sc tumour diameter reached
18 mm (as stipulated by the Project Licence); (2) at the time of signs of ip tumour; (3) at
a pre-set time limit of 100 days. Following termination, macroscopic examination at
necropsy was carried out together with routine harvesting of tumour (if present), lung,
liver and spleen tissue.
149
Donor BLCLs consistently gave rise to sc and/or ip tumours in SCID mice. In
contrast, we (and others) have shown that PBLs from EBV-seropositive donors vary
greatly in their ability to give rise to ip tumours in the hu-PBL-SCID model, (Picchio et
al, 1992; Johannessen et al, 1998, 2000). Therefore, these two SCID models differ in
terms of the ability of the EBV-infected cells to give rise to tumours in vivo although the
specific mechanisms are not yet clear (see General Discussion).
Next, we established and characterized panels of EBV-specific CTLs in vitro
with a view to investigating the capacity of these cells to mediate tumour regression in
the sc hu-BLCL-SCID model.
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3. Adoptive Immunotherapy And Hu-BLCL-SCID Mice
Initially, we established a panel of 28 healthy EBV-seropositive blood donors
(denoted 'donor 1-28'). EBV serostatus was confirmed by indirect immunofluorescence
anti-VCA immunostaining. Tissue typing of donor PBLs was carried out at the Anthony
Nolan Research Institute (London) or the Scottish National Blood Transfusion Service
(Edinburgh) using PCR-based methods. The results are shown in Table A8 in Appendix
1. Using this donor panel, we established BLCL and EBV-specific CTL sets (BLCLs
only were established from donors 26-28).
3.1 Phenotype Of In Vitro Expanded T Cells
In order to expand EBV-specific T cells from PBLs in vitro from donors 1-25
and after an initial in vitro growth period of 10 days, weekly stimulations using x-
irradiated autologous BLCLs were carried out and IL2 was added to cultures every
second day (from day 14). The cell surface phenotype of the 25 T cell lines was
determined using flow cytometry to delineate the relative proportion of T and NK cell
subsets. The results are shown in Table A9 in Appendix 1.
Cells were harvested following 7-17 weeks (median: 10 weeks) of in vitro
culture. At that time, 0-96% (median: 6%) were CD4+ve T cells whereas 3-97%
(median: 84%) were CD8+ve T cells. Of the 19 cell lines tested, 0-20% (median: 1%) of
the cells were CD56+ve NK cells. On all occasions, cultures contained <1% CD19+ve B
cells.
3.2 Cytotoxic Function Of In Vitro Expanded T Cells
In order to assess the cytotoxic function of the T cell lines generated from PBLs
from donors 1-25, we carried out a 4 hour standard 5!Cr-release assay. The target cells
included autologous and allogeneic (MHC mismatched) BLCLs as well as the NK target
K562. Tests were carried out at effector to target ratios of 20:1, 10:1, and 5:1. The
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results for an effectontarget ratio of 10:1 for each individual donor are shown in Table
A10 in Appendix 1.
At a 10:1 effector:target ratio, T cells from the 25 donors lysed 2-91% (median:
36%) of autologous BLCL targets whereas 0-30% (median: 6%) of allogeneic BLCL
targets were killed. Zero to 40% (median: 7%) of the NK cell target K562 were lysed by
the T cells.
An overview of percentage (%) specific lysis is shown in Figure 9.
FIGURE 9
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BLCL: B lymphoblastoid cell line; CTL: Cytotoxic T lymphocytes; NK: Natural killer cell
(For each column, the median is shown as a horizontal bar.)
Further analysis shows a significant difference between median % specific lysis
when comparing autologous targets with either allogeneic target cells, or the NK target
K562 (Mann-Whitney test: p<0.0001 on both occasions). We concluded that our in vitro
expanded T cells were EBV-specific CTLs.
3.3 Sc Hu-BLCL-SCID Model: Tumour Regression
For our studies in the sc hu-BLCL-SCID mouse model, we used (1)
unfractionated CTL populations and (2) T cell subset-enriched T cells.
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3.3.1 Unfractionated CTL Populations
Initially, we examined the anti-tumour capacity of unfractionated CTL
populations in the sc hu-BLCL-SCID model.
In Vivo Sc Tumour Regression Following Iv CTL Transfer
In order to assess the potential effectiveness of in vitro expanded T cell lines in
mediating regression of PTLD-like tumours in vivo, we used autologous BLCL and CTL
cell sets from 4 donors (number 1, 3-5; see Tables A8-10 in Appendix 1). For each
donor, 2xl06 BLCL were used to induce a sc tumour in the right flank of each mouse in
groups of 6-12 animals. At the first sign of macroscopic sc tumour development, direct
thrice weekly tumour measurements were commenced and half of each group (3-6 mice)
were injected iv with autologous CTLs whereas the other half of the animals (3-6 mice)
received iv suspension medium only. Cell transfer details are shown in Table 14.
TABLE 14
CTL Cell Numbers Used In Vivo
(Donors 1, 3-5)
Number Of Cells Inoculated Iv Per Mouse
CTLs CD4+ve CD8+ve CD56+ve
(xlO6) T Cells T Cells NK Cells
(x10") (xlO6) (xlO6)
Range 4-15 0-3 4-13 0
Median 5 1 4 0
CTLs: Cytotoxic T lymphocytes; Iv: Intravenous; NK: Natural Killer
Four million to 15xl06 (median: 5x106) autologous CTLs were inoculated iv into
each mouse. Thereof, 0-3x106 (median: lxl06) cells were CD4+ve T cells whereas
4x106-13x106 (median: 4xl06) cells were CD8+ve T cells. Less than 1x10s NK cells
were detected in the inocula. Individual results showing average tumour volume
including regression lines are shown in Figure 10.
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FIGURE 10
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous CTLs
(Donors 1, 3-5)
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Regression analysis to compare the slopes of regression lines shows that for each
donor the slopes were not significantly different apart from data obtained using donor 5.
For this donor, 15xl06 CTLs (containing 3xl06 CD4+ve T cells) were transferred iv into
each test mouse. The differences between the slopes of donor 5 regression lines were
significant (Linear regression: p=0.03) suggesting that the administration of CTLs had
significantly facilitated tumour progression.
The overall combined results are shown in Figure 11.
FIGURE 11
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous CTLs
(Donors 1, 3-5)
(Standard error, SE, is shown on each column as a vertical bar.)
Regression analysis to compare the slopes of regression lines shows that for the
pooled results, the slopes were not significantly different (Linear regression: p=0.12)
suggesting no overall effect of administration of CTLs. Tumour growth eventually
reached the maximum size permitted by our Project Licence and all animals were
sacrificed.
In light of the above results, in the next set of experiments we administered 2
CTL doses iv. Thus, 2xl06 BLCL from 4 donors (number 1-4; see Tables A8-10 in
Appendix 1) were used to induce a sc tumour in the right flank of each mouse in groups
of 6-12 animals. At the first sign of macroscopic sc tumour development, direct thrice
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weekly tumour measurements were commenced and half of each group (3-6 mice) were
injected iv with autologous CTLs whereas the other half of the animals (3-6 mice)
received iv suspension medium only. Using the same CTL lines, the second iv CTL dose
followed a week later. Cell transfer details are shown in Table 15.
TABLE 15
CTL Cell Numbers Used In Vivo
(Donors 1-4)
Number Of Cells Inoculated Iv Per Mouse: 1st Dose
CTLs CD4+ve CD8+ve CD56+ve
(xlO6) T Cells T Cells NK Cells
(xlO6) (xlO6) (xlO6)
Range 8 0-3 6-8 0
Median 8 1 7 0
Number Of Cells Inoculated Iv Per Mouse: 2nd Dose
CTLs CD4+ve CD8+ve CD56+ve
(xlO6) T Cells T Cells NK Cells
(xlO6) (xlO6) (xlO6)
Range 4-8 0-1 3-7 0
Median 5 1 4 0
CTLs: Cytotoxic T lymphocytes; Iv: Intravenous; NK: Natural Killer
For the first dose, 8x106 (median: 8xl06) autologous CTLs were inoculated iv
into each mouse. Thereof, 0-3x106 (median: lxl06) cells were CD4+ve T cells whereas
6x106-8x106 (median: 7xl06) cells were CD8+ve T cells. For the second dose, 4x106-
8x106 (median: 5xl06) autologous CTLs were inoculated iv into each mouse. Thereof, 0-
lxlO6 (median: lxlO6) cells were CD4+ve T cells whereas 3xl06-7xl06 (median: 4xl06)
cells were CD8+ve T cells. Less than 3x105 NK cells were detected in the inocula.




Sc Tumour Volume Over Time Following Iv Transfer Of
2 Doses Of Autologous CTLs
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(Standard error, SE, is shown on each column as a vertical bar.)
(Arrows indicate timing of 2nd CTL dose.)
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Regression analysis to compare the slopes of regression lines shows that for each
donor the differences between the slopes were not significant apart from data obtained
using donor 2. For this donor, 8x106 CTLs (lxlO6 of which were CD4+ve T cells) were
transferred iv into each test mouse on both occasions. The differences between the
slopes of donor 2 regression lines were highly significant (Linear regression: p=0.0004)
suggesting that the administration of 2 CTL doses significantly delayed tumour
progression. The overall combined results are shown in Figure 13.
FIGURE 13
Sc Tumour Volume Over Time Following Iv Transfer Of
2 Doses Of Autologous CTLs
(Donors 1-4)
(Standard error, SE, is shown on each column as a vertical bar.)















Regression analysis to compare the slopes of regression lines shows that for the
pooled results, the slopes were significantly different (Linear regression: p=0.01)
suggesting a significant delay in tumour development following the administration of 2
doses of CTLs. Tumour growth eventually reached the maximum size permitted by our
Project Licence and all animals were sacrificed.
In light of the above results, we concluded that iv administration of 2 doses of
4x106-8x106 autologous EBV-specific CTLs can significantly delay sc tumour growth in
Days Following CTL Inoculation
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SCID mice. Therefore, the use of CTL therapy at the first sign of macroscopic sc tumour
development can be effective in vivo albeit not consistently so.
Next, we assessed the contribution of T cell subsets in mediating tumour
suppression in the sc hu-BLCL-SCID mouse model. Since the above results suggested
that higher CTL numbers are more effective in vivo, we also increased the size of our
CTT, inocula
3.3.2 Enriched T Cell Subsets
Next, we examined the capacity of CD4- and CD8-enriched T cell subsets to
mediate tumour regression in vivo using our sc hu-BLCL-SCID mouse model. Due to
restricted cell numbers, it was not possible to carry out cytotoxicity testing on enriched T
cell subsets prior to in vivo studies.
First, we used donors 4, 21-22 (see Tables A8-10 in Appendix 1) to test the
magnetic bead separation procedure and determine whether cell manipulation and/or cell
loss during in vitro manipulations significantly affected in vivo experiments. These
experiments were carried out in the ip hu-BLCL-SCID model.
Enrichment Technique
For each of the 3 donors, 2xl06 BLCLs were inoculated ip into each mouse in 3
groups of 3 SCID mice each. Whilst 50x106 unfractionated autologous CTLs were
inoculated into each animal in the first test group of 3 mice, each mouse in a second test
group of 3 animals received 50x106 CTLs that had been fractionated into CD4+ve and
CD8+ve T cell subpopulations using magnetic beads and recombined in the original
CTL subset proportions. The third (control) group received suspension medium only.
The results are shown in Figure 14.
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FIGURE 14
% Survival Using Unfractionated And Fractionated/Recombined CTLs
(Donors 4, 21-22)
(Standard error, SE, is shown as a vertical bar.)
AH 3 Donors
Days Following CTL Inoculation
(Logrank test: p=0.71)
In the ip hu-BLCL-SCID mouse model, unfractionated CTLs and
fractionated/recombined CTLs have similar effect in vivo (Logrank test: p=0.71). We
concluded that in vitro manipulations per se do not significantly affect CTL performance
in the ip hu-BLCL-SCID model. Based on these results, and the restricted availability of
human leukocytes and SCID mice, we used (1) unfractionated CTL populations and (2)
suspension medium only as controls in all subsequent experiments.
Enriched T Cell Subsets
Using donors 6-9 (see Tables A8-10 in Appendix 1), we enriched CD4+ve and
CD8+ve T cells in our CTL samples using magnetic beads and assessed the purity of the
T cell subsets obtained using flow cytometry. The individual results are shown in Table
A11 in Appendix 1.
Following magnetic bead separation, 51-90% (median: 80%) of the CD4-
enriched population consisted of CD4+ve T cells whereas 82-96% (median: 96%) of
CD8-enriched cells were CD8+ve T cells. The CD4-/CD8-depleted subpopulations
consisted of 3-62% (median: 8%) CD4+ve T cells, 4-21% (median: 5%) CD8+ve T
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cells, and 9-84% (median: 80%) CD56+ve NK cells. The monocyte marker CD 14 was
not analyzed.
In Vivo Sc Tumour Regression Following Iv CTL Transfer
For each donor, 2x106 BLCL were used to induce a sc tumour in the right flank
of each mouse in groups of 3 mice each. At the first sign of macroscopic sc tumour
development, direct thrice weekly tumour measurements were commenced and 3 mice
were injected iv with suspension medium only whereas further groups of 3 SCID mice
each were inoculated iv with autologous CTLs and T cell subsets. Cell transfer details
are shown in Table 16.
TABLE 16
Cell Numbers Used In Vivo
(Donors 6-9)
Number Of Cells Inoculated Iv Per Mouse
CTLs CD4-Enriched CD8-Enriched CD4-/CD8-
(xlOfi) T Cells T Cells Depleted T Cells
(xlO6) (xlO6) (xlO6)
Range 50 8-16 12-50 1-8
Median 50 10 31 8
CTLs: Cytotoxic T lymphocytes; Iv: Intravenous
Each mouse received iv either 50x106 autologous EBV-specific CTLs, 8xl06-
16xl06 (median: lOxlO6) autologous CD4-enriched T cells, 12xl06-50xl06 (median:
31x106) autologous CD8-enriched T cells, or 1x106-8x106 (median: 8xl06) autologous
CD4-/CD8-depleted T cells. Individual results showing average tumour volume
including linear regression lines are shown in Figure 15. The results of regression
analysis to compare the slopes of individual regression lines are shown in Table 17.
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FIGURE 15
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous T Cells
(Donors 6-9)
(Standard error, SE, is shown on each column as a vertical bar.)
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Statistical Analysis (Linear Regression):
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous T Cells
(Donors 6-9)
Regression Lines Compared Significant Difference Between
Slopes of Regression Lines?
Donor 6
Medium and CTL No (p=0.06)
CD4-Enriched Yes (p=0.0006)
CD4/CD8-Depleted No (p=0.83)
CTL and CD4-Enriched No (p=0.35)
CD4/CD8-Depleted No (p=0.31)
CD4-Enriehed and CD4/CD8-Depleted Yes (p=0.02)
Donor 7
Medium and CTL No (p=0.18)
CD4-Enriched No (p=0.12)
CD4/CD8-Depleted No (p=0.61)
CTL and CD4-Enriched Yes (p=0.04)
CD4/CD8-Depleted No (p=0.55)
CD4-Enriched and CD4/CD8-Depleted No (p=0.20)
Donor 8
Medium and CTL No (p=0.55)
CD4-Enriched No (p=0.24)
CD8-Enriched No (p=0.37)
CTL and CD4-Enriched No (p=0.53)
CD8-Enriched No (p=0.67)
CD4-Enriched and CD8-Enriched No (p=0.80)
Donor 9
Medium and CD8-Enriched No (p=0.10)
CTL: Cytotoxic T lymphocytes
For donor 6, statistical analysis shows a significant difference between the slopes
of regression lines for medium only and CD4-enriched T cells as well as between CD4-
enriched and CD4-/CD8-depleted cells (Linear regression: p=0.0006 and p=0.02,
respectively). For donor 7, similar analysis shows a significant difference between the
slopes of regression lines for CTLs and CD4-enriched T cells (Linear regression:
p=0.04). Thus, administration of CD4-enriched T cells facilitated tumour development
when using donor 6.
In contrast, mice that received CTLs from donor 7 developed tumours
significantly faster when compared to animals inoculated with CD4-enriched T cells
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(Linear regression: p=0.04). For donor 7, however, there was no significant difference
when either of these groups was compared with animals that received medium only
indicating that neither CTLs nor CD4-enriched T cells had a significant impact on
tumour development in vivo. Tumour growth eventually reached the maximum size
permitted by our Project Licence and all animals were sacrificed.
The overall combined results for the first 10 days post-inoculation of CTLs and T
cell subsets are shown in Figure 16.
FIGURE 16
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous T Cells
(Donors 6-9)
(Standard error, SE, is shown on each column as a vertical bar.)
The results of regression analysis to compare the slopes of individual regression
lines are shown in Table 18. Statistical analysis shows a significant difference between
the slopes of regression lines for medium only and CD4-enriched T cells (Linear




Statistical Analysis (Linear Regression):
Sc Tumour Volume Over Time Following Iv Transfer Of
1 Dose Of Autologous T Cells
(Donors 6-9)
Regression Lines Compared Significant Difference Between
Slopes of Regression Lines?
Medium and CTL No (p=0.71)
CD4-Enriched Yes (p=0.04)
CD8-Enriched No (p=0.39)
CTL and CD4-Enriched No (p=0.07)
CD8-Enriched No (p=0.26)
CD4-Enriched and CD8-Enriched No (p=0.23)
CTL: Cytotoxic T lymphocytes
The sc hu-BLCL-SCID model proved difficult to manage because (1) in a group
of BLCL-inocuIated animals, sc tumours did not always arise at a similar timepoint
making iv administration of T cells difficult. Additionally, (2) it was difficult to inject
large T cell numbers iv without posing some risk to the animals. In order to circumvent
these problems, and in line with constant efforts to refine the in vivo study design, we
repeated the experiments in the ip hu-BLCL-SCID mouse model which circumvents
these difficulties and is technically easier to manage albeit being a prevention model.
3.4 Ip Hu-BLCL-SCID Model: Tumour Prevention
The aim of these experiments was to establish whether T cell-enriched
subpopulations on their own could prevent tumour development in the ip hu-BLCL-
SCID model.
3.4.1 Enriched T Cell Subsets
Using 10 donors (number 6, 8-16; see Tables A8-10 in Appendix 1), we enriched
CD4+ve and CD8+ve T cells in our CTL samples using magnetic beads and assessed the
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purity of the T cell subsets obtained using flow cytometry. The results are shown in
Table A12 in Appendix 1.
Following fractionation, 0-97% (median: 53%) of the CD4-enriched population
consisted of CD4+ve T cells whereas 40-97% (median: 88%) of CD8-enriched cells
were CD8+ve T cells. The CD4-/CD8-depleted subpopulations consisted of 1-49%
(median: 5%) CD4+ve T cells, 14-86% (median: 20%) CD8+ve T cells, and 10-25%
(median: 12%) CD56+ve NK cells. The monocyte marker CD14 was not analyzed.
In Vivo Ip Tumour Prevention Following Ip CTL Transfer
For each donor, 2xl06 BLCL were inoculated ip into each mouse in groups of 3
SCID mice. This was followed 1 hour later by the ip inoculation of suspension medium
only into one group of 3 animals whereas further groups of 3 SCID mice each were
inoculate ip with autologous T cells and T cell subsets. Cell transfer details are shown in
Table 19.
TABLE 19
T Cell Numbers Used In Vivo
(Donors 6, 8-16)
Number Of Cells Inoculated Ip Per Mouse
CTLs CD4-Enriched CD8-Enriched CD4-/CD8- Depleted
(xlO6) T Cells T Cells T Cells
(xlO6) (xlO6) (xlO6)
Range 40-50 3-67 3-50 1-50
Median 50 7 37 16
CTLs: Cytotoxic T lymphocytes; Ip: Intraperitoneal
Each mouse received ip either 40xl06-50xl06 (median: 50x106) autologous
EBV-specific CTL cells, 3xl0ft-67xl06 (median: 7xl06) autologous CD4-enriched T
cells, 3x106-50x106 (median: 37xl06) autologous CD8-enriched T cell, or 1x106-50x106
(median: 16xl06) autologous CD4-/CD8-depleted T cells. Animals were culled when
showing signs of illness, or at a pre-determined time limit of 100 days. On each
occasion, an ill mouse was found to harbour ip macroscopic tumour at necropsy.
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Inoculum Medium Only CTL CD4+ CD8+ CD4-/CD8-
Number Of
Tumours/ 29/30 26/30 25/30 18/30* 11/15*
Number Of Mice (97) (87) (83) (60) (73)
Injected
(%>
*: Statistically significant difference (p<0.05) when compared with mice inoculated with medium only;
CTL: Cytotoxic T lymphocytes; Ip: Intraperitoneal
Tumours developed in 26 (87%), 25 (83%), 18 (60%) and 11 (73%) out of 30
mice injected with CTLs, CD4- or CD8-enriched T cells, and CD4-/CD8-depleted cells,
respectively. In contrast, 29 out of 30 (97%) mice inoculated with suspension medium
only formed ip tumours. Thus, significantly fewer mice inoculated with CD8-enriched T
cells developed ip tumours than animals injected with suspension medium only (Fisher's
exact test: 0.001). Similarly, the transfer of CD4-/CD8-depleted cells resulted in
significantly fewer ip tumours than control mice (Fisher's exact test: p=0.04).
The time to end point (in days) for individual CTL donors is shown in Table A13
in Appendix 1, and the combined results are shown in Figure 17. Statistical analysis of
the data is shown in Table A14 in Appendix 1.
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FIGURE 17
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(For each column, the median is shown as a horizontal bar.)
Overall results showing proportion (%) mouse survival over time (in days) are
shown in Figure 18.
FIGURE 18
% Survival Using CTLs And T Cell Subsets
(Donors 6, 8-16)
(Standard error, SE, is shown as a vertical bar.)
CTL: Cytotoxic T lymphocytes
Individual results together with Logrank test results are shown in Figure 19.
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FIGURE 19
% Survival Using CTLs And T Cell Subsets
(Donors 6, 8-16)
(Standard error, SE, is shown as a vertical bar.)
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(Logrank test: p=0.0002) (Logrank test: p=0.09)
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Overall, the median time to end point is significantly different between the
groups analyzed (Kruskal-Wallis test: p=0.003). Further analysis shows that mice
injected with CTLs or CD8-enriched T cells survived significantly longer than control
animals (Mann-Whitney test: p=0.001 for both analysis; Logrank test: p=0.003 and
p=0.0002, respectively). Conversely, the use of CD4-enriched or CD4-/CD8-depleted T
cells did not significantly impact tumour development in vivo (Logrank test: p=0.101
and p=0.09, respectively).
Following initial CD4-enrichment, the proportion of CD4+ve cells in the
transferred inoculum differed markedly between donors (see Table A12 in Appendix 1).
Therefore, we re-analysed the results using data obtained when using CD4-enriched
cells from the 5 donors (number 6, 8-9, 14-15) whose CD4-enriched populations
contained 70-97% (median: 74%) CD4+ve cells. The results showing proportion (%)
mouse survival over time (in days) together with Logrank test results are shown in
Figure B1 in Appendix 1. The transfer of CD4-enriched cells from these 5 donors did
not significantly impact tumour development in vivo (Logrank test: p=0.35) which is in
line with the results above.
In light of the results, we concluded that autologous CTL and CD8-enriched T
cell subsets significantly delay development of PTLD-like tumours in vivo. Furthermore,
CD8-enriched T cells can prevent tumour formation in a significant proportion of mice
(Table 20).
Role Of CTL Cytotoxicity
The role of CTL cytotoxicity (as assayed in vitro by 51Cr-release studies) in
survival of ip inoculated SCID mice was assessed by statistical testing of the data. The
results of the analysis of the correlation between % specific CTL lysis of autologous
BLCL targets (at a 10:1 effector:target ratio) in vitro (see Table A10 in Appendix 1), and
the average % survival (in days) beyond control animals inoculated with medium only,
is shown in Figure 20.
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Statistical analysis of the data in Figure 20 shows a non-significant correlation
between CTL cytotoxicity in vitro and % survival of CTL-inoculated SCID mice
(Spearman's test: p=0.17). Since cytotoxicity assays could not be carried out on T cell
subsets due to low cell numbers, it was not possible to correlate their cytotoxicity in
vitro and survival of T cell-treated SCID mice.
FIGURE 20
% Survival As A Function Of
% Specific CTL Lysis At A 10:1 Effector:Target Ratio
(Donors 6, 8-16)
"t 1 1 1 1 1 1 i r—i
0 10 20 30 40 50 60 70 80 90 100
In Vitro 5lCr Release Cytotoxicity
(Spearman's test: p=0.17)
3.4.2 Delayed CTL Inoculation
To study the effect of delayed ip inoculation of CTLs on tumour development in
the ip hu-BLCL-SCID mouse, we ip injected 2x106 BLCL from donors 4 and 21 (see
Tables A8-10 in Appendix 1) into each mouse in groups of 3 animals. This was followed
3 weeks later by ip transfer into each mouse of either suspension medium only or 50x106
autologous CTLs. The results are shown in Figure 21.
Delaying ip CTL inoculation for 3 weeks did not significantly improve survival
(Logrank test: p=0.60). However, the impact of delaying CTL transfer needs to be
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analyzed further in future studies where CTLs are administered at pre-determined time
points during the initial 3 weeks post-BLCL injection.
FIGURE 21
% Survival Using Delayed CTL Ip Transfer
(Donors 4 and 21)
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(Logrank test: p=0.60)
3.4.3 Mismatched Allogeneic CTLs
In order to assess the importance of MHC restriction on the effectiveness of
transferred CTLs, we examined the ability of mismatched allogeneic CTLs to prevent ip
tumour development in the ip hu-BLCL-SCID model. Thus, 2x106 BLCLs from donors
27-28 (see Table A8 in Appendix 1) were ip inoculated into each SC1D mouse in groups
of 3 animals followed by ip injection into each mouse of either suspension medium only
or 50x106 mismatched allogeneic CTLs from donors 21-22 (see Tables A8-10 in
Appendix 1). The results are shown in Figure 22.
Mismatched CTLs did not have a significant impact on tumour development in
vivo (Logrank test: p=0.77). Therefore, the data suggests that tumour prevention in vivo
is MHC restricted.
Based on our findings in the hu-BLCL-SCID model, we determined the ability of
in vitro expanded T cell subsets to home to PTLD-like tumour tissue in vivo.
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FIGURE 22
% Survival Using Mismatched Allogeneic CTLs
(Donors 21-22/27-28)
(Standard error, SE, is shown as a vertical bar.)
(Logrank test: p-0.77)
3.5 In Vivo Trafficking Of Human T Cells
Paraffin wax-embedded serial sections from lung, liver, spleen, and tumour
tissue were immunostained using standard methods, and the proportion of specific
antibody-positive cells was assessed using the scheme shown in Table 21.
TABLE 21
Quantification Scheme For Immunostained Tissue Sections
Score Percentage Of Antibody-Positive Cells








Initially, we used the sc hu-BLCL-SCID model to examine human T cell
trafficking in vivo. Using 6 donors (numbers 6, 8, 17-20; see Tables A8-10 in Appendix
1), 2xl06 BLCLs were sc inoculated into each SCID mouse in groups of 3 animals. At
the first sign of macroscopic sc tumour outgrowth, each mouse was iv inoculated with
14xl06-49xl06 (median: 42x106) autologous CTLs. We investigated the cell surface
phenotype of human leukocytes in tissues derived from 31 sc hu-BLCL-SCID (16 test
and 15 control) mice harvested at each of 5 specific time points (1 animal per time point:
1 hour, or 1, 2, 7 or 14 days).
Since we only very rarely detected human CD45+ve leukocytes in lung and liver
tissue, pulmonary and hepatic samples were not analyzed further. The results of the
immunophenotyping studies are shown in Table 22.
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TABLE 22
Immunophenotyping Of Spleen And Sc SCID Mouse Tumour Tissue










CD45 CD20 CD3 CD4 CD8 CD45 CD20 CD3 CD4 CD8
6 Medium Id - - - NT NT 3+ 3+ - - -
CTL Id - - - - - 2+ 3+ - - -
7d - NT - NT NT 1+ 3+ - - -
8 Medium Id - NT NT NT NT 3+ 3+ - - -
7d - - - - - 1+ 1 + - - -
CTL Id - - - - - 3+ 3+ - - -
7d - - - - - 3+ 3+ - - -
17 Medium lhr NT NT NT NT NT 3+ 3+ - - -
Id - - - NT NT 3+ 3+ NT NT NT
2d NT NT NT NT NT 3+ 3+ - - -
7d NT NT NT NT NT 3+ 3+ NT NT NT
14d 1+ 1+ - - - 3+ 2+ - - -
CTL I hr NT NT NT NT NT 3+ 1 + - - -
Id - - (+) - (+) 3+ 2+ 1+ - -
2d 2+ 2+ 2+ 2+ 2+ 3+ 2+ - - -
7d NT NT NT NT NT 3+ 2+ (+) - -
14d - - - - - 3+ 2+ " - -
18 Medium lhr NT NT NT NT NT 3+ 3+ - - -
Id NT NT NT NT NT 3+ 3+ - - -
2d - - - - - 3+ 2+ - - -
7d - - - - - 3+ 1 + - - -
14d - - - - - 3+ 1 + - - -
CTL lhr - - (+) - - 2+ 1 + - - -
Id - - (+) (+) - 3+ 3+ - - -
2d - - - - - 3+ 3+ (+) - -
7d (+) (+) - - - 3+ 3+ - - -
14d - - - 3+ 1 + - - -
19 Medium Id - - NT . - 3+ 1 + - - -
CTL Id - - - - - 3+ 1 + - - -
20 Medium Id - NT NT NT NT 2+ 1 + - - -
CTL Id - - - - - 3+ 1 + (+) (+) (+)
CTL: Cytotoxic T lymphocytes; d: Day; hr: hour; Iv: Intravenous; No: Number; NT: Not tested;
Sc: Subcutaneous
Representative results are shown in Figure 23.
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FIGURE 23
Immunophenotyping Of Sc SCID Mouse Tumour Tissue:
Human Leukocyte Markers
(Donors 6, 8, 17-20)
(Paraffin Wax-Embedded Sections)
Figures 23A,B (x400): Photomicrographs of immunostaining of the human pan-
leukocyte marker CD45 on tumour sections using an alkaline phosphatase (AP) label.
Figure 23A shows CD45-positive human cells (red membrane staining) counterstained
with Mayer's haemalum. Figure 23B shows the conjugate control with counterstained
cells only. Figures 23C,D (x400): Photomicrographs of immunostaining of the human
pan-T cell CD3 marker on tumour sections using an alkaline phosphatase (AP) label.
Figure 23C shows CD3-positive human cells (red membrane staining) counterstained
with Mayer's haemalum. Figure 23D shows the conjugate control with counterstained
cells only. Figures 23E,F (x400): Photomicrographs of immunostaining of the human T
helper cell CD4 marker on tumour sections using an alkaline phosphatase (AP) label.
Figure 23E shows CD4-positive human cells (red membrane staining) counterstained
with Mayer's haemalum. Figure 23F shows the conjugate control with counterstained
cells only. Figures 23G,H (x400): Photomicrographs of immunostaining of the human T
cytotoxic CDS marker on tumour sections using an alkaline phosphatase (AP) label.
Figure 23G shows CD8-positive human cells (red membrane staining) counterstained
with Mayer's haemalum. Figure 23H shows the conjugate control with counterstained
cells only.
The panels represent data obtained when using cells from donor 20 (see Table 22).
Arrows point to examples of specific antibody+ve cells.
176
23A: CD45 23B: CD45 Control
• 7-*&Si'* ■ "^^v£&- 'tSvsJSi,
&-v
• •
-•''¥ r r - -
-/' ?c V , ^V

















,»?r * ■ *
■ *+ ..
■"
■■* tu • ii T*-
>V...v. •.-«:■■ * >


















23G: CD8 23H: CD8 Control
a
■ >w ■






l':\ ■ ■■ .
¥' • ■
. - ■ '' -
'
5,*.
V ' - • *
■i
- ' »„•*
••• * n " •* « -
:i* .
__ a* • •»





Human CD45+ve/CD20+ve B cells made up the vast majority of cells in all sc
tumours that arose in control and test animals. In contrast, human B cells were only
detected in splenic tissue from 1 out of 8 (13%) control animals tested (day 14).
Similarly, only 2 out of 13 (15%) test animals examined had detectable human B cells in
spleen (day 2 and 7).
Human T cells were not detected in control mice. CD3+ve T cells were found in
splenic tissue from 4 out of 14 (29%) test mice analyzed (1 hour and day 1, 1 and 2,
respectively) and in tumour tissue from 4 out of 16 (25%) test animals (day 1,1,2 and 7,
respectively). Both tissues from 1 of these mice contained detectable CD3+ve T cells.
Overall, 7 out of 16 (44%) test mice had detectable human CD3+ve T cells in either
splenic and/or tumour tissue at time points up to 7 days following CTL infusion. Of
these 7 test mice, samples from 2 (29%) animals contained CD4+ve T and CD8+ve T
cells. Samples from further 2 (29%) test mice contained CD4+ve or CD8+ve T cells,
respectively. However, tissues from the remaining 3 test animals did not immunostain
with antibodies against the CD4 or CD8 surface markers. Overall, T cells comprised <1-
29% of each T marker+ve tumour section. Immunostaining against NK markers was not
carried out.
We concluded that human T cells can home to spleen and tumour tissue in the sc
hu-BLCL-SCID mouse model. Next, we determined whether human T cells could be
detected in tissues harvested at necropsy from ip hu-BLCL-SCID mice.
3.5.2 Ip Hu-BLCL-SCID Model
Serial sections of 32 paraffin wax-embedded ip tumour samples obtained in
experiments described in section 3.4.1 using 10 donors (number 6, 8-16) were examined.
Since human CD45+ve leukocytes were very rarely detected in lung, liver and splenic
tissue, these samples were not analyzed further. The results of the immunophenotyping
study are shown in Table 23.
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TABLE 23






CD45 CD3 CD4 CD8
6 CTL 3+ - - -
CD4 Enriched 1+ - - -
CD8 Enriched NT NT NT NT
CD4/CD8 Depleted NT NT NT NT
8 CTL 1+ - - -
CD4 Enriched (+) - - -
CD8 Enriched (+) - - -
CD4/CD8 Depleted NT NT NT NT
9 CTL 2+ 1+ - 1+
CD4 Enriched 2+ (+) - (+)
CD8 Enriched 1+ - - -
CD4/CD8 Depleted 3+ 1+ - 1+
10 CTL 1 + - - -
CD4 Enriched 3+ - - -
CD8 Enriched 1+ 1+ - 1 +
CD4/CD8 Depleted 2+ - - -
11 CTL 3+ 1 + - 1+
CD4 Enriched 3+ - - -
CD8 Enriched 2+ 1 + - 1+
CD4/CD8 Depleted 3+ - - -
12 CTL 2+ 1+ - 1 +
CD4 Enriched 2+ 1 + - 1+
CD8 Enriched (+) - - -
CD4/CD8 Depleted NT NT - NT
13 CTL 3+ 1 + - 1 +
CD4 Enriched 3+ 1+ - 1 +
CD8 Enriched NT NT NT NT
CD4/CD8 Depleted 3+ 1 + - -
14 CTL 1+ 1+ - 1 +
CD4 Enriched 3+ 1 + 1 + 1 +
CD8 Enriched 2+ 1 + - -
CD4/CD8 Depleted 2+ 1 + - -
15 CTL 3+ - - -
CD4 Enriched 2+ - - -
CD8 Enriched 2+ - - -
CD4/CD8 Depleted 1+ (+) (+) -
16 CTL NT NT NT NT
CD4 Enriched 2+ 1 + (+) -
CD8 Enriched NT NT NT NT
CD4/CD8 Depleted NT NT NT NT
CTL: Cytotoxic T lymphocytes; Ip: Intraperitoneal; No: Number; NT: not tested
Human CD3+ve T cells were found in 17 out of 32 (53%) tumour samples tested.
Whilst 2 out of these 17 (12%) samples contained CD4+ve T cells, 11 (65%) of the
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samples had detectable CD8+ve T cells and 1 (6%) sample contained CD4+ve and
CD8+ve T cells. Three (18%) samples were CD3+ve only by immunostaining. Overall,
T cells comprised <1-29% of each T marker+ve tumour section. Immunostaining against
NK markers was not carried out.
Taken together, we concluded that human T cells are able to home to human
tumour tissue in vivo in sc and ip hu-BLCL-SCID mice. Therefore, we examined the
possible mechanisms involved in mediating tumour rejection in vivo.
3.5.3 Cytotoxic Mechanisms Used By CTLs In Vivo
Using serial sections of the 17 paraffin wax-embedded ip tumours shown to
contain CD3+ve T cells in section 3.5.2 (donors 6 and 8-16), immunostaining was used
to determine whether T cells employed perforin or granzyme B cytoloytic molecules in
vivo. Representative results are shown in Figure 24.
Six out of 17 (35%) tumour samples contained granzyme B+ve cells whereas a
further 8 out 17 (47%) samples contained perforin+ve cells by immunostaining. Overall,
therefore, 14 out of 17 (82%) tumour samples tested expressed one or the other cytoxic
granule molecule (see Figure 24).
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FIGURE 24
Immunophenotyping Of Ip SCID Mouse Tumour Tissue:
Human Leukocyte Markers And Cytotoxic Granule Molecules
(Donors 6, 8-16)
(Paraffin Wax-Embedded Sections)
Figures 24A,B (x400): Photomicrographs of immunostaining of the human pan-leukocyte
marker CD45 on tumour sections using an alkaline phosphatase (AP) label. Figure 24A
shows CD45-positive human cells (red membrane staining) counterstained with Mayer's
haemalum. Figure 24B shows the conjugate control with counterstained cells only. Figures
24C,D (x400): Photomicrographs of immunostaining of the human pan-T cell CD3 marker
on tumour sections using an alkaline phosphatase (AP) label. Figure 24C shows CD3-
positive human cells (red membrane staining) counterstained with Mayer's haemalum.
Figure 24D shows the conjugate control with counterstained cells only. Figures 24E,F
(x400): Photomicrographs of immunostaining of the cytotoxic granule molecule perforin on
tumour sections using a peroxidase (HRP) label. Figure 24E shows perforin-positive human
cells (brown cytoplasmic staining) counterstained with Mayer's haemalum. Figure 24F
shows the conjugate control with counterstained cells only. Figures 24G,H (x400):
Photomicrographs of immunostaining of the cytotoxic granule molecule granzyme B on
tumour sections using an alkaline phosphatase (AP) label. Figure 24G shows granzyme B-
positive human cells (red cytoplasmic staining) counterstained with Mayer's haemalum.
Figure 24FI shows the conjugate control with counterstained cells only.
Arrows point to examples of specific antibody+ve cells.
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3.6 Conclusions And Discussion
The initial aim of these experiments was to examine the effect of autologous
CTLs and T cell subsets on sc PTLD-like tumours in the sc hu-BLCL-SCID model in
which macroscopic tumour growth can be measured directly. When 1 dose of CTLs was
iv inoculated into the animals, no overall significant effect on tumour development was
noted (Linear regression: p=0.12; see Figures 10-11), and lesions continued to grow in
all treated animals. In contrast, Lacerda et al (1996) demonstrated significantly
improved survival of iv CTL-treated SCID mice with established BLCL-derived sc
tumours when compared to untreated control animals. Although 6 out of 10 (60%)
treated mice subsequently succumbed to malignant disease, 4 (40%) animals
experienced complete tumour regression.
CTLs from donor 5 facilitated sc tumour growth in vivo compared to untreated
control animals (Linear regression: p=0.03). The cell inoculum from this donor (15xl06
CTLs) contained the highest number (3x106) of transferred CD4+ve T cells of the 4 CTL
lines used (from donors 1, 3-5; see Table 14) and, thus, it is plausible that these cells
provided the malignant cells with growth factors that encouraged their expansion.
Further support for this hypothesis comes from a similar observation in the current study
when using CD4-enriched T cells from donor 6 (see Figures 15-16). Animals that
received these cells developed sc tumours significantly faster than controls (Linear
regression: p=0.0006) suggesting that CD4+ve T helper cells facilitated tumour
formation in vivo. This is in line with our previous results obtained in the hu-PBL-SCID
model (see Figure 2 in Introduction) highlighting key role of CD4+ve T cells in
lymphomagenesis in vivo (Johannessen et al, 2000). Interestingly, CTL line 6 showed
91% lysis of autologous targets in vitro (see Table A10 in Appendix 1) underlining the
non-correlation of in vitro assays with regression data obtained in vivo (see Figure 20 in
Results). These observations are in line with results from our laboratory demonstrating
non-correlation of CTL cytotoxicity as measured by 51Cr-release assay and CTL
treatment outcome in the PTLD patient setting (Haque et al, 2007). Whilst the reasons
for this are not clear, it appears that the 51Cr-release assay is a crude in vitro system for
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determining CTL function in vivo. Clearly, the assay does not mimic the in vivo
microenvironment in which T cells exert their cytotoxic effect and is, therefore, an
artificial approach to gauging T cell function. In the clinical setting, infused T cells may
prompt an inflammatory response within PTLD tumours by recruiting non-specific
cytotoxic cells or activating endogenous EBV specific CTLs. When administering
allogeneic CTLs on a 'best MHC match' basis to PTLD patients, such an inflammatory
reaction may be similar to the graft-vers«.v-1eukaemia (GVL) effect that is considered to
be of benefit against leukaemia following allogeneic bone marrow transplant (Bonini et
al, 1997; Ciceri et al, 2007).
CD8-enriched T cells did not significantly delay sc tumour development in SCID
mice (Figure 16) which is in contrast with results obtained in the ip hu-BLCL-SCID
model in the current study (see below).
Administration of a CTL dose iv at time of macroscopic sc tumour formation
followed a week later by a second autologous iv CTL dose significantly delayed sc
tumour development in SCID mice (Linear regression: p=0.01; see Figures 12-13).
Although the results agree with the observations by Lacerda et al (1996) cited above,
they only transferred a single dose of CTLs iv.
Since the highest number of CTL cells administered in the current study was
most likely to have a significant impact on sc tumour development in vivo (see Tables
14-16), the size of the inoculum appears to be important. Therefore, we increased the
number of cells used in subsequent experiments. However, the sc hu-BLCL-SCID model
proved difficult to manage because:
(1) in animals inoculated sc with BLCLs, sc tumours did not always arise at a
similar timepoint making iv administration of CTL and T cell subsets
problematic in terms of experimental planning,
and
(2) it proved difficult to inject large T cell inocula iv without posing some risk to
the circulatory stability of the animals.
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Because of continuous efforts to refine our in vivo study approach (see the '3 Rs'
in section 4 in Introduction), we repeated the experiments in the ip hu-BLCL-SCID
mouse model which circumvents these difficulties and is technically easier to manage.
In the ip hu-BLCL-SCID model, inoculating CTL lines significantly improved
survival of mice injected 1 hour after ip BLCL transfer with unfractionated autologous
CTLs, or CD8-enriched T cells, when compared with control animals inoculated with
suspension medium only (Logrank test; p=0.003 and p=0.0002, respectively; see Figures
18-19). Furthermore, animals inoculated with CTLs, or CD8-enriched T cells, showed a
significant delay in median time to tumour when compared to control mice (Mann-
Whitney test: p=0.001 for both analysis; Figure 17). The importance of CD8+ve T cells
is further highlighted in the current study by the observation that significantly fewer
animals inoculated with CD8-enriched T cells developed ip tumours than controls
(Fisher's exact test: p=0.001) and, thus, these cells not only significantly delay ip tumour
development in vivo, but they can also prevent it altogether in a significant proportion
(40%) of mice (see Table 20). These results are supported by data obtained in other
laboratories. In their study, Boyle et al (1993) engrafted SCID mice ip with BLCL
followed by simultaneous administration of autologous whole population (or CD8-
enriched) CTLs. Whilst mice inoculated only with BLCL developed PTLD-like lesions
on average 20 days after transfer, simultaneous administration of autologous whole
population (or CD8-enriched) CTLs significantly delayed tumour formation in vivo.
Similar results were obtained if T cell inoculation took place 7 days after BLCL transfer
into mice. In contrast, mismatched CTLs failed to have an effect on tumour
development. Further support for the data comes from studies by DiMaio et al (1995)
and Buchsbaum et al (1996) when assessing the preventative effect of ex vivo expanded
autologous CTLs on tumorigenic B cell lines transferred ip into SCID mice.
CD4+ve T cells can portray cytotoxic function in vitro and in vivo (Appay,
2004). Norris et al (2001) demonstrated perforin-mediated cytolytic function in vitro of
group-specific antigen (gag)-specific CD4+ve T cell clones generated from HIV+ve
PBLs. In the current project, the highest CTL killing of autologous targets in vitro was
carried out by CTL line 6 which contained 49% CD4+ve T cells (see Figure 9 and
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Tables A9-10 in Appendix 1). Similar in vivo data from Appay et al (2002) demonstrate
the presence of a small subpopulation of perforin+ve, CD4+ve cytolytic T cells in
healthy individuals, which is markedly expanded in patients with chronic viral infections
(in particular, HIV). Additionally, CD4+ve T cells produce cytokines (mainly INFy and
TNFa) which have an anti-tumour effect whilst others are essential for priming CD8+ve
CTL responses and for maintaining CTL function and proliferation (Wang, 2001). B cell
tumours like PTLD express MHC2 molecules (Thomas et al, 1990) although most other
tumour cell types do not (and therefore can not directly interact with CD4+ve T cells)
suggesting the possibility of direct CD4+ve T cell-mediated cytotoxic action in PTLD.
However, inoculation of CD4-enriched T cells did not have a significant impact on
tumour development in the ip hu-BLCL-SCID mouse model (Figure 19). This finding
also contrasts with results obtained in the hu-PBL-NOD/SCID model where treatment of
mice with a depleting anti-human CD4 mab resulted in loss of both CD4+ve and
CD8+ve T cells (Wagar et al, 2000), and data from our laboratory showing a significant
trend towards better responses to allogeneic 'best MHC match' CTL treatment of PTLD
patients with higher numbers of CD4+ve T cells in infused CTL lines (Haque et al,
2007). Further support for the importance of CD4+ve T cells comes from studies on ex
vivo expanded biopsy-derived melanoma antigen-specific tumour infiltrating
lymphocytes (TILs) showing that both CD4+ve and CD8+ve T cells are essential to
obtain an effective anti-melanoma response in the patient setting (Dudley et al, 2002). In
the hu-BLCL-SCID model, therefore, the most effective combination of CD4+ve and
CD8+ve T cells still needs to be identified.
In light of the apparent discrepancy between the SCID model and the clinical
setting, further analysis of the association between the number of inoculated CD4+ve T
cells and survival of treated animals beyond non-treated control mice in the ip hu-
BLCL-SCID model is shown in Figure 25. Similar analysis of the CD8+ve T cell
population is shown in Figure 26.
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FIGURE 25
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(Spearman's test: p>0.05 for all analysis)
Statistical analysis of the data in Figures 25-26 shows non-correlation between
the number of CD4+ve, or CD8+ve, T cells (included in the CTL, CD4-enriched, or
CD8-enriched T cell inoculum transferred ip into SCID mice) and the average %
survival (in days) beyond control animals inoculated with medium only (Spearman's
test: p>0.05 for all analyzes). Similar results were obtained when analysing the
CD8:CD4 ratio of cells inoculated (Spearman's test: p>0.05 for all analyzes). Therefore,
it does not appear that survival of SCID mice treated with autologous CTLs, or T cell
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In both sc and ip hu-BLCL-SCID models, human T cells were detected in T cell
treated animals for up to 64 days (see Tables 22-23; Table A13 in Appendix 1). This is
in line with previous (unpublished) results from our laboratory as well as observations
by others underlining that T cells can home to PTLD-like tumours in SCID mice. Thus,
in their study, Lacerda et al (1996) showed preferential homing of CD8+ve T cells to
autologous tumour tissue but not to MHC-mismatched sc tumours. Similar results have
been obtained in imaging studies by Koehne et al (2003) using radioactive labelling of
human EBV-specific T cells to track the cells in vivo. Thus, Koehne et al (2003) have
demonstrated selective homing of human T cells to autologous sc EBV-induced tumours
in SCID mice despite subtle species-specific differences that are assumed to exist
between the two species. The advent of novel in vivo biophotonic imaging technology
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permits labelling of T cells with light-emitting reagents that can be visualized in real
time by a light-sensitive photon counting-coupled device (CCD) camera connected to a
dark box over a heated pad. Whilst our laboratory has only recently embarked on using
this new technology, it permits analysis of homing of therapeutic T cells in vivo. On¬
going studies in our laboratory using such an approach will permit a better insight into T
cell trafficking in the SCID mouse model (for further information about the imaging
technology, see the website: www.xenogen.com).
CTLs employ 2 main cytolytic pathways: one involves cytotoxic perforin-
granzyme A/B granule exocytosis, and the other entails Fas (CD95)-Fas ligand (FasL;
CD178) interactions resulting in activation of the caspase enzyme cascade in target cells
leading to apoptosis. Additional pathways involve the tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and its cognate receptor (De Bueger et al, 1992).
Whilst our immunostaining data (see section 3.5) suggest that the cytotoxic molecules
perforin and granzyme B are likely to be the T cell effector mechanisms in the current
study (see Figure 24), we did not analyze the role of T cell-derived cytokines [for
example, TNFa] or apoptotic mechanisms in mediating tumour regression/prevention.
Based on our results, we propose a scheme for T cell-mediated destruction of
PTLD-like lesions in the ip hu-BLCL-SCID mice (Figure 27). In our model, transfer of
autologous CTLs results in homing of CD4+ve and CD8+ve T cells to tumorigenic
EBV+ve B cells in SCID mice. Upon recognition of EBV-derived peptides in an
autologous MHC context, T cells are triggered to release the cytotoxic granule
molecules perforin and granzyme B which results in target cell lysis. The model is
supported by recent studies from our laboratory demonstrating that the main CTL




A Model Of CTL Function In The Ip Hu-BLCL-SCID Mouse
CD4+ve and CD8+ve T Cells
u
Ip Transfer Into SCID Mice
u
CD4+ve and CD8+ve T Cells Home To Autologous Tumorigenic EBV+ve B Cells
u
T Cells Recognize EBV Peptides In An MHC-Restricted Manner
u
T Cells Release Perforin And Granzyme B Cytotoxic Molecules
u
Tumour Cell Lysis
Next, we explored ways of improving the hu-BLCL-SCID model.
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4. Attempts To Improve The Hu-BLCL-SCID Model
In order to improve the efficiency of the hu-BLCL-SCID model, we investigated
the role of (1) cytokine stimulation and (2) MRI imaging as adjuncts to the in vivo
model. First, we examined the effect of cytokine conditioning of CTLs in vitro on their
capacity to prevent tumour development in the ip hu-BLCL-SCID model.
4.1 Cytokine Conditioning Of CTLs
Cytokines have the ability to enhance homing of T cells by promoting their
expansion, function and survival in vivo. Thus, cytokines that signal through the
common y-chain (IL2, 4, 7, 15 and 21) are important for the homeostasis of CD4+ve and
CD8+ve T cells (Ku et al, 2000; Schluns et al, 2000). The aim of this set of experiments
was to examine the impact of in vitro CTL cytokine conditioning prior to in vivo transfer
into the ip hu-BLCL-SCID model. In light of the large cell numbers required for these
experiments, viably frozen CTLs were used in these experiments.
4.1.1 In Vitro CTL Cytokine Conditioning
CTL lines (day -1) from donors 5, 17 and 22-24 (see Tables A8-10 in Appendix
1) were placed in culture medium containing 20% v/v FCS and either human IL2
(routine CTL culture conditions), 7, 15, 21, 7 and 15, or 7 and 21, at a final
concentration of 20 IU/mL (IL2) or 10 ng/mL (all other growth factors) for 24 hours
(Parada et al, 1998; Ayyoub et al, 2002). The following day (day 0), the cytokine
conditioned cells were washed and reconstituted in suspension medium for in vivo use
(see below). We also assessed the EBV-specific cytotoxicity of the cell lines on day 0
using standard 5lCr-release assay. The results are shown in Figure 28.
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FIGURE 28
% Specific CTL Lysis At A 10:1 Effector:Target Ratio
























BLCL: B lymphoblastoid cell line; IL: Interleukin
(For each column, the median is shown as a horizontal bar.)
Overall, no significant difference between median % specific lysis was found
when comparing autologous targets conditioned with IL2, 7, 15, 21, 7 and 15, or 7 and
21 (Kruskal-Wallis test: p=0.74). We concluded that cytokine conditioning CTLs with
IL2, 7, 15, 21, 7 and 15, or 7 and 21, for 24 hours in vitro does not significantly
influence their cytotoxic potential as measured by 5lCr-release assays.
4.1.2 In Vivo Tumour Prevention Following Ip CTL Transfer
For each of the 5 donors, 2x106 BLCL were inoculated ip into each mouse in
groups of 3 SCID mice each. This was followed 1 hour later by the ip inoculation of
suspension medium only into one group of 3 animals, whereas further groups of 3 SCID
mice each were inoculate ip with 50x106 autologous CTLs that had been conditioned for
24 hours in vitro with either IL2, 7, 15, 21, 7 and 15, or 7 and 21. Individual results
showing proportion (%) mouse survival over time (in days) together with logrank test
results is shown in Figure 29.
192
FIGURE 29
% Survival Using Cytokine Conditioned CTLs
(Donors 5, 17, 22-24)
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No significant difference was found between any survival curves apart from
experiments using CTLs conditioned with a combination of IL7 and 15 when compared
to cells conditioned with 1L2 (Logrank test: p=0.04).
Next, we examined whether MR1 imaging enabled us to monitor tumour
development in the ip hu-BLCL-SCID model in a non-invasive manner.
4.2 Ip Hu-BLCL-SCID Mice And MRI Imaging: Treatment Model
The aim of these experiments was to determine whether MRI imaging could be
used to assess T cell-mediated tumour regression in the ip hu-BLCL-SCID tumour
model. We ip inoculated 2xl06 BLCL from donors 4 and 20 (see Tables A8-10 in
Appendix 1) into each SCID mouse in a group of 5 animals. Two weeks later, weekly
MRI scans were commenced until animals developed signs of illness and were culled.
MRI imaging was carried out with either T1 or T2 weighting and with or without iv
injections of the contrast medium gadolinium. Representative results of weekly scans are
shown in Figure 30.
MRI imaging enabled us to detect ip tumour development. The radiological signs
of tumour formation included loss of normal anatomical architecture and the blurring of
organ outline together with the appearance of an ip mass at the under surface of the liver




30A: Control 30B: At 2 Weeks
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4.3 Conclusions And Discussion
In an effort to improve the ip hu-BLCL-SCID model:
(1) CTLs were pre-conditioned with cytokines in vitro prior to transfer ip into
SCID mice,
and
(2) MRI imaging was carried out to assess tumour formation in vivo in a non¬
invasive, non-destructive manner.
A combination of IL7 and 15 may have enhanced the ability of CTLs to mediate
tumour prevention in hu-BLCL-SCID mice although individually IL7, IL15, and IL21
did not (Figure 29). Furthermore, a combination of IL7 and IL21 did not have an impact
in vivo. We postulate that the cytokines improved the ability of the in vitro conditioned
T cells to home to, and mediate destruction of, human PTLD-like tumour cells in vivo.
Cytokines that signal through the common y-chain (for example, IL7 and 15) are known
to improve T cell trafficking and function in vivo. In their study of ovalbumin (OVA)-
specific transgenic murine CD8+ve T cells (denoted 'OT-1 cells'), Schluns et al (2000)
demonstrated that nai've OT-1 cells transferred into lymphopenic recombination
activating gene (RAG) -/-, and IL7 -/- RAG-/-, mice (both of which lack mature B and T
cells) only survived and expanded in the former, but not in the latter, murine host.
Furthermore, using OT-1 and IL7R -/- OT-1 cells in an immunocompetent mouse, the
group showed survival and expansion of the former, but not of the latter, memory T cell
population following OVA challenge in vivo. Similarly, using anti-IL15 blocking mabs
in an immunocompetent mouse model, Ku et al (2000) showed that IL15 was required
for survival and expansion of memory CD8+ve murine T cells in vivo.
Whilst in vitro cytokine conditioning did not significantly affect CTL
cytotoxicity in vitro as measured by 51Cr-release assay (Figure 28), additional results in
the current project (see section 3 in Results), and data from clinical studies in our
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laboratory (Haque et al, 2007), suggest that in vitro cytotoxicity does not correlate with
CTL function in vivo.
We did not examine the possible role of cytokine administration in sustaining
transferred T cells in vivo since previous studies have given conflicting results of such
an approach. In their study, Baiocchi el al (2001) demonstrated that combined therapy
with human granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose
IL2 can prevent tumour formation in the presence of human effector (CD8+ve T) cells in
the hu-PBL-SCID model (Baiocchi et al, 1994, 2001). Furthermore, autologous and
allogeneic LAK cells prolong survival of sc and ip BLCL-inoculated SCID-beige mice
(that also lack endogenous NK cell activity; Randhawa et al, 1998). In contrast, Boyle et
al (1993) and Rencher et al (1994) have shown that IL2 is not required when CTLs, or
CD8-enriched T cells, are transferred into ip hu-BLCL-SCID mice. In both these studies,
T cells significantly prolonged survival of treated mice compared with untreated control
animals in the absence of IL2 supplementation.
Animals were imaged with an MRI scanner with a view to establishing an ip
treatment model (see Figure 30). The MRI scanner consists of a magnetic cylinder in the
centre of which an anaesthetized animal is placed and subjected to radiowave energy
pulses. These pulses are absorbed by hydrogen ions, which resonate at a frequency
particular to the tissue type. At the end of the pulse, the hydrogen ions re-align with the
magnetic field and release the stored energy which is detected by sensors enabling image
construction. Structures within the thoracic and abdominal cavity can be clearly seen (to
within 50-100 pm resolution), but contrast dyes (such as gadolinium) may be injected to
alter the local magnetic field and enhance image quality. Small animal MRI permits:
(1) imaging of internal structures in great detail,
(2) the assembly of 3 dimensional (3D) images,
and
(3) non-invasive, non-destructive longitudinal studies on the same animal.
However, the technology is very costly.
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Tumours could be identified in the murine peritoneal cavity on MRI images
taken as early as 2 weeks after BLCL transfer. Published data by other research teams
using athymic nude mice to model liver metastasis of human colorectal disease have
shown similar results. In their study, Wu et al (2003) implanted a highly liver-metastatic
human colon cancer into the caecum of animals, whilst Cai et al (2005) inoculated
human colon cancer cells directly into the portal vein of nude mice. Using regular MRI
scans, tumour growth in the animals was analyzed in a non-invasive, non-destructive
manner, and the scan images were found to correlate with macroscopic findings at
necropsy.
In the current study, the radiological signs included obliteration of the normal
liver contour and general signs of a space-occupying lesion in the abdomen. These signs
grew more apparent with subsequent weekly scans and the iv administration of
gadolinium aided interpretation of the images. However, in contrast to the metastatic
colorectal cancer models described above, it was not possible in the current study to
demarcate clearly the ip tumours. The main reason was that BLCL-derived tumour
consistency appeared to be very similar to that of the liver itself and, therefore, it was
difficult to separate the two tissues. Whilst gadolinium contrast helped highlighting the
tumours, use of the agent did not result in circumscribed lesions that could be measured
directly on scanned images. Thus, it is not yet possible to quantify a T cell-mediated
treatment response on MRI scans.
Whilst the results are encouraging, the role of MRI imaging as an adjunct to the
ip hu-BLCL-SCID model needs to be clarified further in future studies in order to
establish the optimized manner in which to achieve clear visualization of BLCL-derived
ip tumours in vivo. In light of the very costly nature of MRI imaging, the role of small
animal computed tomography (CT) scanning could also be assessed although such
facilities are not available to us. Thus, in a recent study, Pittet et al (2007) demonstrated
that fused single photon emission CT (SPECT) and x-ray CT technology enabled
localization and quantification of11 'in-oxine-labelled CTLs at tumour sites in vivo.
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5. Tumour Prevention Using Antibodies Against Gp350
Transfer of donor EBV isolates to a recipient via a transplanted organ can be
documented in EBV-seronegative recipients (Haque et al, 1996), but has not been
observed in EBV-seropositive graft recipients. It is postulated that pre-existing
neutralizing antibodies directed against the envelope gp350 antigen in EBV+ve patients
may play a key role in preventing donor virus infecting recipient cells following
transplantation (Haque et al, 2006). We hypothesized that passive immunization of
EBV-seronegative organ graft recipients prior to transplant surgery, leading to
circulating neutralizing antibodies directed against the envelope gp350 antigen, may
prevent EBV transmission via the transplanted organ and, thereby, reduce the risk of
PTLD development.
To test our hypothesis, we obtained a mouse mab against EBV envelope gp350
produced by the hybridoma cell line 72A1 from Johns Hopkins University Medical
School (Baltimore, Maryland, USA). Previous studies have shown the mab to prevent
EBV infection of B lymphocytes in vitro (Hoffman et al, 1980; Thorley-Lawson &
Geilinger, 1980; Miller et al, 1982; Sairenji et al, 1988). Initially, we characterized the
cell line and its mab. We have previously reported on the study results (Haque et al,
2006 - see Appendix 2).
5.1 Characterization Of 72A1 MAb
The 72A1 mab was manufactured at the Therapeutic Antibody Centre (Oxford,
UK) in accordance with 'Good Manufacturing Practice' guidance (see General
Discussion). As described previously, the purified 72A1 mab was found to be a mouse
IgGl containing k and X light chains in equal proportions (Hoffman et al, 1980). Since
the IgGl k-secreting myeloma cell line P3X63Ag8 had been employed to create the
72A1 hybridoma, the purified mab was probably a mixture of active and inactive
species. Thus, only a minor proportion may have had full bivalent binding to gp350.
Using immortalization assays, the EBV neutralizing titer was determined to be 10"4.
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Next, we examined the capacity of the 72A1 mab to prevent EBV infection in
vivo using a modified version of our ip hu-PBL-SCID model (Johannessen et al, 2000).
5.2 Tumour Prevention: Modified Hu-PBL-SCID Model
In order to test the ability of the 72A1 mab to hinder EBV infection in vivo, we
used the development of PTLD-like lesions in a modified ip hu-PBL-SCID model as the
experimental read-out (Cannon et al, 1990). In this version of the model, PBLs from an
EBV-seronegative donor are inoculated into an animal followed by the administration of
a concentrated EBV preparation resulting in virus infection of B cells in vivo and
formation of PTLD-like lesions. Twenty million to 30xl06 PBLs from one of 4 EBV-
seronegative donors were injected ip into each animal in a group of 6 SCID mice each
on day 0. For each group of 6 mice, 3 test mice were also injected ip with the 72A1 mab
preparation on day -1,0 and 1, and then thrice weekly for 3 weeks. Since a minimum
serum mab level of 1 pg/mL is considered to be effective for in vivo studies (Renner et
al, 1994), each antibody inoculum comprised of 680 pg of the 72A1 mab as determined
in our initial in vivo titration experiments to be adequate to maintain circulating mab
above this level. Conversely, 3 control mice received ip suspension medium only at the
same time points. Overall, a total of 12 mice received 72A1 mab whilst 12 animals
served as controls. On day 1, all mice received 50 pL ip of a concentrated EBV
preparation with an immortalizing titer of 10"4. Mice were sacrificed when they showed
signs of illness, or after a preset limit of 100 days. The results are shown in Table 24.
None out of 12 (0%) mice treated with the 72A1 mab developed ip tumours,
whereas 8 out of 12 (67%) of control mice inoculated with medium only succumbed to
malignant disease. All ip tumours were EBER+ve as determined by in situ hybridization.
The results showed a statistically significant difference between the test and control
groups (Fisher's exact test: p=0.001).
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TABLE 24
72A1 MAb And Lymphomagenesis In Hu-PBL-SCID Mice
Treatment Number Of PBL Number Of Tumours/






Hu: Human; lp: Intraperitoneal; mAb: Monoclonal antibody; PBL: Peripheral blood leukocytes;
*: p=0.001
5.3 Conclusions And Discussion
Primary EBV infection following organ transplantation is a risk factor for PTLD
(Cockfield, 2001). Furthermore, EBV-seronegative organ transplant recipients can
acquire the virus via the grafted organ (Haque et al, 1996). In contrast, such virus
transfer has not been observed in EBV-seropositive graft recipients. Therefore, pre¬
existing neutralizing antibodies directed against the envelope gp350 antigen may protect
against infection with donor virus isolates, and efforts of developing EBV vaccine have
focused on gp350 to elicit protective humoral immunity (Moutschen et al 2007). We
postulated that conferring passive virus immunity to EBV-seronegative patients about to
undergo organ transplantation using the 72A1 mab could reduce the risk of primary
EBV infection during the immediate post-transplant period and, thereby, reduce the risk
of PTLD development.
Our initial results confirmed the in vitro neutralizing potential of the 72A1 mab,
and we used SCID mice to assess its efficacy in vivo. Using PTLD-like tumour
formation as the read-out of the experiments, the ip SCID model mimicked as far as
possible the patient situation where a virus is transferred from a seropositive donor to a
seronegative organ recipient. The 72A1 mab provided complete and significant
protection against EBV-driven lymphomagenesis in the mice (p=0.001; Table 24) which
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is in line with previous studies showing that administration of purified Ig pooled from
EBV-seropositive donor plasma prevents outgrowth of PTLD-like lesions in hu-PBL-
SCID mice inoculated with leukocytes from EBV-seropositive individuals (Abedi et al,
1997).
Whilst we assessed lymphomagenesis in vivo, the study did not examine directly
whether the 72A1 mab prevents virus infection in SCID mice. It is possible that the
antibody did not completely prevent EBV infection of B cells in vivo, and if this was the
case, the 72A1 mab (of IgG isotype) may produce its effects through ADCC lysis of B
cells since the target gp350 virus antigen is expressed on the surface of infected cells
(Thorley-Lawson & Geilinger, 1980). Cells involved in such ADCC destruction of
infected B cells may include murine NK cells and granulocytes (which exist at normal
levels in SCID mice), or human NK cells and monocytes transferred in the PBL
inoculum. Equally, gp350 is a component of the virus envelope and becomes accessible
to the antibody upon release of virions during lytic infection which occurs in the SCID
model (see section 2.4 in Results). Therefore, the 72A1 mab may neutralize infectious
virus at the time of lytic infection and, thus, prevent infection and recruitment of
uninfected B cells which may be one mechanism by which PTLD-like lesions arise in
vivo.
Following successful completion of our SCID mouse experiments, inoculation of
a single 10 mg dose of 72A1 mab iv into a healthy adult proceeded without any side
effects [for example, human anti-mouse antibody (HAMA) production]. Peak mab
serum levels (0.08-0.12 mg/mL) persisted for 52 hours following iv administration and
then gradually declined, becoming undetectable after day 43. Anti-72A1 HAMA was not
detected in serum samples at any stage during an 18 months observation period and the
antibody was, therefore, considered to be safe.
These safety data were sufficient for ethical approval for a pilot study in which 7
children about to undergo liver transplantation were recruited (Haque et al, 2006).
Details of the patients are shown in Table 25. Four children (denoted 'patient 1—4')
received 1 mg of 72A1 mab per kg of body weight by iv infusions immediately before,
and 6 hours after, organ transplant, and then every 2 days for up to 3 weeks. 72A1 mab
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was detected in serum samples from all 4 infused children. Three patients (denoted
'patient 5-7') served as controls. Routine immunosuppressive treatment was
administered to all 7 patients.
TABLE 25
Patient Details, 72A1 Mab Status, And Outcome Of Study





Time (Months) Of Detection Post-Tx
VCA IgG VCA IgM EBV DNA
1 11 M 11 3 3 43
2 16 M 6 - - 48
3 75 M 4 - - ND
4 18 F 7 - - 42
5 17 M 0 3 - 40
6 10 F 0 2.5 - ND
7 9 F 0 41 - 18
F: Female; M: Male; ND: Not detected; No: Number; Tx: Transplant; VCA: Viral capsid antigen;
Negative (Adapted from Flaque et al, 2006)
Three out of 4 (75%) 72A1 -infused patients (number 2-4) remained EBV-
seronegative during the 6 months follow-up period whereas l (25%) patient (number 1)
developed anti-VCA IgG antibodies 12 weeks after transplant (9 weeks after the last
72A1 dose infused). Two out of 3 (67%) non-infused control patients (number 5 and 6)
became seropositive at 10 and 12 weeks whereas the remaining control patient (number
7) seroconverted 41 months following liver transplantation. All EBV+ve organ graft
recipients tested EBNA IgG-negative. When plasma samples were analyzed by PCR,
EBV DNA was detected in 5 out of 7 (71%) patients (numbers 1, 2, 4, 5, and 7) during a
post-transplant follow-up period of up to 4 years despite none of these patients having
developed any symptoms of EBV disease. Conversely, 2 out of 7 (29%) patients
(numbers 3 and 6) did not have detectable EBV in plasma samples, and patient 3
remained EBV DNA, EBNA IgG, and VCA IgM and IgG seronegative for 4 years after
organ grafting. Retrospective analysis did not detect EBV DNA in pre-transplant PBL
samples from any of the patients.
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Taken together, there is some evidence that the 72A1 mab may have prevented
EBV infection immediately after transplantation surgery. However, the study is small in
scale and it is difficult to draw firm conclusions about the effect of the 72A1 mab on
EBV infection in the children. All 7 liver transplant recipients were alive with a
functioning organ graft 4 years after transplantation surgery, and none had developed
PTLD.
All 4 (100%) children infused with the 72A1 antibody developed HAMA despite
being on iatrogenic immunosuppressive treatment. One child (patient 4) suffered a
severe reaction (hypotension, peripheral cyanosis, and vomiting) during the seventh
infusion that required cessation of treatment. Patient 4 also developed staphylococcus
aureus septicaemia. Whilst the hypersensitivity reaction required cessation of antibody
infusion, the actual cause of the reaction (including an IgE-mediated response to
HAMA) could not be identified.
Based on the above results, we concluded that the 72A1 mab was effective in
preventing EBV-driven lymphomagenesis in SCID mice. However, the mab in its native
form may not be safe in humans. Alternatives include humanizing the 72A1 mab, or
producing a human mab (Breedveld, 2000).
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
EBV-associated PTLD is an aggressive disease with high mortality despite
current treatment. Therefore, novel therapeutic strategies are urgently needed to combat
the lesions and improve patient prognosis. One such strategy involves the use of EBV-
specific CTLs. In order to test the efficacy of such novel immunotherapy, PTLD can be
modelled in SCID mice which are deficient in functional B and T cells and, thus, readily
accept human xenografts (Bosma et al, 1983; Reddy et al, 1987; Mosier et al, 1988).
Using either EBV-seropositive PBLs or BLCLs, the tumours that develop in vivo closely
resemble that of BLCLs and PTLD in terms of cell surface phenotype and virus gene
expression (Rowe et al, 1991; Johannessen et al, 2000; Figures 7-8 in Results), and the
SCID model has become the small animal model of choice for in vivo studies on EBV-
associated malignancies (for a review, see Mosier, 1996).
The current project was designed to set up a SCID mouse model in our
laboratory suitable for investigating adoptive CTL immunotherapy for EBV+ve PTLD.
In this section, (1) general aspects of the role of the SCID mouse in PTLD modelling,
and (2) some future perspectives, will be addressed.
1. SCID Mice And PTLD Modelling
Following the original description of EBV+ve PTLD-like tmours in SCID mice
inoculated with seropositive PBLs (Mosier et al, 1988), the animal became the model of
choice in which to study EBV-associated neoplasia. Our laboratory has used the animals
for nearly 15 years to investigate EBV pathogenesis and lymphomagenesis.
The SCID mouse is a small animal model which is relatively easy to manage and
maintain. Furthermore, the animals are not endangered and can be bred in captivity with
ease and at a releatively low cost. The importance of the SCID mouse is further
underlined by the fact that the use of higher order mammals (for example, non-human
primates) for experimental purposes is difficult in the UK due to strict Flome Office
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guidance and adverse public attitude towards such in vivo research. The humanized
SCID mouse offers a valuable model in which to study human neoplasia although care
must be taken when extrapolating between data obtained in the animals and a human
patient. The relative advantages and disadvantages of the (1) hu-PBL-SCID and (2) hu-
BLCL-SCID mouse models are shown below.
(1) Hu-PBL-SCID Mouse
The advantages of this model are summarized below:
(1) EBV+ve PBLs give rise to ip PTLD-like tumours.
(2) Model of choice for studies of PTLD pathogenesis.
(3) EBV infection of seronegative PBLs can be used to model primary infection.
However, some disadvantages exist:
(i) Healthy virus carriers vary in their ability to give rise to ip tumours.
(ii) Large PBL numbers (>50xl 06) are required for each ip inoculum.
(iii) Tumour formation takes a long time (up to 100 days).
(2) Hu-BLCL-SCID Mouse
As demonstrated in this thesis, in this model:
(1) EBV+ve B cells consistently give rise to sc or ip tumours.
(2) Direct sc tumour measurements enable assessment of treatment response.
(3) Ip tumour formation can be used as the read-out of preventative therapy.
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However, some disadvantages exist:
(i) Time to sc tumour can vary between inoculated animals in a test group.
(ii) Administration of large cell inocula iv is difficult.
(iii) Imaging techniques need to be optimized.
In light of 2.i and 2.ii above, we developed the ip hu-BLCL-SCID model for
therapy testing.
The importance of animal modelling has not diminished over the years despite
efforts to offer alternative in vitro options (for further information, see the FRAME
website: www.frame.org.uk), and pre-clinical data obtained in suitable animal models
are vital to support testing in the clinical (patient) setting. Events in March 2006 at
Northwick Park Hospital in London underline the importance of such relevant in vivo
pre-clinical data prior to phase I clinical (safety) trials. During the Northwick Park study,
6 healthy volunteers became seriously ill within 3 hours of iv administration of a fully
humanized new anti-CD28 mab (labelled 'TGN1412') to be used to modulate T cell
immunity in autoimmune and inflammatory disease and leukaemia by a German firm
(Mayor, 2006). The trial was approved by the Medicines and Healthcare Products
Regulatory Agency (MHRA), the executive agency of the UK Department of Health that
oversees and regulates clinical trials in the UK, and a local ethics committee. In a
subsequent report, the MHRA did not identify any errors made in the manufacture, or
administration, of TGN1412. However, whilst the mab had been tested in rabbits and
monkeys prior to human use, it did not cross react with CD28-like molecules in these
animals, and there was no reporting of the reagent having been studied in relevant
humanized immunodeficient models.
The MHRA is the final regulator of clinical trials in the UK (for further
information, see the Agency's website: www.mhra.gov.uk), and the regulator expects
pre-clinical data to demonstrate medicinal product quality and in vivo safety to avoid
such incidents as the one detailed above. During medicinal product development, both
pre-clinical and clinical studies must be performed to quality standards and follow
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quality guidelines (collectively referred to as 'GxP'). Important GxP include 'Good
Clinical Practice' (GCP), 'Good Laboratory Practice' (GLP), and 'Good Manufacturing
Practice' (GMP). GCP provides an international quality standard [as defined by the
'International Conference On Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use' (ICH) to which the European Union
(EU) is signatory; see the website: www.ich.org] on how clinical trials should be carried
out, whereas GLP addresses systems of management controls to ensure product
consistency and quality as defined by the 'Organization For Economic Co-Operation
And Development (OECD) Principles of Corporate Governance' (see the website:
www.oecd.org) as well as national legislation. GMP centres on the control and
management of product manufacturing and quality control testing (for further
information on GxP, see the European Medicines Evaluation Agency website:
www. emea. earopa. eu).
Taken together, pre-clinical testing of novel therapy/medicinal product in a relevant
animal model is essential to gather data on its quality and safety before an application
can be made to the MHRA for a clincial trial. One such new treatment strategy is
genetically engineered T cells against PTLD that may offer an exciting alternative to
CTLs in the near future.
2. Future PTLD Immunotherapy
Using a bank of EBV-specific CTLs generated in vitro from PBLs of EBV+ve
healthy blood donors, our laboratory successfully infused patients suffering from EBV-
driven PTLD with virus-specific CTLs on a 'best MHC match' basis (see section 3.5 in
Introduction; Haque el al, 2002, 2007). This proof-of-principle trial showed that CTL
therapy could succeed. However, a mechanism for bypassing MHC restriction would
facilitate its dissemination to the clinic.
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Since the TCR defines T cell recognition of antigen, a chimeric TCR (cTCR; or
chimeric immune receptor, CIR) can be constructed that directs T cells against a novel
antigen (Schumacher, 2002; Mansoor et al, 2005). In order to:
(1) broaden the application of CTLs,
and
(2) bypass MHC restriction,
cTCRs may be engineered to re-direct CTLs to EBV-derived surface antigens on
infected malignant cells.
Current CTL immunotherapy for EBV-associated malignancies (for example, HL
subsets, NPC) is limited by (a) the need for MHC-matched donors and (b) bias towards
immunodominant antigens (the EBNA3 complex) that are not expressed by all tumours.
One way of improving efficacy is to re-target CTLs to widely expressed EBV antigens
such as LMP1 and LMP2 (see Table 3 in Introduction). LMP1 is a 58-63 kDa protein
encoded by the BNLF1 ORF (Fennewald et al, 1984; Liebowitz et al, 1986) that consists
of 6 hydrophobic transmembrane domains with both terminal sequences in the
cytoplasm so that 3 reverse turn loops are exposed on the outer surface of the host
plasma membrane. Similarly, LMP2a and 2b are 54 and 40 kDa proteins, respectively,
that are encoded by the BARF1/BNRF1 ORF (Laux et al, 1988; Sample et al, 1989) that
consist of 12 hydrophobic transmembrane domains with both terminal sequences in the
cytoplasm so that 6 reverse turn loops are exposed on the outer surface of the host
plasma membrane. Since both LMP1 and 2 are expressed by PTLD (and most other
EBV-associated malignancies; see Table 2 in Introduction), they are an ideal choice for
cTCR immunotherapy.
Using a single chain antibody variable domain fragment (scFv) as the antigen
recognition molecule, cTCRs can be made to target antigens expressed on the surface of
a target cell (Eshhar et al, 1993; Schuhmacher, 2002; see Figure 31). Antigen targetting
becomes independent of MHC resctriction when such paratope recognition is employed.
Chimeric TCRs have been used to re-direct T cells to non-virus infected cells. In their
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study, Hwu et al (1993) transduced human T cells with cTCR against folate binding
protein (FBP), a surface antigen present on most human ovarian carcinomas, and
showed specific lysis of human ovarian carcinoma cells in vitro. Similar methods have
been used to re-direct T cells to virus infected tumour cells. Thus, Orentas et al (2001)
were able to use TCR sequences of an in vitro expanded LMP2-specific CTL clone to
re-direct PBLs to autologous LMP2 peptide-pulsed cells although their approach can not
entirely be considered to have circumvented MHC restriction. Since LMP1 and 2 are
expressed on the surface of EBV-infected cells, these EBV antigens are candidate targets
for cTCR immunotherapy.
FIGURE 31
T Cell Receptor (TCR) And Chimeric TCR (cTCR)
Chimeric T cell receptors (cTCRs) consist of a single-chain antibody fragment (scFv) that is
coupled to additional molecular machinery to enhance function of the re-directed T cell, or 'T
body'. These T bodies confer non-MHC restricted antigen recognition of target molecule. Ig-
VH: Ig heavy-chain variable domain; Ig-VL: Ig light-chain variable domain; ITAM:
Immunoreceptor tyrosine-based activation motif. [Reprinted from Schumacher (2002) with
permission from Nature Publishing Group. Copyright © 2002 Nature Publishing Group. All
rights reserved. ]
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A number of tumour cell surface antigens are poorly immunogenic, and mabs
against many of them do not exist. In order to identify novel antibody targets, phage
display technology employs genetically-engineered phage to 'display' human scFv
antibody fragments on its surface (Dermime et al, 2004). Thus, a human scFv gene is
fused to a phage gene coding for one of its surface coat protein molecules. As a result,
the recombinant phage 'displays' a unique human antibody fragment on its surface and
carries the antibody gene in its genome. Using millions of phages, an antibody phage
display library contains millions of diverse antibody genes collected from the blood of
healthy individuals using different donor B lymphocytes and reverse genetics. Using
target protein-derived peptides, the large non-immune ('nai've') human scFv libraries are
a rich source of human antibodies to virtually any target/antigen (Schumacher, 2002).
Once novel antibody fragments have been identified, individual scFv fragments specific
for a designated antigen can be selected and incorporated into vectors containing
additional molecular machinery (for example, the lymphocyte triggering receptors TCR-
C, and FcR-y as well as the costimulatory molecule CD28) to enhance homing,
activation, cytotoxicity and survival of the transfected CTLs, to create novel cTCR
CTLs, or 'T bodies'.
Using cTCR against carcinoembryonic antigen (CEA), which is expressed by
gastrointestinal cancers (and other neoplasia) but rare in healthy tissue, Hawkins et al
have transduced colorectal patient-derived T cells creating CEA-specific T bodies that
recognize and lyse CEA+ve colorectal tumour cell lines in vitro (Sheen et al, 2003a,b).
Similarly, CEA-specific human monocytes hindered CEA+ve tumour cell growth in
vitro and in nude mice (Biglari et al, 2006). The team has used a similar approach to
demonstrate:
(1) destruction of autologous CD19+ve NHL lymph node tumour biopsy cells in
vitro by patient-derived T lymphocytes transduced with a cTCR specific for
CD 19 (Cheadle et al, 2005),
and
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(2) lysis of renal cell carcinoma (RCC) cells in vitro by RCC patient-derived T
bodies transduced with a cTCR specific against the oncofetal antigen 5T4 that is
expressed by RCC (as well as other tumours) but is rarely found in healthy tissue
(Griffiths et al, 2005).
The data have formed the basis for the group's current applications for phase I/II
clinical trials using their cTCR constructs. Recent pilot studies employing cTCRs
against FBP on ovarian cancer cells (Kershaw et al, 2006) and LI-cell adhesion
molecule (CD 171) overexpressed by neuroblastoma cells (Park et al, 2007) have shown
that T bodies are well tolerated in patients. However, careful target selection and
extensive pre-clinical testing in relevant animal models is vital for treatment success in
the clinical setting as evidenced by a study by Lamers et al (2006) using cTCR against
carboxy-anhydrase IX (CAIX) in RCC patients. The group demonstrated unexpected
targeting of bile duct epithelial cells probably as a result of these cells expressing the
same target molecule (CAIX) as the RCC cells. The ensuing hepatic toxicity
necessitated cessation of treatment and the study was halted.
Recently, our laboratory has embarked on a study to identify novel LMP-derived
targets in order to re-target CTLs (T bodies) against EBV-associated cancers. Once we
have identified candidate phage antibody fragments, they will be used to engineer LMP-
specific CTLs to generate novel T bodies (and soluble antibody fragments). These will




(2) efficacy against tumours in vivo prior to introduction into the clinical
(patient) setting.
The principle remains the same for other viral and non-viral tumour antigens and,
thus, the same approach is applicable to other malignancies where a tumour-specific
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marker is known. Furthermore, a similar approach can be used to target virus-infected
non-tumour cells. For example, the matrix 2 (M2) protein of influenza A virus is highly
conserved across influenza A strains, and the ectodomain (M2e) is expressed on the
surface of influenza A virus-infected cells (Pinto & Lamb, 2006). Our aim is to generate
M2e-specific T bodies and investigate their efficacy against influenza A in a pre-clinical
SCID mouse model (Sidwell & Smee, 2000; Ison et al, 2006) in order to generate
translational data prior to introduction into the clinical setting.
The above projects in our laboratory will provide proof-of-principle in vitro and
in vivo data supporting the use of re-directed CTLs in humans. Based on the data, we
will formulate an approach to future clinical trials. Thus, it will eventually be possible to
use the cTCRs to generate cells lines for use in the clinical (patient) setting.
In order to assess the (1) safety and (2) efficacy of the novel approaches to
immunothereapy for EBV-associated neoplasia that are being developed and have been
outlined above, in vivo testing in a humanized small animal model is essential prior to
clinical trials. The SCID mouse is the ideal model for this purpose, and the animal
provides researchers with the in vivo tool required to hone new therapeutic strategies
before introduction into the clinical (patient) setting.
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CD3 1:100 Vision BioSystems
4B12
(IgG)
CD4 1:20 Vision BioSystems
1A5
(IgG)









Granzyme B 1:40 Vision BioSystems
5B10
(IgG)



















CD: Cluster Designation; Jg: Immunoglobulin; LCMV: Laboratory for Clinical & Molecular Virology;
LSHTM: London School of Hygiene & Tropical Medicine; MHC: Major Histocompatibility Complex
Additional primary antibodies used for study presented in Table 9 of Results (Johannessen et al, 2002):
Anti-CD 19 (HD37, DakoCytomation)
Anti-CD23 (MHM6, DakoCytomation)
Anti-EA(D) (11 Of-1, Biogenesis)
Anti-EBNAl (OT1X; Kindly donated by Prof JM Middeldorp,
Amsterdam Free University Hospital, the Netherlands)
Anti-MA (Serotec)













CD3 FITC, PE BD Pharmingen
RPA-T4
(IgGi, k)
CD4 FITC, PE BD Pharmingen
RPA-T8
(IgG,, k)
CD8 FITC, PE BD Pharmingen
HIB19
(IgGi, k)
CD19 FITC, PE BD Pharmingen
H130
(IgG,, k)
CD45 FITC BD Pharmingen
B159
(IgGi, ic)





_* FITC, PE BD Pharmingen
CD: Cluster Designation; FITC: Fluorescein isothiocyanate; Ig: Immunoglobulin; PE: Phycoerythrin;





FITC-conjugated goat anti-human C3 IgG 1:10 Capell
Monoclonal mouse anti-FITC IgG 1:10 DakoCytomation
Mouse monoclonal AP-anti-AP complexes (APAAP) IgG 1:25 DakoCytomation
Mouse monoclonal Px-anti-Px complexes (PAP) IgG 1:100 DakoCytomation
Polyclonal AP-conjugated rabbit anti-mouse IgG,A,M 1:20 DakoCytomation
Polyclonal FITC-conjugated rabbit anti-human IgG 1:50 DakoCytomation
Polyclonal FITC-conjugated rabbit anti-mouse IgG,A,M 1:50 DakoCytomation
Polyclonal Px-conjugated goat anti-human IgG 1:10000 Sigma
Polyclonal Px-conjugated goat anti-rabbit IgG 1:10000 Nordic
Polyclonal Px-conjugated goat anti-rat IgG 1:4000 Sigma
Polyclonal Px-conjugated rabbit anti-human C3c 1:25 DakoCytomation
Polyclonal rabbit anti-mouse IgG,A,M 1:25/1:100/1:1000 DakoCytomation
Polyclonal TRITC-conjugated rabbit anti-mouse IgG,A,M 1:20 DakoCytomation






Normal Balb/c mouse serum 1:40 LCMV
Normal human serum (heat-treated) 1:25 LCMV
Normal rabbit serum 1:100 Dako




Cell Line Cell Type EBV Status Reference
B95-8 Marmoset BLCL + Miller et al, 1972
Namalwa BL + Klein & Dombos, 1973
P3HR1 BL + Hinuma et al, 1967
Ramos BL - Klein et al, 1975
BL: Burkitt's lymphoma; BLCL: B lymphoblastoid cell line
Additional cell/tissue controls included:
Human CD4+ve T cells (Laboratory for Clinical & Molecular Virology)
Human CD8+ve T cells (Laboratory for Clinical & Molecular Virology)
Immunocompetent murine Balb/c splenocytes (Laboratory for Clinical & Molecular Virology)
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TABLE A5
Primers Used For RT-PCR Reactions










5' GTG GGG CGC CCC AGG CAC CA 3'





5' ACT CAC CAG GAT GCT CAC AT 3'





5' CTT CCC CCT CTG TTC TTC CT 3'





5' CGG CAA CTT TGA CCA CGG ACA CAA GTG CGA TA 3'





5' ATG AGG ATG CTT CTG CAT TTG 3'





5' ATG TAG CCG CCC CAC ACA GA 3'





5' AAG CTG AGA ACC AAG ACC CAG ACA TCA AGG CG 3'





5' AGT TAT ATC TTG GCT TTT CA 3'
5' ACC GAA TAA TTA GTC AGC TT 3'
356















p-Actin4 1.5 2.5 65 40 I
IL24 1.5 3.5 55 40 i
IL45 1.5 2.0 60 35 0.2
IL54 1.5 2.5 65 40 1
IL64 2.5 2.5 65 40 1
IL105 1.5 2.5 60 35 1
IFNy4 2.5 2.5 55 40 1
Taq DNA Polymerase;2: Annealing temperature (= Annealing/Extension temperature as regards primers
from Yamamura et al, 1991, 1992); 3: Refers to the concentration of each primer; 4: Yamamura el al,
1991, 1992;5: Clontech Laboratories, Inc., USA; mM: 103 M; pM: 10~5M; U:Units
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TABLE A7
Probes Used For RT-PCR Reactions
(P-Actin; Human IL2, 4, 5, 6, 10, And IFNy)
Human Gene Probe Sequence
(5'->3')
P-Actin1 5' GGA TAG CAA CGT ACA TGG CT 3'
IL21 5' CCC TGG GTC TTA AGT GAA AG 3'
IL41 5' GTC TGT TAC GGT CAA CTC GG 3'
IL52 5' GCC AAT GAG ACT CTG AGG ATT CCT G 3'
IL62 5' TCT TGT TAC ATG TCT CCT TTC TCA G 3'
1L102 5' CAG GTG AAG AAT GCC TTT AAT AAG CTC CAA GAG AAA GGC ATC
TAC AAA GCC ATG AGT GAG TTT GAC ATC 3'
IFNy1 5' GCT ACA TCT GAA TGA CCT GC 3'
: Designed by IJ; : Yamamura et al, 1991, 1992
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TABLE A8




A B C DR
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
1 02 32 44 44 05 16 04 07
2 02 02 08 44 05 07 03 13
3 01 02 08 44 05 07 04 15
4 02 31 35 51 NT NT 07 17
5 01 03 07 07 NT NT 04 15
6 03 31 27 45 01 06 NT NT
7 02 03 40 44 03 05 NT NT
8 24 68 14 15 03 08 NT NT
9 23 23 44 49 04 07 NT NT
10 02 29 44 44 NT NT 01 07
11 02 32 07 14 NT NT 07 15
12 01 31 08 44 NT NT 07 17
13 01 03 07 14 07 08 NT NT
14 01 02 35 73 04 15 NT NT
15 03 68 40 44 03 08 NT NT
16 01 29 07 08 07 07 NT NT
17 02 68 50 60 NT NT 04 17
18 23 25 44 45 NT NT 04 12
19 01 32 08 35 NT NT 01 17
20 02 02 37 44 NT NT 01 07
21 01 02 07 57 NT NT 07 09
22 02 11 27 44 NT NT 01 14
23 03 03 51 60 NT NT 04 15
24 11 32 27 62 NT NT 01 11
25 01 02 08 57 NT NT 01 07
26 02 03 35 44 NT NT 15 15
27 24 31 49 60 NT NT 04 17
28 03 74 53 72 NT NT 11 15
MHC: Major Histocompatibility Complex; No: Number; NT: Not tested; Bold type: Common UK MHC
A or B allele
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TABLE A9
Cell Surface Phenotype Of A Panel Of T Cell Lines
(Donors 1-25)
Donor Period Of In Vitro % CD4+/CD45+ % CD8+/CD45+ % CD56+/CD45+
No Growth (Weeks) T Cells T Cells NK Cells
I 9 34 78 1
2 7 11 88 4
3 17 3 93 0
4 10 0 97 0
5 8 17 83 0
6 9 49 42 12
7 8 6 64 NT
8 10 37 68 4
9 11 12 86 4
10 8 2 84 NT
11 8 1 74 NT
12 12 15 68 0
13 10 1 96 NT
14 10 25 58 20
15 11 71 24 3
16 11 2 97 0
17 11 96 3 NT
18 12 12 81 4
19 11 4 93 0
20 12 4 96 8
21 8 3 96 1
22 8 4 69 1
23 9 33 89 5
24 8 4 87 NT
25 7 1 97 1
CTL: Cytotoxic T lymphocytes; No: Number; NT: Not tested; PBL: Peripheral blood leukocytes
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TABLE A10





Autologous BLCL Allogeneic BLCL K562
I 59 26 7
2 22 7 0
3 39 1 7
4 50 6 0
5 30 3 2
6 91 6 2
7 31 1 1
8 44 14 7
9 27 3 9
10 36 13 17
11 6* 0 19
12 26 1 7
13 34 30 3
14 16 12 28
15 2* 0 1
16 31 10 4
17 65 4 21
18 39 7 14
19 44 6 10
20 51 22 40
21 39 4 0
22 34 4 0
23 10 0 2
24 45 0 0
25 61 7 10
*: Cytotoxicity was assessed following in vivo transfer ofCTLs; BLCL: B lymphoblastoid cell line;
CTL: Cytotoxic T lymphocytes; No: Number
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TABLE A11
Cell Surface Phenotype Of CTL And Enriched T Cell Subsets
(Donors 6-9)





6 CD4-Enriched 8 71 6 NT
CD8-Enriched 2 95 NT
CD4/CD8-Depleted 3 5 84
7 CD4-Enriched 8 51 50 NT
CD8-Enriched 1 96 NT
CD4/CD8-Depleted 8 4 80
8 CD4-Enriched 10 88 17 1
CD8-Enriched 20 96 1
CD4/CD8-Depleted 62 21 9
9 CD4-Enriched 10 90 NT NT
CD8-Enriched 5 82 15
CD4/CD8-Depleted NT NT NT
*: Percentage of CD45+ve leukocytes; CTL: Cytotoxic T lymphocytes; No: Number; NT: not tested
271
TABLE A12
Ceil Surface Phenotype Of CTL And Enriched T Celt Subsets
(Donors 6, 8-16)




6 CD4-Enriched 9 70 10 NT
CD8-Enriched 10 80 NT
C D4/C D8-Depleted NT NT NT
8 CD4-Enriched 15 74 71 NT
CD8-Enriched 35 89 NT
CD4/CD8-Depleted NT NT NT
9 CD4-Enriched 11 71 26 4
CD8-Enriched 2 96 4
C D4/CD8-Depleted 49 20 12
10 CD4-Enriched 8 0 48 NT
CD8-Enriched 1 87 NT
CD4/CD8-Depleted 2 86 NT
11 CD4-Enriched 8 2 24 NT
CD8-Enriehed 1 87 NT
CD4/CD8-Depleted NT 83 NT
12 CD4-Enriched 12 2 14 0
CD8-Enriched 0 40 0
CD4/CD8-Depleted NT NT NT
13 CD4-Enriehed 10 21 96 10
CD8-Enriched 3 97 9
CD4/CD8-Depleted 3 14 12
14 CD4-Enriched 10 85 8 5
CD8-Enriched 6 93 24
CD4/CD8-Depleted 6 18 10
15 CD4-Enriched 11 97 2 2
CD8-Enriched 20 67 19
CD4/CD8-Depleted 7 14 25
16 CD4-Enriched 11 36 42 10
CD8-Enriched 0 92 2
CD4/CD8-Depleted 1 35 13
*: Percentage of CD45+ve leukocytes; CTL: Cytotoxic T lymphocytes; No: Number; NT: not tested
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TABLE A13
Time To End Point
(Donors 6, 8-16)
Donor Days To Ip Tumour Development
No Medium Only CTL CD4+ CD8+ CD4-/8-
Range Range Range Range Range
(Median) (Median) (Median) (Median) (Median)
6 17-18(18) 45-53 (53) 17-100(19) 100(100) (NT)
8 36-40(37) 66-72 (69) 47-53 (47) 61-100(100) (NT)
9 19-20 (20) 24-32 (25) 25 (25) 19-41 (26) 20 (20)
10 33-73 (54) 49-56 (54) 53-100(54) 50-61 (54) (NT)
11 34-39 (36) 36-47 (41) 31-39 (39) 34-39 (36) (NT)
12 25-72 (34) 46-54 (49) 31-100 (31) 31-100 (33) (NT)
13 27-100 (29) 51-71 (64) 34-37 (37) 100(100) 28-40 (37)
14 37-51 (37) 44-100 (48) 34-35 (35) 33-63 (51) 30-100 (35)
15 20-21 (20) 17-35 (18) 17-24(17) 20-21 (20) 18-42 (42)
16 24-52 (30) 100(100) 57-100(100) 100(100) 100(100)
CTL: Cytotoxic T lymphocytes; No: Number; (NT): Not tested (inasmuch as a complete data
set is not available)
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TABLE A14
Statistical Analysis (Mann-Whitney Test):
Time To End Point Following Ip Transfer Of Autologous T Cell Subets
(Donors 6, 8-16)
Groups Compared Significant Difference Between
The Groups?




CTL and CD4-Enriched Yes (p=0.04)
CD8-Enriched No (p=0.56)
CD4/CD8-Depleted No (p=0.14)
CD4-Enriched and CD8-Enriched Yes (p=0.03)
CD4/CD8-Depleted No (p=0.91)
CD8-Enriched and CD4/CD8-Depleted No (p=0.16)
CTL: Cytotoxic T lymphocytes
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FIGURE B1
% Survival Using CD4-Enriched T Cell Subsets
(Donors 6, 8-9, 14-15)
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Expansion in scid mice of Epstein-Barr virus-associated post¬
transplantation lymphoproliferative disease biopsy material
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Post-transplant lymphoproliferative disease (PTLD)
biopsy material is rarely available in adequate
quantity for research. Therefore, the present study
was designed to expand biopsy material in scid
mice. Epstein-Barr virus (EBV)+ve PTLD samples
from five transplant patients were established in
scid mice. PCR analysis of immunoglobulin gene
rearrangements demonstrated that four of the five
biopsies (80%) gave rise to scid tumours which
represented the original tumour cell clones. Im-
munophenotyping showed that these four biopsies
(and all scid tumours) expressed all EBV latent
genes and a B lymphoblast phenotype; >26% T
cells were found in the biopsy material whereas scid
tumours showed a paucity of T lymphocytes. RT-
PCR analysis revealed expression of IL-2, -4, -6,
-10 and IFN-y in all tumour material, suggesting key
roles for these factors in tumour growth. The results
show that EBV+ve PTLD material can be expanded
in scid mice giving rise to quantities of homo¬
geneous malignant tissue sufficient for research
studies.
Post-transplant lymphoproliferative disease (PTLD) de¬
velops in up to 10% of solid organ transplant recipients and
carries up to 70% mortality despite treatment (Armitage el al.,
1991; Opelz & Henderson, 1993). The majority of PTLD cases
are associated with Epstein—Barr virus (EBV). Main risk factors
are primary EBV infection in previously seronegative organ
recipients, and high-level immunosuppressive drug therapy
(Ho et al., 1985; Thomas et al., 1990). Typically, tumour cells
display an activated B lymphoblastic phenotype and express
all EBV latent genes [six EBV nuclear antigens (EBNAs); three
latent membrane proteins (LMPs)] and two EBV-encoded small
non-polyadenylated RNAs (EBERs), although more restricted
viral gene expression has been described (Cen et al.,
1993; Oudejans et al., 1995). A minority of cells support lytic
virus infection. PTLDs range from diffuse polymorphic lesions
with polyclonal immunoglobulin (Ig) gene expression to
malignant monoclonal lymphomas. The latter generally consist
of large immunoblasts but include Hodgkin's disease (HD) and
plasmacytoma (reviewed in Crawford, 2001).
PTLD biopsy material is scant and does not generally grow
in vitro. The few cell lines available do not reflect initial tumour
phenotype (Cen et al., 1993; Itoh et al., 1993). Additionally,
biopsies generally contain heavy infiltrates of non-malignant T
cells (Perera et al., 1998) which can limit their use in molecular
studies. The aim of this study was to expand original PTLD
biopsies in scid mice, which readily accept human xenografts
due to lack of functional B and T cells (Bosma et al.,
1983; Johannessen & Crawford, 1999).
PTLD biopsies were obtained from five solid organ graft
patients (designated ' patient 1—5'; for patient details, see Table
1). For each biopsy, 25 x 10s—50 x 106 cells (denoted 'biopsy')
were injected intraperitoneally (i.p.) into a scid mouse within
12 h of biopsy (sample from patient 2 was inoculated into two
animals). Tumours (denoted 'scid tumour') formed in all mice.
It was possible to passage material from patient 3. Patients 3
and 5 experienced primary EBV infection following trans¬
plantation whereas patients 1, 2 and 4 were persistently
infected. All five biopsies gave rise to i.p. tumours in scid mice.
EBER in situ hybridization was performed on all sample
material using standard methods (Howe & Steitz, 1986).
Similar to biopsies, all scid tumours were EBER + ve [for an
assessment of the relative proportion of EBV + ve cells in the
sample material, see '(2) Cell phenotype' below].
Our tissue panel of five sets of biopsy and scid tumours was
analysed for (1) Ig and EBV clonality, (2) cell surface phenotype,
(3) in vitro proliferation and (4) cytokine expression. Sample
material was limited, and a full complement of tests could not
always be carried out.
(1) Clonality. In order to ascertain whether scid tumours
represented the corresponding biopsy, samples were assessed
for Ig and EBV clonality. Ig clonality was analysed by PCR
Author for correspondence: Dorothy Crawford.
Fax +44 131 650 3711. e-mail d.crawford@ed.ac.uk
0001-8056 © 2002 SGM
277
173
I. Johannessen and others
Table 1. Patient details
HD, Hodgkin's disease; BLPD, B cell lymphoproliferative disease; M, male; F, female.
Pathological
Patient Age* Transplanted Onset of 1 ° tumour EBV-serostatus at diagnosis of 1 °
no. (years) Sex organ (months)t time of 1° tumour Site of 10 tumour tumour
1 5 M Kidney 72 Carrier Lymph node Myeloma
2 9 M Liver 344 Carrier4 Lymph node BLPD
3 o-x F Liver 16 Primary infection Tonsil BLPD
4 7 M Heart 45§ Carrier§ Lymph node HD
5 15 M Heart 7 Primary infection Lymph node BLPD
* At time of transplantation.
+ Time from graft to tumour.
4 Recurrence; original lesion arose 2 months post-graft.
§ Recurrence; original lesion arose 29 months post-graft.
using primers specific for a conserved region of the variable (V)
segment of framework (Fr) 3 and junction (J) segments of the
Ig heavy chain (IgH) gene locus (McCarthy et al., 1990; Stetler-
Stevenson el al., 1990). Fr3 PCR products were analysed on an
ABI PRISM 310 Genetic Analyser. Primers derived from Frl
were used to analyse samples from patient 2. Based on
sequence analysis of the amplification products, a TaqMan
PCR assay specific for the rearrangement in this case was
designed and performed using standard methodology
(Kuppers el al., 1995). PCR analysis showed that biopsy and
scid tumours from patients 1, 2 and 5 consisted of monoclonal
material (for patient 2, see Fig. 1A; data not shown for patients
1 and 5). Matching clones were found in each sample set
demonstrating that each tumour pair was identical. Sequence
analysis of material from patient 2 confirmed the identical
clonal nature of biopsy and scid lesions. TaqMan PCR analysis
confirmed these results and further detected the malignant
clone in a peripheral blood leukocyte sample taken from
patient 2 at time of PTLD. Biopsy and scid tumour from patient
3 were oligoclonal with an identical dominant rearrangement
(Fig. IB). Passaged scid tumours were clonal, one of which was
identical to the dominant biopsy and scid rearrangement.
Biopsy from patient 4 contained a dominant clone in a
polyclonal background (Fig. 1C). The scid tumour was clonal,
but did not reflect the biopsy. EBV clonality was assessed using
the standard Gardella gel technique (Gardella et al., 1984; Raab-
Traub & Flynn, 1986). The number of reiterated 500 bp EBV
genome terminal direct repeats involved in forming the virus
episome following infection of a target B cell is characteristic of
any infection event. Progeny EBV + ve cells retain the same
episome thus giving rise to an EBV clonal population which
can be studied using the Gardella gel technique (Hurley &
Thorley-Lawson, 1988). Material from cases 2, 4 and 5 was
analysed with this assay. All lesions contained a single band
indicating virus clonality (data not shown). Each set of samples
from patients 2 and 5 contained bands of identical size,
indicating a common infection event in each case, whereas
material from patient 4 contained different EBV clones,
suggesting that the scid tumour arose from a latently infected,
non-malignant B cell.
(2) Cell phenotype. Primary antibodies against human and
EBV antigens were applied to tumour sections (see Table 2).
Bound antibody was detected as previously described
(Reedman & Klein, 1973; Van Noorden, 1986). Immunopheno-
typing studies on biopsy and scid tumours from patients 2, 3,
4 and 5 demonstrated that all lesions expressed B cell surface
antigens CD19 and CD23, indicating an activated, lympho-
blastoid phenotype (Table 2). Biopsies from patients 2, 3 and 5
showed full EBV latent gene expression (EBNA-l,-2/LMP-l).
Similarly, all scid tumours demonstrated full latent gene
expression. In biopsies, low level (< 5 % of cells) expression of
lytic cycle antigens BZLF1, early antigen [EA(D)], viral capsid
antigen (VCA) and membrane antigen (MA) was detected.
Increased lytic cycle antigen expression (5—10%) was observed
in corresponding scid tumours. The patient 4 biopsy showed a
restricted pattern of EBV gene expression typical of HD
(Deacon et al., 1993): only LMP-1 was visualized by immuno-
staining, although EBNA-1 transcripts were detected by
RT—PCR (data not shown). No lytic cycle antigens were
expressed. Conversely, patient 4 scid tumour showed full EBV
latent gene expression with lytic antigen expression similar to
other scid tumours tested, further emphasizing differences in
tumour cell type of the biopsy and scid lesion in this case.
(3) In vitro proliferation. In order to determine in vitro
growth characteristics of biopsy and scid tumours, lesions from
patients 1 and 3 were teased out into single cell suspensions
and placed in culture. The proliferative response was assessed
by [3H]thymidine incorporation using standard methods (data
not shown; Taylor et al., 1957; Rubini et al., 1960). Whilst scid-
derived material grew continuously in vitro for up to 56 days
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Fig. 1. Analysis of immunoglobulin gene rearrangements. All samples were analysed for Ig clonality in order to ascertain
whether scid tumours represented the corresponding biopsy. PCR was performed with 1 pg of DNA using primers specific for a
conserved region of the V segment of Fr1 or Fr3 and J segments of IgH gene locus. PCR product (30 pi) was purified using a
QIAquick 8 PCR purification kit (Qiagen), eluted in 60 pi of buffer, and 3 pi of purified product run on an ABI PRISM 310
Genetic Analyser with 0-5 pi of GS350 marker and 10 pi of formamide. Results were analysed using GeneScan software. (A)
Electropherogram of Fr1 PCR from patient 2. Top panel: biopsy result. Middle and bottom panels: results from two scid
tumours derived from biopsy. VH3 rearrangement of 328 bp is indicated in each panel. (B) Electropherogram of Fr3 PCR
products from patient 3. Top panel: biopsy result showing oligoclonal distribution. Second panel from top: scid tumour showing
oligoclonal distribution with three dominant rearrangments. Third panel from top: scid tumour (passage 1) showing one
dominant rearrangement. Bottom panel: scid tumour (passage 2) showing a single rearrangement. (C) Electropherogram of Fr3
PCR products from patient 4. Top panel: biopsy result. Bottom panel: scid tumour result. Dominant clones were detected at
109 and 91 bp, respectively, as indicated. The arrowheads (V) indicate GeneScan 350 ROX labelled size standard. —97
bp; —?■, 100 bp; <nt, 109 bp.
(when the experiment was terminated), the biopsies failed to
expand, which is in agreement with the experience of others
(Itoh et al., 1993; unpublished observations from our lab¬
oratory). This is unexpected since the majority of PTLD
express all EBV growth-promoting latent viral genes. How¬
ever, this phenomenon may be due to lack of necessary growth
factors in vitro resulting in programmed cell death.
(4) Cytokine expression. Extensive T cell infiltrates (26%
of all cells; see Table 2) were apparent in all biopsies as
previously described (Perera et al., 1998). Conversely, only
occasional T cells were identified in corresponding scid
tumours. To address the possible role of T cell-derived factors
in tumour growth, human cytokine gene expression of all
material from patients 1—5 was analysed by RT—PCR (Fig. 2).
Analysis of human cytokine mRNAs [interleukin (IL)-2, -4, -6,
-10 and interferon (IFN)-y] was carried out using published
conditions (Yamamura et al., 1991,1992). Primers for IL-10 did
not cross-amplify EBV-encoded viral IL-10. Biopsy and scid
lesions demonstrated a similar cytokine profile with expression
of the B cell growth factors IL-2, -4, -6, -10 and IFN--/
suggesting a key role in tumour growth. In situ hybridization
studies in our laboratory have demonstrated that these growth
factors are expressed by PTLD cells themselves (unpublished
observations). The results suggest that T cells may contribute
growth factors in the original malignancy whilst lack of T cells
in scid tumours indicates that tumour cells supply themselves
with necessary factors in an autocrine fashion supporting
autonomous growth. This is in line with our previously
proposed model of PTLD pathogenesis (Johannessen et al.,
2000).
The results demonstrate that biopsies from four out of five
(80%) patients (numbers 1, 2, 3 and 5) were successfully
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Table 2. Immunophenotypic comparison of biopsy and scid tumours
±, < 5% (of total cells counted); ( + ), 5-10%; 1+, 11-25%; 2 + , 26-50%; 3 + , 51-75%; 4 + , > 75%;
oc, occasional positive cell; nt, not tested; TCR, T cell receptor; Pt, patient. Antibody reagents: anti-TCR
x/P (BFT1, T Cell Science), anti-CD3 (UCHT, Dako), anti-CD19 (HD37, Dako), anti-CD23 (MHM6, Dako),
polyclonal EBV + ve human serum (London School of Hygiene & Tropical Medicine), anti-EBNAl (OTlX;
donated by J. Middeldorp, The Netherlands), anti-EBNA2 (PE2, Dako), anti-LMPl (CSl-4, Dako), anti-BZLFl
(Dako), anti-EA(D) (110f-l, Biogenesis), anti-VCA (Serotec), anti-MA (Serotec), anti-mouse MHClD"
(Serotec).
Sample
Antibody specificity Pt 2 scid 2 Pt 3 scid 3 Pt 4 scid 4 Pt 5 scid 5
TCR a/P 3 + oc 2 + 4 + oc 3 +
CD3 3 + oc 2 + — 4 + oc 3 + —
CD19 2 + 3 + 2 + 2 + 2 + 2 + 3 + 3 +
CD23 2 + 2 + 2 + 2 + 2 + 2 + 2 + 3 +
Polyclonal serum 3 + 3 + 3 + 3 + — 3 + 3 + 3 +
EBNAl 3 + 3 + 3 + 3 + * 3 + 3 + 3 +
EBNA2 2 + 2 + 2 + 2 + — 2 + 2 + 2 +
LMPI 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 +
BZLF1 ± ( + ) ± ( + ) — ( + ) ± ( + )
EA(D) ± ( + ) ± ( + ) — ( + ) ± ( + )
VCA ± ( + ) ± ( + ) — ( + ) ± ( + )
MA ± ( + ) ± ( + ) — ( + ) ± ( + )
Mouse MHClD" nt ( + ) nt ( + ) nt ( + ) nt ( + )
• EBNAl + ve on RT-PCR.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
< 328 bp
{ 328 bp
Fig. 2. Human cytokine gene expression: interleukin-10. Cytokine gene expression was analysed to determine the possible role
of B cell growth factors in tumour formation. Representative results of the amplification of human cytokine gene transcripts in
tumour material: IL-10. cDNA from 5 pg of RNA was amplified in a 35 cycle RT-PCR reaction using human IL10 primers. PCR
product (20 pi) was run on a 2-5% (w/v) NuSieve agarose gel, Southern transferred onto a nylon membrane, and hybridized
using human IL10-specific 32P-labelled oligonucleotide probe. Top panel: biopsy results. Lane 1, H/nfl-digested 1 74 DNA
radiolabelled marker; lane 2, 1 kbp non-radiolabelled DNA ladder; lane 3, phytohaemagglutinin (PHA)-treated human peripheral
blood leukocytes; lane 4, PHA-treated BALB/c murine splenocytes; lane 5, sterile distilled water; lanes 6-9, four EBV in vitro
immortalized B cell lymphoblastoid cell lines; lanes 10-14, biopsy material from patients 1 -5, respectively. Bottom panel: scid
tumour results. Lanes 1-9, as above; lanes 10-1 5, scid tumours from patients 1-5, respectively (lanes 11 and 1 2 represent
two scid tumours derived from patient 2). The size of the IL10 RT-PCR product (328 bp) is indicated.
expanded in scid mice (we have previously reported on in vivo represents a non-malignant EBV + ve B cell in the HD biopsy,
outgrowth of PTLD biopsy from patient 5; see Perera et al„ This finding has been reported by others (Meggetto et al.,
1996). Conversely, scid tumour from patient 4 probably 1996).
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Expansion of EBV + ve PTLD in scid mice
To our knowledge, this is the first report demonstrating
outgrowth of a panel of PTLD biopsies in scid mice and
contrasts with an earlier study by Randhawa et al. (1997)
suggesting that biopsies did not grow in vivo. Analysis of
passaged scid tumours from patient 3 showed progression
from oligoclonal to monoclonal tumour (Fig. IB), thus
providing possible insight into PTLD clonal progression.
Our study provides an adequate quantity of homogeneous
PTLD material from four graft recipients which is uncon-
taminated with infiltrating non-malignant cells, thus providing
opportunity for further molecular studies on PTLD patho¬
genesis.
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A Mouse Monoclonal Antibody
against Epstein-Barr Virus Envelope
Glycoprotein 350 Prevents Infection
Both In Vitro and In Vivo
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A mouse monoclonal antibody (MAb) against Epstein-Barr
virus (EBV) envelope glycoprotein 350, 72A1, inhibited EBV
infection of B lymphocytes in vitro. When severe combined
immunodeficient mice were injected with EBV-seronegative
donors' peripheral-blood mononuclear cells and challenged
with EBV, 72A1 MAb prevented development ofEBV-positive
tumors: none of the test mice (0/12) developed EBV-positive
tumors. In contrast, 67% (8/12) of control mice developed
EBV-positive tumors (P = .001). Purified 72A1 MAb was in¬
fused into 1 healthy adult and 4 EBV-seronegative children
after liver transplant. No adverse reactions were seen in the
adult or in 3 of the transplant recipients. The remaining
patient developed a hypersensitivity reaction, thus underlin¬
ing the need to humanize the MAb.
Epstein-Barr virus (EBV), a human herpesvirus, is associated
with development of posttransplant lymphoproliferative disease
(PTLD), particularly after primary EBV infection in previously
seronegative transplant recipients. An EBV-seronegative recip¬
ient can acquire EBV from a seropositive organ donor, and
primary EBV infection thus acquired is a risk factor for PTLD
[1], This transfer of donor virus via the graft has not been
observed in EBV-seropositive recipients. Because latent EBV in
donor B lymphocytes has to undergo lytic replication and then
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infect recipient B lymphocytes, it is hypothesized that preex¬
isting neutralizing antibodies directed against envelope gp350
in EBV-seropositive patients may be important in preventing
the infection of recipient cells by donor EBV isolates during
the immediate posttransplant period. If this is the case, then
active or passive immunization of EBV-seronegative recipients
before transplant that results in production of neutralizing anti-
gp350 antibodies could prevent EBV transmission via the graft
and thereby reduce the risk of PTLD development.
A mouse monoclonal antibody (MAb) against EBV gp350
produced by the hybridoma cell line 72A1 has previously been
shown to prevent EBV infection of B lymphocytes in vitro [2-
5], The present study was undertaken to characterize the effect
of 72A1 anti-gp350 MAb in SCID mice, an in vivo preclinical
model for PTLD [6, 7]. We also aimed to assess the in vivo
safety of 72A1 MAb and the effects on acquisition of EBV
during the immediate posttransplant period and the subsequent
development of PTLD in EBV-seronegative liver transplant re¬
cipients whose organ donors were EBV seropositive.
Subjects, materials, and methods. The 72A1 cell line was
obtained from Johns Hopkins University Medical School, after
a transfer agreement was signed. The antibody was manufac¬
tured in accordance with European Union good manufacturing
practice guidelines at the Therapeutic Antibody Centre, Oxford.
A master cell bank was made and tested for potential contam¬
inants. Cells were cultured in a hollow fiber fermentor, and
72A1 MAb was purified by chromatography on protein A, with
elution at pH 3.2, followed by cation exchange on S-Sepharose
at pH 4. The purified antibody was a mouse IgGl containing
k and X light chains in approximately equal proportions. The
hybridoma had been created using P3X63Ag8, a myeloma line
that secretes mouse IgGl k [2], It is likely that the purified
antibody was a mixture of active and inactive species, with only
a minor proportion having full bivalent binding to gp350.
To determine the EBV-neutralizing titer of 72A1, 2 X 106
peripheral-blood mononuclear cells (PBMCs) from an EBV-
seronegative donor were incubated at 37°C for 1 h with 10-
fold serial dilutions of concentrated EBV preparations and, for
each virus dilution, with 10-fold serial dilutions of 72A1 MAb
(starting concentration, 1 mg/mL). Cells (2 X 105 per well) were
cultured on microtiter plates and were observed for 4 weeks
for signs of outgrowth of EBV-immortalized lymphoblastoid
cell lines (LCL). Control plates were set up with PBMCs infected
with EBV but without 72A1 MAb. The dilution of antibody
that prevented LCL formation in >50% of wells was taken as
the neutralizing titer of that particular batch of 72A1 MAb [8].
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Table 1. Effect of passive immunoprophylaxis with 72A1 mono¬
clonal antibody (MAb) on Epstein-Barr virus (EBV)-driven lym-
phomagenesis in SCID mice inoculated with peripheral-blood
mononuclear cells (PBMCs) from EBV-seronegative donors.
No. of mice
Intraperitoneally with tumors/total
Treatment group injected PBMCs, no. no. of mice (%)
Untreated (PBS) 2 x 107-3 X 107 8/12a (67)
Treated (72A1 MAb) 2 x 107-3 x 107 0/12a (0)
" P = .001.
An in-house EIA was set up to capture 72A1 MAb in plasma
by coating the plates with goat anti-mouse IgG (Dako) and us¬
ing peroxidase-conjugated rabbit anti-mouse IgG as a detection
antibody. Similarly, an in-house EIA for detection of anti-72Al
human anti-mouse antibody (HAMA) was set up using 72A1
as a capture antibody and biotin-labeled 72A1 as a detection
antibody. The HAMA assay was not isotype specific and could
not differentiate between IgM and IgG.
PBMCs from 4 EBV-seronegative donors were injected in-
traperitoneally (ip) into SCID mice. For each donor, 2 X 107-
3 X 107 PBMCs were inoculated into each mouse in a group
of 6 SCID mice. For each such group of 6 mice, 3 test mice
were injected with 72AlMAb ip the day before injection of
PBMCs, on the day of PBMC injection, the day after (day 1),
and then 3 times weekly for 3 weeks [9], whereas 3 control
mice were injected according to the same schedule with PBS
only. A total of 12 mice received 72A1, and 12 acted as controls.
On day 1, all mice received 50 /rl. ip of a concentrated EBV
preparation (immortalizing titer, 10~4). Mice were monitored
regularly and culled when they showed signs of illness or after
a preset limit of 100 days. Assessment of tumor development
was performed by necropsy, and EBV association was deter¬
mined by routine staining for EBV nuclear antigen and small
RNAs [10, 11]. Fisher's exact test was used to analyze the in
vivo data.
Infusion of 72A1 into an adult volunteer was approved by
the Medicine and Clinical Oncology Research Ethics Sub-com¬
mittee, Edinburgh. A pilot study on EBV-seronegative pediatric
liver transplant recipients at King's College Hospital, London,
was approved by the Local Research Ethics Committee. In¬
formed written consent was obtained from guardians.
Results. The purified 72A1 MAb was shown to be IgGl,
as previously reported [2]. Exclusion of the presence of any
human DNA and mouse xenotropic and ectotropic viruses in
the hybridoma cell line was performed by the Forensic Labo¬
ratory, Lothian and Borders Police, Edinburgh (human DNA),
and Q-One Biotech, Glasgow (mouse viruses). In vitro neu¬
tralizing assays showed that 72A1 MAb at a dilution of 1:100
(10 fig/mL) inhibited EBV immortalization of B lymphocytes
by concentrated, 10"' and 10~2 virus dilutions in all (100%)
culture wells. Even at a dilution of 1:10,000 (100 ng/mL), 72A1
inhibited LCL outgrowth in >50% of wells when the EBV prep¬
aration was used at a 10~4 dilution (the virus immortalizing
titer).
To test the efficacy of the 72A1 MAb preparation in pre¬
venting EBV infection in vivo, we used the development of
PTLD-like lesions in SCID mice as a readout [9]. SCID mice
were inoculated with PBMCs from 4 EBV-seronegative donors
and then infected with EBV. On the basis of initial titration
experiments to identify the 72A1 MAb half-life in SCID mice
and to maintain circulating antibody levels >1 /tg/mL (data not
shown), test mice received 680 pg of 72A1 ip before PBMC
inoculation and then 3 times weekly for 3 weeks, whereas the
control mice received PBS only. After 100 days, the results
showed that none (0%) of the total of 12 mice that received
the antibody preparation developed ip tumors, whereas 8 (67%)
out of the 12 control mice developed EBV-positive PTLD-like
lesions ip (table 1). The outcome showed a statistically signif¬
icant difference between the 2 groups (P = .001).
To assess the half-life and identify any adverse effects of 72A1
MAb on humans, an EBV-seropositive adult volunteer was in¬
jected intravenously (iv) with a single 10-mg dose of antibody.
No adverse reactions occurred during or after the infusion.
Peak 72A1 MAb levels persisted in serum samples (0.08-0.12
pg/mL) for 52 h after infusion, after which they gradually de¬
clined, becoming undetectable after day 43. Anti-72A1 HAMA
was not detected in serum samples when tested up to 18 months
after infusion. Purified 72A1 was considered safe for use, and
7 EBV-seronegative children undergoing liver transplantation
from EBV-seropositive donors were enrolled (table 2). Four
children (denoted "patients 1—4") received 1 mg of 72A1 MAb/
kg of body weight by iv infusions immediately before and 6 h
after transplant, then every 2 days for up to 3 weeks, whereas
3 patients ("patients 5-7") served as controls. All patients were
receiving routine posttransplant immunosuppressive therapy.
Three (75%) of the 4 MAb-infused patients (patients 2—4)
Table 2. Demographic data, monoclonal antibody 72A1 infusion
status, and outcome in the Epstein-Barr virus (EBV)-seronegative




Patient months Sex 72A1 IgG VCA IgM VCA EBV DNA
1 11 M 11 3 3 43
2 16 M 6 - - 48
3 75 M 4 - - ND
4 18 F 7 - - 42
5 17 M 0 3 - 40
6 10 F 0 2.5 - ND
7 9 F 0 41 - 18
NOTE. ND, not detected; VCA, viral capsid antigen; —, seronegative.





































Time after last 72A1 MAb infusion
Figure 1. A, Levels of 72A1 monoclonal antibody (MAb). B, Levels of anti-72A1 human anti-mouse antibody (HAMA) in serum samples from patients
infused with 72A1 MAb, as determined by EIA. X-axes indicate the points at which antibody levels were measured, both before each 72A1 MAb
infusion and at different time points after the last infusion.
remained EBV seronegative during the 6-month follow-up pe¬
riod [12] (table 2). Patient 1 (1 [25%] of 4 infused) became
IgG anti-viral capsid antigen (VCA) seropositive 12 weeks after
transplant (9 weeks after the last MAb dose). Two (67%) of
the 3 noninfused control patients (patients 5 and 6) became
seropositive at 10 and 12 weeks. The remaining control patient
(patient 7) seroconverted at 41 months after transplant. All
seroconverted patients were seronegative for IgG to Epstein-
Barr nuclear antigen (EBNA). Long-term follow-up showed
that EBV DNA was detected by polymerase chain reaction 1.5-
4 years after transplant in plasma from patients 1, 2, 4, 5, and
7 (performed at the Health Protection Agency Virology Lab¬
oratory, King's College Hospital, London) (table 2), although
none of these patients developed any features of EBV disease.
Patient 3 remained EBV DNA, EBNA IgG, and VCA IgM and
IgG seronegative for 4 years after transplant. EBV DNA was
not detected in pretransplant PBMC samples from any patient
when retrospective analysis was performed.
72A1 MAb was detected in serum samples from all the in¬
fused children. However, the levels were lower in the child who
seroconverted at 3 months (patient 1) than in those (patients
2—4) who remained EBV seronegative at 6 months after infu¬
sions (figure 1A). All children had detectable anti-72Al HAMA
in serum samples (figure IB). Three of the 4 infused children
(patients 1-3) tolerated the infusions well, with no reactions
attributable to the antibody. Patient 4 (an 18-month-old girl)
had a severe reaction (peripheral cyanosis, hypotension, and
vomiting) during the seventh infusion, requiring cessation of
treatment. The patient also had Staphylococcus aureus septi¬
cemia. From day 7 onward, anti-72Al HAMA levels in patient
4 serum samples were higher (maximum, 8.5 /xg/mL) than
those in samples from the other infused children (figure IB).
Total serum IgE levels measured in samples obtained before
72A1 infusion and samples obtained up to 18 days after 72A1
infusion from this patient were within normal range (mea¬
surements were performed at the Scottish National Blood
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Transfusion Services, Edinburgh), ruling out an IgE-mediated
response to HAMA. No 72A1 MAb or anti-72Al HAMA was
detected in the noninfused control patients. Four years after
the transplant, all the children (infused and control) were alive
with a functioning graft, and none had developed PTLD.
Discussion. EBV infects B lymphocytes via the attachment
of envelope gp350 to cell surface CD21/CR2 receptors, and
antibodies to gp350 are neutralizing. For this reason, research
into a vaccine to prevent EBV-associated diseases has focused
on gp350 to elicit a protective antibody response [13]. Thus,
we have argued that it may be possible to provide short-term
protection to individuals at high risk for EBV disease, such as
EBV-seronegative transplant recipients, by passive infusion of
anti-gp350. To this end, the present study aimed to characterize
the anti-gp350 mouse MAb 72A1 and assess its potential to
protect against acquiring EBV from the graft during the im¬
mediate posttransplant period, thus reducing the risk for PTLD.
Initial results confirmed that, as reported elsewhere [2-5], 72A1
MAb neutralizes EBV infection of B lymphocytes in vitro, and
we therefore proceeded with in vivo studies. The development
of PTLD-like tumors in SC1D mice after injection of PBMCs
from EBV-seropositive donors can be prevented with purified
immunoglobulin pooled from plasma from seropositive donors
[14], suggesting that neutralizing antibody plays a role in pro¬
tection against tumors. With a similar SCID mouse model,
using development of PTLD-like lesions as a readout [9], we
attempted to mimic the situation of EBV transfer from an EBV-
seropositive donor to seronegative transplant recipients by in¬
jecting PBMCs from an EBV-seronegative donor followed by
concentrated EBV. The results show that 72A1 provides com¬
plete and significant protection from EBV-driven PTLD-like le¬
sions (table 1). Although further studies will assess whether EBV
infection can be completely prevented by the antibody, the results
suggest that neutralization of gp350 in vivo prevented EBV-
driven lymphoproliferation.
Injection of a single large dose of 72A1 MAb into a healthy
adult induced no adverse reactions and no HAMA production,
and we, therefore, performed a pilot study on 4 liver transplant
recipients. One of 4 infused and 2 of 3 control children sero-
converted during the 6-month observation period (table 2).
Although it is difficult to draw conclusions from this small
group, it appears that 72A1 MAb provided short-term protec¬
tion against acquiring EBV during the early posttransplant pe¬
riod. Detection of EBV DNA in plasma from 3 of 4 infused
children (patients 1, 2, and 4) 1.5-4 years later indicated that
they had acquired EBV infection without any features of EBV-
related disease.
Although they were on iatrogenic immunosuppression, all 4
children who received the antibody developed HAMA, and one
(patient 4) developed a hypersensitivity reaction, although the
actual cause of the reaction could not be identified. Thus, in
vivo use of 72A1 MAb in its native form may not be safe.
Further clinical studies would require either humanizing the
MAb or producing a human MAb [15].
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